日本臨牀　81/増刊3　新リンパ腫学

出版社： 日本臨牀社
発行日： 2023-03-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 新リンパ腫学
電子書籍版： 2023-03-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　新リンパ腫学
    　　　―基礎・臨床の最新動向―

    序　文
    1
    I．悪性リンパ腫診療に求められる疾患背景因子の基礎知識
    　1．HTLV-1による成人T細胞性白血病・リンパ腫の発症機構
    　2．小児悪性リンパ腫の病型・臨床病理的特徴
    　3．ウイルス性肝炎における悪性リンパ腫リスク
    　4．HIV関連悪性リンパ腫の発症リスクとメカニズム
    　5．重複悪性リンパ腫の臨床病理的特徴
    　6．自己免疫疾患・慢性炎症と悪性リンパ腫
    　7．リンパ腫発症の遺伝的素因
    　8．臓器移植/造血幹細胞移植とリンパ増殖性疾患
    　9．医原性免疫不全に関連するリンパ増殖症

    II．悪性リンパ腫の分子腫瘍学的異常・病態形成機序
    　1．CLLの発症・病態形成と分子腫瘍学的異常
    　2．LPLの病態形成と分子腫瘍学的異常
    　3．マントル細胞リンパ腫の病態形成と分子腫瘍学的異常
    　4．濾胞性リンパ腫の分子病態
    　5．びまん性大細胞型B細胞性リンパ腫の分子腫瘍学的異常
    　6．血管免疫芽球性T細胞リンパ腫の病態形成と分子腫瘍学的異常
    　7．PTCL- NOSの分子腫瘍学的異常
    　8．成人T細胞性リンパ腫の病態形成と分子遺伝学的異常
    　9．ホジキンリンパ腫の病態形成と分子病態
    　10．Epstein-Barr VirusによるT,NK細胞の腫瘍化のメカニズム
    　11．悪性リンパ腫の病態形成と腫瘍微小環境の分子腫瘍学

    III．悪性リンパ腫の診断概論
    　1WHO分類第5版(2022)の骨格とキーポイント
    　2．臨床医が知っておくべき悪性リンパ腫の病理診断の基本と応用
    　3．悪性リンパ腫の染色体異常　診断法と臨床的意義
    　4．悪性リンパ腫の細胞表面抗原解析　診断の基本と応用
    　5．悪性リンパ腫のFDG-PET/CTによる画像診断と効果判定のエッセンス
    　6．悪性リンパ腫のクリニカル・シーケンス　臨床的意義と展望

    IV．悪性リンパ腫の予後予測因子
    　1．B細胞性リンパ腫の臨床的予後予測指標
    　2．T細胞性リンパ腫の臨床的予後予測指標
    　3．ホジキンリンパ腫の臨床的予後予測指標
    　4．悪性リンパ腫の中枢神経浸潤リスクと治療的アプローチ

    V．病型各論　―疾患概念・疫学・分類・臨床像・診断・治療・予後・話題―
    　1．ホジキンリンパ腫
    　2．Bリンパ芽球性白血病・リンパ腫, 非特異型
    　3．慢性リンパ性白血病/小リンパ球性リンパ腫
    　4．B細胞前リンパ球性白血病
    　5．特異的遺伝子異常を伴うBリンパ芽球性白血病/リンパ腫, 非特定型
    　6．ヘアリーセル白血病
    　7．リンパ形質細胞性リンパ腫・原発性マクログロブリン血症
    　8．節外性粘膜関連リンパ組織型辺縁帯リンパ腫
    　9．節性辺縁帯リンパ腫
    　10．濾胞性リンパ腫
    　11．マントル細胞リンパ腫
    　12．びまん性大細胞型B細胞リンパ腫, 非特定型
    　13．高悪性度B細胞リンパ腫の診断と治療
    　14．B細胞リンパ腫, 分類不能型, びまん性大細胞型B細胞リンパ腫と
    　　　　古典的ホジキンリンパ腫の中間型
    　15．縦隔原発大細胞型B細胞リンパ腫
    　16．血管内大細胞型B細胞リンパ腫
    　17．形質芽球性リンパ腫
    　18．原発性体腔液リンパ腫
    　19．HHV8関連リンパ増殖性疾患
    　20．バーキットリンパ腫
    　21．Tリンパ芽球性白血病・リンパ腫, 非特定型
    　22．T細胞前リンパ球性白血病(T-PLL)
    　23．T細胞大型顆粒リンパ球性白血病
    　24．アグレッシブNK細胞白血病
    　25．成人T細胞白血病・リンパ腫 (ATL)
    　26．未分化大細胞型リンパ腫（ALK陽性、ALK陰性, 乳房インプラント関連）
    　27．血管免疫芽球型T細胞性リンパ腫 (AITL), および その他のT濾胞ヘルパーT細胞リンパ腫
    　28．節外性NK/T細胞リンパ腫・鼻型
    　29．腸管T細胞リンパ腫
    　30．肝脾T細胞リンパ腫
    　31．皮下脂肪織炎様T細胞リンパ腫
    　32．菌状息肉腫・セザリー症候群
    　33．末梢性T細胞リンパ腫, 非特定型
    　34．キャッスルマン病
    　35．TAFRO症候群

    VI．節外リンパ腫の臓器別特徴に基づく診断と治療
    　1．中枢神経系原発リンパ腫
    　2．皮膚リンパ腫
    　3．眼付属器リンパ腫
    　4．眼内悪性リンパ腫
    　5．乳腺リンパ腫
    　6．精巣リンパ腫
    　7．肺リンパ腫・リンパ腫様肉芽腫症・膿胸関連リンパ腫
    　8．消化管リンパ腫
    　9．子宮・卵巣リンパ腫

    VII．悪性リンパ腫に対する新規治療戦略の現状と展望
    　1．B細胞性リンパ腫に対するモノクローナル抗体薬・抗体薬剤複合体
    　2．T細胞性リンパ腫に対するモノクローナル抗体薬・抗体薬剤複合体
    　3．悪性リンパ腫における免疫チェックポイント阻害抗体薬のエビデンスと展望
    　4．成熟B細胞性腫瘍におけるB細胞受容体シグナル標的治療薬と分子病態
    　5．エピジェネティクスを標的とした悪性リンパ腫に対する治療戦略
    　6．悪性リンパ腫に対するBCL-2阻害剤の治療応用のエビデンスと展望
    　7．二重特異性抗体の開発経緯と臨床応用の進歩
    　8．悪性リンパ腫に対するキメラ抗原受容体T細胞療法の現在地と展望
    　9．悪性リンパ腫に対する同種造血幹細胞移植の適応, エビデン, 展望

    VIII．悪性リンパ腫治療における支持療法・患者管理のチップス
    　1．悪性リンパ腫に特徴的な感染対策としての予防投薬・予防接種
    　2．悪性リンパ腫診療における栄養管理
    　3．悪性リンパ腫の免疫化学療法・分子標的治療における腫瘍崩壊症候群対策
    　4．悪性リンパ腫における化学療法誘発性末梢神経障害の診断と対策
    　5．悪性リンパ腫治療と重複がん
    　6．悪性リンパ腫診療における妊孕性温存
    7. その他の合併症（infusion reaction、B型肝炎再活性化、心毒性）の対策

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[I] 悪性リンパ腫診療に求められる疾患背景因子の基礎知識

P.11 掲載の参考文献
1) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group(1984-87). Br J Haematol 79:428-437, 1991.
 
2) Uchiyama T, Yodoi J, Sagawa K, et al:Adult T-cell leukemia:clinical and hematologic features of 16 cases. Blood 50:481-492, 1977.
PubMed
3) Watanabe T:Current status of HTLV-1 infection. Int J Hematol 94:430-434, 2011.
PubMed
4) Takeda S, Maeda M, Morikawa S, et al:Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 109:559-567, 2004.
PubMed
5) Gaudray G, Gachon F, Basbous J, et al:The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 76:12813-12822, 2002.
PubMed
6) Yoshie O, Fujisawa R, Nakayama T, et al:Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99:1505-1511, 2002.
PubMed
7) Nakagawa M, Schmitz R, Xiao W, et al:Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med 211:2497-2505, 2014.
PubMed
8) Kataoka K, Nagata Y, Kitanaka A, et al:Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47:1304-1315, 2015.
PubMed
9) Yamagishi M, et al:Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun 12:4821, 2021.
PubMed
10) Yashiki S, Fujiyoshi T, Arima N, et al:HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia:the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 17:1047-1061, 2001.
PubMed
11) Satou Y, Miyazato P, Ishihara K, et al:The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome. Proc Natl Acad Sci USA 113:3054-3059, 2016.
PubMed
12) Matsuo M, Ueno T, Monde K, et al:Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Nat Commun 13:2405, 2022.
PubMed
13) Tan BJ, Sugata K, Reda O, et al:HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma. J Clin Invest 131:e150472, 2021.
PubMed
P.17 掲載の参考文献
1) 日本小児血液・がん学会:疾患登録 2017年診断症例集計. [https://www.jspho.org/pdf/2017.pdf]
 
2) Murphy SB:Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas:dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980.
PubMed
3) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
4) 古賀友紀, 熊谷昌明, 瀧本哲也, ほか:本邦における小児Hodgkinリンパ腫157例の後方視的検討. -小児がん研究4グループによる調査-. 臨床血液 53:443-449, 2012.
 
5) 日本小児血液・がん学会(編):小児血液・腫瘍学 改訂第2版, p513, 診断と治療社, 2022.
 
6) Bonn BR, Rohde M, Zimmermann M, et al:Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 121:3153-3160, 2013.
 
7) Pinkel D, Johnson W, Aur RJ:Non-Hodgkin's lymphoma in children. Br J Cancer Suppl 2:298-323, 1975.
PubMed
8) Reiter A, Schrappe M, Ludwig WD, et al:Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma:a BFM group report. Blood 95:416-421, 2000.
 
9) Sunami S, Sekimizu M, Takimoto T, et al:Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma:A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer 63:451-457, 2016.
 
10) Tsurusawa M, Mori T, Kikuchi A, et al:Improved treatment results of children with B-cell non-Hodgkin lymphoma:a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer 61:1215-1221, 2014.
 
11) Minard-Colin V, Auperin A, Pillon M, et al:Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med 382:2207-2219, 2020.
PubMed
12) Brugieres L, Le Deley MC, Rosolen A, et al:Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma:Results of a randomized trial of the EICNHL Group. J Clin Oncol 27:897-903, 2009.
 
13) Kobayashi R, Yamato K, Tanaka F, et al:Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer 54:212-215, 2010.
PubMed
14) Kobayashi R, Tanaka F, Nakazawa A, et al:Pediatric follicular lymphoma in Japan. Int J Hematol 105:849-853, 2017.
PubMed
P.20 掲載の参考文献
1) Ferlay J, Ervik M, Lam F, et al:Global Cancer Observatory:Cancer Today. International Agency for Research on Cancer, Lyon, 2020. [https://gco.iarc.fr/today].
 
2) Thandra KC, Barsouk A, Saginala K, et al:Epidemiology of Non-Hodgkin's Lymphoma. Med Sci(Basel) 9:5, 2021.
PubMed
3) Lavanchy D:Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115, 2011.
PubMed
4) Negro F, Alberti A:The global health burden of hepatitis C virus infection. Liver Int 31(Suppl 2):1-3, 2011.
 
5) Kuniyoshi M, Nakamuta M, Sakai H, et al:Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol 16:215-219, 2001.
PubMed
6) Negri E, Little D, Boiocchi M, et al:B-cell non-Hodgkin's lymphoma and hepatitis C virus infection:a systematic review. Int J Cancer 111:1-8, 2004.
PubMed
7) Matsuo K, Kusano A, Sugumar A, et al:Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma:a meta-analysis of epidemiological studies. Cancer Sci 95:745-752, 2004.
PubMed
8) Abe SK, Inoue M, Sawada N, et al:Hepatitis B and C virus infection and risk of lymphoid malignancies:A population-based cohort study(JPHC Study). Cancer Epidemiol 39:562-566, 2015.
 
P.26 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:Lymphomas associated with HIV infection. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed(ed by Swerdlow SH, Campo E, Harris NL, et al), P:449-452, IARC, Lyon, 2017.
 
2) Morlat P, Roussillon C, Henard S, et al:Causes of death among HIV-infected patients in France in 2010(national survey):trends since 2000. AIDS 28:1181-1191, 2014.
PubMed
3) Nishijima T, Inaba Y, Kawasaki Y, et al:Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan. AIDS34:913-921, 2020.
PubMed
4) Katano H, Hishima T, Mochizuki M, et al:The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan. BMC Infect Dis 14:229, 2014.
PubMed
5) Engels EA, Biggar RJ, Hall HI, et al:Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187-194, 2008.
PubMed
6) Carbone A, Vaccher E, Gloghini A:Hematologic cancers in individuals infected by HIV. Blood 139:995-1012, 2022.
PubMed
7) Raphael M, Said J, Borisch B, et al:Lymphomas associated with HIV infection. In:WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues(ed by Swerdlow SH, Campo E, Harris NL, et al), p340-342, IARC, Lyon, 2008.
 
8) Rubinstein PG, Aboulafia DM, Zloza A:Malignancies in HIV/AIDS:from epidemiology to therapeutic challenges. AIDS 28:453-465, 2014.
PubMed
9) Ambinder RF:Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer 37:1209-1216, 2001.
PubMed
10) Miuma S, Hidaka M, Takatsuki M, et al:Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan. Exp Ther Med 15:2148-2155, 2018.
PubMed
11) Schollkopf C, Smedby KE, Hjalgrim H, et al:Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 122:1885-1890, 2008.
PubMed
12) Besson C, Noel N, Lancar R, et al:Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. AIDS 34:599-608, 2020
PubMed
13) Housri N, Yarchoan R, Kaushal A:Radiotherapy for patients with the human immunodeficiencyvirus:are special precautions necessary? Cancer 116:273-283, 2010.
 
14) Nagai H, Odawara T, Ajisawa A, et al:Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 84:499-505, 2010.
PubMed
15) Kelly GL, Rickinson AB:Burkitt lymphoma:revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007:277-284, 2007.
PubMed
16) Kojima Y, Hagiwara S, Uehira T, et al:Clinical Outcomes of AIDS-related Burkitt Lymphoma:A Multi-institution Retrospective Survey in Japan. Jpn J Clin Oncol 44:318-323, 2014.
PubMed
17) Ota Y, Hishima T, Mochizuki M, et al:Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Med 3:143-153, 2014.
PubMed
18) Okada S, Goto H, Yotsumoto M:Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res 3:65-74, 2014.
PubMed
19) Hagiwara S, Nagai H, Tanaka J, et al:The current state of human immunodeficiency virus-associated lymphoma in Japan:a nationwide retrospective study of the Japanese Society of Hematology Blood Disease Registry. Int J Hematol 110:244-249, 2019.
PubMed
20) Castillo JJ, Bibas M, Miranda RN:The biology and treatment of plasmablastic lymphoma. Blood 125:2323-2330, 2015.
PubMed
21) Herida M, Mary-Krause M, Kaphan R, et al:Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447-3453, 2003.
 
22) Re A, Casari S, Cattaneo C, et al:Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 92:2739-2745, 2001.
 
23) Yotsumoto M, Hagiwara S, Ajisawa A, et al:Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan. Int J Hematol 96:247-253, 2012.
PubMed
24) Mahale P, Ugoji C, Engels EA, et al:Cancer risk following lymphoid malignancies among HIV-infected people. AIDS 34:1237-1245, 2020.
PubMed
P.31 掲載の参考文献
1) Swerdlow SH, Campo E, Pileri SA, et al:The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016.
PubMed
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) Miranda-Filho A, Pineros M, Znaor A, et al:Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control 30:489-499, 2019.
PubMed
4) Armitage JO, Gascoyne RD, Lunning MA, et al:Non-Hodgkin lymphoma. Lancet 390:298-310, 2017.
PubMed
5) 国立研究開発法人国立がん研究センター:がん情報サービス, 悪性リンパ腫. [https://ganjoho.jp/public/cancer/ML/index.html]
 
6) Siebert JD, Mulvaney DA, Vukov AM, et al:Utility of flow cytometry in subtyping composite and sequential lymphoma. J Clin Lab Anal 13:199-204, 1999.
PubMed
7) Acker B, Hoppe RT, Colby TV, et al:Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1:11-16, 1983.
PubMed
8) Al-Mansour M, Connors JM, Gascoyne RD, et al:Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 28:793-799, 010.
 
9) Kim H:Composite lymphoma and related disorders. Am J Clin Pathol 99:445-451, 1993.
PubMed
10) Niino D, My Hanh LT, Miura S, et al:Incidence Patterns of Sequential or Composite Lymphoma:A Population-Based Cancer Registry Study. Tohoku J Exp Med 254:123-127, 2021.
PubMed
11) Fritz A, Percy C, Jack A, et al:International Classification of Diseases for Oncology(ICD-O), 3rd ed, World Health Organization, Geneva(Switzerland), 2001.
 
12) Tucci A, Motta M, Ungari M, et al:The development of more than one histologic type of lymphomain the same patient is frequent and confers a worse prognosis. Haematologica 90:348-352, 2005.
 
13) Khristi J, Mey U, Kirfel J, et al:Sequential Hodgkin's and non-Hodgkin's lymphoma in non-immunocompromised patients. Ann Hematol 92:1565-1567, 2013.
PubMed
14) Aussedat G, Traverse-Glehen A, Stamatoullas A, et al:Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. Br J Haematol 189:244-256, 2020.
 
P.35 掲載の参考文献
1) Khanmohammadi S, Shabani M, Tabary M, et al:Lymphoma in the setting of autoimmune diseases:A review of association and mechanisms. Crit Rev Oncol Hematol 150:102945, 2020.
PubMed
2) Ekstrom Smedby K, Vajdic CM, Falster M, et al:Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes:a pooled analysis within the InterLymph Consortium. Blood 111:4029-4038, 2008.
PubMed
3) Kaiser R:Incidence of lymphoma in patients with rheumatoid arthritis:a systematic review of the literature. Clin Lymphoma Myeloma 8:87-93, 2008.
PubMed
4) Baecklund E, Iliadou A, Askling J, et al:Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692-701, 2006.
 
5) Lofstrom B, Backlin C, Sundstrom C, et al:A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort:a nested case-control study. Ann Rheum Dis66:1627-1632, 2007.
 
6) Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, et al:Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 41:415-423, 2011.
PubMed
7) Goules AV, Argyropoulou OD, Pezoulas VC, et al:Primary Sjogren's Syndrome of Early and Late Onset:Distinct Clinical Phenotypes and Lymphoma Development. Front Immunol 11:594096, 2020.
PubMed
8) Cornec D, Devauchelle-Pensec V, Tobon GJ, et al:B cells in Sjogren's syndrome:from patho-physiology to diagnosis and treatment. J Autoimmun 39:161-167, 2012.
 
9) Hansen A, Reiter K, Pruss A, et al:Dissemination of a Sjogren's syndrome-associated extranodal marginal-zone B cell lymphoma:circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy-and light-chain variable-region gene rearrangements. Arthritis Rheum 54:127-137, 2006.
PubMed
10) Baecklund E, Smedby KE, Sutton LA, et al:Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces? Semin Cancer Biol 24:61-70, 2014.
PubMed
11) Tsai HF, Hsu PN:Interplay between Helicobacter pylori and immune cells in immune pathogenesis of gastric inflammation and mucosal pathology. Cell Mol Immunol 7:255-259, 2010.
PubMed
12) Kuo SH, Yeh KH, Chen LT, et al:Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach:a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J 4:e220, 2014.
 
13) Bizjak M, Selmi C, Praprotnik S, et al:Silicone implants and lymphoma:The role of inflammation. J Autoimmun 65:64-73, 2015.
 
14) Alotaibi S, Hamadani M, Al-Mansour M, et al:Breast Implant-associated Anaplastic Large Cell Lymphoma. Clin Lymphoma Myeloma Leuk 21:e272-e276, 2021.
PubMed
15) U. S. Food and Drug Administration:Anaplastic Large Cell Lymphoma(ALCL) In Women with Breast Implants:Preliminary FDA Findings and Analysis. 2011.
 
16) Kim B, Predmore ZS, Mattke S, et al:Breast implant-associated anaplastic large cell lymphoma:updated results from a structured expert consultation process. Plast Reconstr Surg Glob Open 3:e296, 2015.
PubMed
P.39 掲載の参考文献
1) Kerzin-Storrar L, Faed MJ, MacGillivray JB, et al:Incidence of familial Hodgkin's disease. Br J Cancer 47:707-712, 1983.
PubMed
2) Alligon M, Mahlaoui N, Courteille V, et al:An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies:A study of a national retrospective cohort of 1375 patients over 10 years. J Allergy Clin Immunol 149:2116-2125, 2022.
PubMed
3) Morio T:Common variable immunodeficiency:the spectrum of disease manifestations and molecular basis of the disorder. Rinsho Ketsueki 54:1983-1991, 2013.
PubMed
4) Egg D, Schwab C, Gabrysch A, et al:Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. Front Immunol 9:2012, 2018.
PubMed
5) Bougeard G, Renaux-Petel M, Flaman JM, et al:Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol 33:2345-2352, 2015.
PubMed
6) Ripperger T, Schlegelberger B:Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur J Med Genet 59:133-142, 2016.
PubMed
7) Wang SS, Vajdic CM, Linet MS, et al:B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. Cancer Epidemiol Biomarkers Prev 31:1103-1110, 2022.
PubMed
8) Cerhan JR, Slager SL:Familial predisposition and genetic risk factors for lymphoma. Blood 126:2265-2273, 2015.
PubMed
9) Skibola CF, Curry JD, Nieters A:Genetic susceptibility to lymphoma. Haematologica 92:960-969, 2007.
PubMed
10) Cerhan JR, Berndt SI, Vijai J, et al:Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 46:1233-1238, 2014.
PubMed
11) Skibola CF, Berndt SI, Vijai J, et al:Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am J Hum Genet 95:462-471, 2014.
PubMed
12) Vijai J, Wang Z, Berndt SI, et al:A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nat Commun 6:5751, 2015.
 
13) Cozen W, Timofeeva MN, Li D, et al:A meta-analysis of Hodgkin lymphoma reveals 19p13. 3 TCF3 as a novel susceptibility locus. Nat Commun 5:3856, 2014.
 
14) Sud A, Thomsen H, Orlando G, et al:Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. Blood 132:2040-2052, 2018.
PubMed
15) Chen C, Song N, Dong Q, et al:Association of Single-Nucleotide Variants in the Human Leukocyte Antigen and Other Loci With Childhood Hodgkin Lymphoma. JAMA Netw Open 5:e2225647, 2022.
PubMed
P.45 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. IARC Press, Lyon, 2017.
 
2) Takehana CS, Twist CJ, Mosci C, et al:(18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. Nucl Med Commun 35:276-281, 2014.
PubMed
3) Natkunam Y, Gratzinger D, Chadburn A, et al:Immunodeficiency-associated lymphoproliferativedisorders:time for reappraisal? Blood 132:1871-1878, 2018.
 
4) Dierickx D, Habermann TM:Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med 378:549-562, 2018.
PubMed
5) Fujimoto A, Hiramoto N, Yamasaki S, et al:Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Bio Blood Marrow Transplant 25:1441-1449, 2019.
 
6) Petrara MR, Giunco S, Serraino D, et al:Post-transplant lymphoproliferative disorders:from epidemiology to pathogenesis-driven treatment. Cancer Lett 369:37-44, 2015.
PubMed
7) van der Velden WJFM, Mori T, Stevens WBC, et al:Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant 48:1465-1471, 2013.
PubMed
8) Dierickx D, Tousseyn T, Gheysens O:How I treat posttransplant lymphoproliferative disorders. Blood 126:2274-2283, 2015.
 
9) Choquet S, Leblond V, Herbrecht R, et al:Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:results of a prospective multicenter phase 2 study. Blood 107:3053-3057, 2006.
 
10) Trappe RU, Dierickx D, Zimmermann H, et al:Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter Phase II trial. J Clin Oncol 35:536-543, 2017.
 
11) Schiefer AI, Salzer E, Fureder A, et al:PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease(PTLD) of childhood and adolescence:An inter-and intra-individual descriptive study covering the whole spectrum of PTLD categories. Cancer Med 8:4656-4668, 2019.
PubMed
12) Vase MO, Maksten EF, Bendix K, et al:Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. Leuk Lymphoma 56:1677-1685, 2015.
PubMed
13) Evens AM, David KA, Helenowski I, et al:Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease:outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038-1046, 2010.
PubMed
14) Ricciardelli I, Blundell MP, Brewin J, et al:Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 124:2514-2522, 2014.
PubMed
15) Luttwak E, Hagin D, Perry C, et al:Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series. Bone Marrow Transplant 56:1031-1037, 2021.
PubMed
P.50 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and lymphoid Tissues, Revised 4th Edition, IARC Press, Lyon, 2017.
 
2) リウマトレックス適正使用情報 vol.27, 重篤な副作用及び死亡症例の発現状況. ファイザー株式会社, 2021.
 
3) 関節リウマチ関連リンパ増殖性疾患の診断と管理の手引き(3学会合同RA関連LPDワーキンググループ(日本リウマチ学会, 日本血液学会, 日本病理学会)編), 羊土社, 2022.
 
4) Kurita D, Miyoshi H, Ichikawa A, et al:Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis:Clinicopathologic Features and Prognostic Factors. Am J Surg Pathol 43:869-884, 2019.
PubMed
5) Zintzaras E, Voulgarelis M, Moutsopoulos HM:The risk of lymphoma development in autoimmune diseases:a meta-analysis. Arch Intern Med 165:2337-2344, 2005.
PubMed
6) Hashimoto A, Chiba N, Tsuno H, et al:Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 42:564-571, 2015.
 
7) Kameda T, Dobashi H, Miyatake N, et al:Association of higher methotrexate dose with lymproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res(Hoboken) 66:1302-1309, 2014.
 
8) Harada T, Iwasaki H, Muta T, et al:Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Br JHaematol 194:101-110, 2021.
PubMed
9) Hemminki K, Li X, Sundquist K, et al:Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology(Oxford) 47:698-701, 2008.
PubMed
10) Di M, Huntington SF, Olszewski AJ:Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. Oncologist 26:120-132, 2021.
PubMed
11) Castillo JJ, Beltran BE, Miranda RN, et al:EBV-positive diffuse large B-cell lymphoma, not otherwise specified:2018 update on diagnosis, risk-stratification and management. Am J Hematol 93:953-962, 2018.
 
12) Wolfe F:Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis:a 25-year study of 1, 767 RA patients. Arthritis Rheum 41(Suppl):931S, 1998.
 
13) Yamakawa N, Fujimoto M, Kawabata D, et al:A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 41:293-299, 2014.
PubMed
14) Takada H, Kaneko Y, Nakano K, et al:Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan:A retrospective, multicenter, descriptive study. Mod Rheumatol 32:32-40, 2022.
PubMed
15) Kuramoto N, Saito S, Fujii T, et al:Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course:A retrospective, multicenter, case-control study. Mod Rheumatol 32:24-31, 2022.
PubMed

[II] 悪性リンパ腫の分子腫瘍学的異常・病態形成機序

P.57 掲載の参考文献
1) Marti GE, Rawstron AC, Ghia P, et al:Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 130:325-332, 2005.
PubMed
2) Landgren O, Albitar M, Ma W, et al:B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 360:659-667, 2009.
 
3) Lanasa MC, Allgood SD, Volkheimer AD, et al:Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia 24:133-140, 2010.
PubMed
4) Sanchez ML, Almeida J, Gonzalez D, et al:Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood 102:2994-3002, 2003.
 
5) Kikushige Y, Ishikawa F, Miyamoto T, et al:Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20:246-259, 2011.
PubMed
6) Damm F, Mylonas E, Cosson A, et al:Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4:1088-1101, 2014.
PubMed
7) Quijada-Alamo M, Hernandez-Sanchez M, Robledo C, et al:Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. J Hematol Oncol 10:83, 2017.
PubMed
8) Zenz T, Mertens D, Kuppers R, et al:From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50, 2010.
PubMed
9) Fabbri G, Dalla-Favera R:The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer 16:145-162, 2016.
PubMed
10) Landau DA, Tausch E, Taylor-Weiner AN, et al:Mutations driving CLL and their evolution in progression and relapse. Nature 526:525-530, 2015.
PubMed
11) Burger JA, Chiorazzi N:B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34:592-601, 2013.
PubMed
12) Hoogeboom R, van Kessel KP, Hochstenbach F, et al:A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 210:59-70, 2013.
PubMed
13) Kostareli E, Gounari M, Janus A, et al:Antigen receptor stereotypy across B-cell lymphoprolifera-tions:the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia 26:1127-1131, 2012.
 
14) Hoogeboom R, Wormhoudt TA, Schipperus MR, et al:A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient. Leukemia 27:738-740, 2013.
PubMed
15) Herve M, Xu K, Ng YS, et al:Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115:1636-1643, 2005.
PubMed
16) Chu CC, Catera R, Hatzi K, et al:Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112:5122-5129, 2008.
PubMed
17) Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al:A new perspective:molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 111:3838-3848, 2008.
 
18) Duhren-von Minden M, Ubelhart R, Schneider D, et al:Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489:309-312, 2012.
PubMed
19) Tsujimoto Y, Cossman J, Jaffe E, et al:Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985.
PubMed
20) McDonnell TJ, Deane N, Platt FM, et al:bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88, 1989.
PubMed
21) Cimmino A, Calin GA, Fabbri M, et al:miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944-13949, 2005.
PubMed
22) Klein U, Lia M, Crespo M, et al:The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:28-40, 2010.
PubMed
P.62 掲載の参考文献
1) Alaggio R, et al:The 5th edition of the World Health Organization Classification of Hematolymphoid Tumors:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
 
2) Campo E, et al:The International Consensus classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
3) Treon SP, Xu L, Yang G, et al:MYD88 L265P somatic mutation in Waldenstrom's macroglobuline-mia. N Engl J Med 367:826-833, 2012.
 
4) Bonnert TP, Garka KE, Parnet P, et al:The cloning and characterization of human MyD88:a member of an IL-1 receptor related family. FEBS Lett 402:81-84, 1997.
 
5) Ngo VN, Young RM, Schmitz R, et al:Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-119, 2011.
PubMed
6) Watters TM, Kenny EF, O'Neill LA:Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 85:411-419, 2007.
PubMed
7) Lam LT, Wright G, Davis RE, et al:Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713, 2008.
 
8) Poulain S, Roumier C, Venet-Caillault A, et al:Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. Clin Cancer Res 22:1480-1488, 2016.
PubMed
9) Treon SP, Tripsas CK, Meid K, et al:Ibrutinib in previously treated Waldenstroms macroglobuline-mia N Engl J Med 372:1430-1440, 2015.
 
10) Poulain S, Roumier C, Bertrand E, et al:TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clin Cancer Res 23:6325-6335, 2017.
PubMed
11) Sekiguchi N, Nomoto J, Nagata A, et al:Gene expression profile signature of aggressive Waldenstrom macroglobulinemia with chromosome 6q deletion. Biomed Res Int 2018:6728128, 2018.
PubMed
12) Dimopoulos MA, Kastritis E, Owen RG, et al:Treatment recommendations for patients with Waldenstrom macroglobulinemia(WM) and related disorders:IWWM-7 consensus. Blood 124:1404-1411, 2014.
PubMed
13) Owen RG, Kyle RA, Stone MJ, et al:Response assesment in Waldenstrom macroglobulinemia:update from the VIth International Workshop. Br J Haematol 160:171-176, 2013.
 
14) Kastritis E, Morel P, Duhamel A, et al:A revised international prognostic score system for Waldenstrom's macroglobulinemia. Leukemia 33:2654-2661, 2019.
PubMed
P.69 掲載の参考文献
1) Nadeu F, Martin-Garcia D, Clot G, et al:Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 136:1419-1432, 2020.
PubMed
2) Chen RW, Bemis LT, Amato CM, et al:Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 112:822-829, 2008.
PubMed
3) Chinen Y, Tsukamoto T, Maegawa-Matsui S, et al:Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities. Exp Hematol 84:45-53. e1, 2020.
 
4) Palomero J, Vegliante MC, Rodriguez ML, et al:SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood 124:2235-2247, 2014.
PubMed
5) Vegliante MC, Palomero J, Perez-Galan P, et al:SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 121:2175-2185, 2013.
PubMed
6) Balsas P, Palomero J, Eguileor A, et al:SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood 130:501-513, 2017.
PubMed
7) Kuo PY, Jatiani SS, Rahman AH, et al:SOX11 augments BCR signaling to drive MCL-like tumor development. Blood 131:2247-2255, 2018.
PubMed
8) Vilarrasa-Blasi R, Verdaguer-Dot N, Belver L, et al:Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia 36:583-587, 2022.
PubMed
9) Mohanty A, Sandoval N, Phan A, et al:Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood 133:306-318, 2019.
PubMed
10) Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, et al:Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. Cancer Med 9:5185-5199, 2020.
 
11) Thurner L, Fadle N, Bittenbring JT, et al:LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. Blood 137:3251-3258, 2021.
PubMed
12) Queiros AC, Beekman R, Vilarrasa-Blasi R, et al:Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. Cancer Cell 30:806-821, 2016.
PubMed
13) Agarwal R, Chan YC, Tam CS, et al:Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med 25:119-129, 2019.
PubMed
14) Chiron D, Bellanger C, Papin A, et al:Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood 128:2808-2818, 2016.
PubMed
15) Balsas P, Veloza L, Clot G, et al:SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood 138:2202-2215, 2021.
PubMed
P.74 掲載の参考文献
1) Carbone A, Roulland S, Gloghini A, et al:Follicular lymphoma. Nat Rev Dis Primers 5:83, 2019.
PubMed
2) Beguelin W, Teater M, Meydan C, et al:Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell 37:655-673. e11, 2020.
 
3) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
4) Otsuka Y, Nishikori M, Arima H, et al:EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol 119:35-45, 2020.
 
5) Solal-Celigny P, Lepage E, Brousse N, et al:Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas:final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16:2332-2338, 1998.
 
6) Marcus R, Davies A, Ando K, et al:Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 377:1331-1344, 2017.
PubMed
7) Leonard JP, Trneny M, Izutsu K, et al:AUGMENT:A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J ClinOncol 37:1188-1199, 2019.
PubMed
8) Morschhauser F, Tilly H, Chaidos A, et al:Tazemetostat for patients with relapsed or refractory follicular lymphoma:an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21:1433-1442, 2020.
PubMed
9) Alonso-Alvarez S, Manni M, Montoto S, et al:Primary refractory follicular lymphoma:a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. Eur J Cancer 157:132-139, 2021.
PubMed
10) Link BK, Maurer MJ, Nowakowski GS, et al:Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era:a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272-3278, 2013.
 
11) Kridel R, Chan FC, Mottok A, et al:Histological Transformation and Progression in Follicular Lymphoma:A Clonal Evolution Study. PLoS Med 13:e1002197, 2016.
PubMed
12) Freeman CL, Kridel R, Moccia AA, et al:Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134:761-764, 2019.
PubMed
13) Mozas P, Nadeu F, Rivas-Delgado A, et al:Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades:a single-center experience. Blood Cancer J 10:31, 2020.
PubMed
14) Bolen CR, Mattiello F, Herold M, et al:Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood 137:2704-2707, 2021.
PubMed
15) Haebe S, Shree T, Sathe A, et al:Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. Blood 137:2869-2880, 2021.
PubMed
P.80 掲載の参考文献
1) Swerdlow SH, Campo E, Pileri SA, et al:The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016.
PubMed
2) Alizadeh AA, Eisen MB, Davis RE, et al:Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.
PubMed
3) Rosenwald A, Wright G, Chan WC, et al:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002.
PubMed
4) Lenz G, Wright G, Dave SS, et al:Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008.
 
5) Scott DW, Wright GW, Williams PM, et al:Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214-1217, 2014.
PubMed
6) Scott DW, Mottok A, Ennishi D, et al:Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol 33:2848-2856, 2015.
PubMed
7) Ennishi D, Jiang A, Boyle M, et al:Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 37:190-201, 2019.
PubMed
8) Sha C, Barrans S, Cucco F, et al:Molecular High-Grade B-Cell Lymphoma:Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol 37:202-212, 2019.
PubMed
9) Scott DW, King RL, Staiger AM, et al:High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060-2064, 2018.
PubMed
10) Ennishi D, Mottok A, Ben-Neriah S, et al:Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood 129:2760-2770, 2017.
PubMed
11) Chong LC, Ben-Neriah S, Slack GW, et al:High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv 2:2755-2765, 2018.
PubMed
12) Jamal-Hanjani M, Wilson GA, McGranahan N, et al:Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med 376:2109-2121, 2017.
PubMed
13) Pasqualucci L, Trifonov V, Fabbri G, et al:Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43:830-837, 2011.
PubMed
14) Morin RD, Mendez-Lago M, Mungall AJ, et al:Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303, 2011.
PubMed
15) Lohr JG, Stojanov P, Lawrence MS, et al:Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma(DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 109:3879-3884, 2012.
PubMed
16) Roschewski M, Staudt LM, Wilson WH:Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11:12-23, 2014.
PubMed
17) Basso K, Dalla-Favera R:Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15:172-184, 2015.
 
18) Boice M, Salloum D, Mourcin F, et al:Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell 167:405-418. e13, 2016.
 
19) Muppidi JR, Schmitz R, Green JA, et al:Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature 516:254-258, 2014.
 
20) Pfeifer M, Grau M, Lenze D, et al:PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:12420-12425, 2013.
PubMed
21) Teater M, Dominguez PM, Redmond D, et al:AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat Commun 9:222, 2018.
PubMed
22) Ennishi D, Mottok A, Ben-Neriah S, et al:Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood 129:2760-2770, 2017.
PubMed
23) Chapuy B, Stewart C, Dunford AJ, et al:Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679-690, 2018.
PubMed
24) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
25) Wright GW, Huang DW, Phelan JD, et al:A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37:551-568. e14, 2020.
 
26) Lacy SE, Barrans SL, Beer PA, et al:Targeted sequencing in DLBCL, molecular subtypes, and outcomes:a Haematological Malignancy Research Network report. Blood 135:1759-1771, 2020.
 
27) Ennishi D, Hsi ED, Steidl C, et al:Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. Cancer Discov 10:1267-1281, 2020.
 
28) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
29) Ennishi D, Healy S, Bashashati A, et al:TMEM30A loss-of-function mutations drive lymphomagene-sis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med 26:577-588, 2020.
 
P.86 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed(ed by Swerdllow S, Campo E, Harris NL, et al), IARC, Lyon, 2017.
 
2) Chiba S, Sakata-Yanagimoto M:Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia 34:2592-2606, 2020.
PubMed
3) Sakata-Yanagimoto M, Enami T, Yoshida K, et al:Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171-175, 2014.
PubMed
4) Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al:Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia 32:694-702, 2018.
PubMed
5) Sakata-Yanagimoto M:Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol 102:523-527, 2015.
PubMed
6) Nguyen TB, Sakata-Yanagimoto M, Asabe Y, et al:Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J 7:e516, 2017.
PubMed
7) Dobson R, Du PY, Raso-Barnett L, et al:Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. Haematologica 107:489-499, 2022.
 
8) Nagao R, Kikuti YY, Carreras J, et al:Clinicopathologic Analysis of Angioimmunoblastic T-cell Lymphoma With or Without RHOA G17V Mutation Using Formalin-fixed Paraffin-embeddedSections. Am J Surg Pathol 40:1041-1050, 2016.
PubMed
9) Ondrejka SL, Grzywacz B, Bodo J, et al:Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. Am J Surg Pathol 40:335-341, 2016.
PubMed
10) Nguyen PN, Tran NTB, Nguyen TPX, et al:Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma:A Meta-analysis:RHOA mutations in AITL. ClinLymphoma Myeloma Leuk 21:431-438, 2021.
PubMed
11) Steinhilber J, Mederake M, Bonzheim I, et al:The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. Mod Pathol 32:1123-1134, 2019.
PubMed
12) Muto H, Sakata-Yanagimoto M, Nagae G, et al:Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J 4:e264, 2014.
 
13) Nishizawa S, Sakata-Yanagimoto M, Hattori K, et al:BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. Int J Hematol 105:465-469, 2017.
PubMed
14) Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, et al:Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. Cancer Res 80:1875-1884, 2020.
PubMed
15) Fujisawa M, Nguyen TB, Abe Y, et al:Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood 140:1937-1950, 2022.
 
P.94 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Chihara D, Ito H, Matsuda T, et al:Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164:536-545, 2014.
PubMed
3) Ng SY, Yoshida N, Christie AL, et al:Targetable vulnerabilities in T-and NK-cell lymphomas identified through preclinical models. Nat Commun 9:2024, 2018.
 
4) Parrilla Castellar ER, Jaffe ES, Said JW, et al:ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473-1480, 2014.
PubMed
5) Iqbal J, Wright G, Wang C, et al:Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915-2923, 2014.
PubMed
6) Amador C, Greiner TC, Heavican TB, et al:Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 134:2159-2170, 2019.
PubMed
7) Heavican TB, Bouska A, Yu J, et al:Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 133:1664-1676, 2019.
PubMed
8) Herek TA, Bouska A, Lone W, et al:DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood 140:1278-1290, 2022.
PubMed
9) Wai CMM, Chen S, Phyu T, et al:Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica 107:1864-1879, 2022.
PubMed
10) Sakata-Yanagimoto M, Fukumoto K, Karube K, et al:Molecular understanding of peripheral T-cell lymphomas, not otherwise specified(PTCL, NOS):A complex disease category. J Clin Exp Hematop 61:61-70, 2021.
PubMed
11) Ghione P, Faruque P, Mehta-Shah N, et al:T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv 4:4640-4647, 2020.
PubMed
12) Watatani Y, Sato Y, Miyoshi H, et al:Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia 33:2867-2883, 2019.
 
13) Sugio T, Miyawaki K, Kato K, et al:Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv 2:2242-2252, 2018.
PubMed
14) Yoshida N, Nishikori M, Izumi T, et al:Primary peripheral T-cell lymphoma, not otherwise specified of the thyroid with autoimmune thyroiditis. Br J Haematol 161:214-223, 2013.
 
P.101 掲載の参考文献
1) Matsuoka M, Jeang KT:Human T-cell leukaemia virus type 1(HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7:270-280, 2007.
PubMed
2) Cook LB, Fuji S, Hermine O, et al:Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 37:677-687, 2019.
PubMed
3) Ishitsuka K, Tamura K:Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 15:e517-e526, 2014.
PubMed
4) Kataoka K, Nagata Y, Kitanaka A, et al:Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47:1304-1315, 2015.
PubMed
5) Kogure Y, Kameda T, Koya J, et al:Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood 139:967-982, 2022.
PubMed
6) Fujikawa D, Nakagawa S, Hori M, et al:Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood 127:1790-1802, 2016.
PubMed
7) Kataoka K, Shiraishi Y, Takeda Y, et al:Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534:402-406, 2016.
PubMed
8) Rowan AG, Dillon R, Witkover A, et al:Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. Blood 135:2023-2032, 2020.
PubMed
9) Stoeckius M, Hafemeister C, Stephenson W, et al:Simultaneous epitope and transcriptome measurement in single cells. Nat Methods 14:865-868, 2017.
PubMed
10) Koya J, Saito Y, Kameda T, et al:Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discov 2:450-467, 2021.
PubMed
11) Kobayashi S, Nakano K, Watanabe E, et al:CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res 20:2851-2861, 2014.
PubMed
12) Satou Y, Utsunomiya A, Tanabe J, et al:HTLV-1 modulates the frequency and phenotype of FoxP3+ CD4+ T cells in virus-infected individuals. Retrovirology 9:46, 2012.
PubMed
13) Kawashima M, Carreras J, Higuchi H, et al:PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia 34:2405-2417, 2020.
PubMed
14) Yamagishi M, Kubokawa M, Kuze Y, et al:Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun 12:4821, 2021.
PubMed
15) Tan BJ, Sugata K, Reda O, et al:HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma. J Clin Invest 131:e150472, 2021.
PubMed
P.106 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(Revised 4th edition), IARC, Lyon, 2017.
 
2) Brice P, de Kerviler E, Friedberg JW:Classical Hodgkin lymphoma. Lancet 398:1518-1527, 2021.
PubMed
3) Kuppers R, Engert A, Hansmann ML:Hodgkin lymphoma. J Clin Invest 122:3439-3447, 2012.
PubMed
4) Kapatai G, Murray P:Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol 60:1342-1349, 2007.
 
5) Weniger MA, Kuppers R:NF-κB deregulation in Hodgkin lymphoma. Semin Cancer Biol 39:32-39, 2016.
 
6) Joos S, Kupper M, Ohl S, et al:Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549-552, 2000.
PubMed
7) Green MR, Monti S, Rodig SJ, et al:Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010.
 
8) Roemer MGM, Redd RA, Cader FZ, et al:Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950, 2018.
PubMed
9) Carey CD, Gusenleitner D, Lipschitz M, et al:Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420-2430, 2017.
PubMed
10) Reinke S, Brockelmann PJ, Iaccarino I, et al:Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood 136:2851-2863, 2020.
 
11) Cader FZ, Hu X, Goh WL, et al:A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med 26:1468-1479, 2020.
 
12) Nagasaki J, Togashi Y, Sugawara T, et al:The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv 4:4069-4082, 2020.
PubMed
13) Kawashima M, Carreras J, Higuchi H, et al:PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia 34:2405-2417, 2020.
PubMed
14) Ho WT, Pang WL, Chong SM, et al:Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res 73:652-661, 2013.
PubMed
P.111 掲載の参考文献
1) Epstein MA, Barr YM:Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. Lancet 1:252-253, 1964.
 
2) Henle G, Henle W, Diehl V:Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci USA 59:94-101, 1968.
PubMed
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Montes-Mojarro IA, Fend F, Quintanilla-Martinez L:EBV and the Pathogenesis of NK/T Cell Lymphoma. Cancers(Basel) 13:1414, 2021.
 
5) Okuno Y, Murata T, Sato Y, et al:Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4:404-413, 2019.
PubMed
6) Peng RJ, Han BW, Cai QQ, et al:Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. Leukemia 33:1451-1462, 2019.
PubMed
7) Iizasa H, Wulff BE, Alla NR, et al:Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 285:33358-33370, 2010.
PubMed
8) Fischer E, Delibrias C, Kazatchkine MD:Expression of CR2(the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 146:865-869, 1991.
 
9) Arai A:Chronic Active Epstein-Barr Virus Infection:The Elucidation of the Pathophysiology and the Development of Therapeutic Methods. Microorganisms 9:180, 2021.
PubMed
10) Anagnostopoulos I, Hummel M, Kreschel C, et al:Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis:implications for the interindividual infection route of Epstein-Barr virus. Blood 85:744-750, 1995.
PubMed
11) Nomura K, Kanegane H, Otsubo K, et al:Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. Int J Hematol 93:760-764, 2011.
PubMed
12) Bi XW, Wang H, Zhang WW, et al:PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol 9:109, 2016.
 
13) Kataoka K, Miyoshi H, Sakata S, et al:Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 33:1687-1699, 2019.
PubMed
14) Yoshimori M, Shibayama H, Imadome KI, et al:Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. Blood Adv 5:1805-1815, 2021.
PubMed
15) Nakamura M, Iwata S, Kimura H, et al:Elevated expression of activation-induced cytidine deaminase in T and NK cells from patients with chronic active Epstein-Barr virus infection. Eur J Dermatol 21:780-782, 2011.
 
P.117 掲載の参考文献
1) Aoki T, Chong LC, Takata K, et al:Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Cancer Discov 10:406-421, 2020.
PubMed
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) de Charette M, Houot R:Hide or defend, the two strategies of lymphoma immune evasion:potential implications for immunotherapy. Haematologica 103:1256-1268, 2018.
PubMed
4) Lamaison C, Tarte K:B cell/stromal cell crosstalk in health, disease, and treatment:Follicular lymphoma as a paradigm. Immunol Rev 302:273-285, 2021.
PubMed
5) Kumar E, Pickard L, Okosun J:Pathogenesis of follicular lymphoma:genetics to the microenviron-ment to clinical translation. Br J Haematol 194:810-821, 2021.
 
6) Scott DW, Gascoyne RD:The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14:517-534, 2014.
 
7) Miyawaki K, Sugio T:Lymphoma Microenvironment in DLBCL and PTCL-NOS:the key to uncovering heterogeneity and the potential for stratification. J Clin Exp Hematop 62:127-135, 2022.
PubMed
8) Kotlov N, Bagaev A, Revuelta MV, et al:Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov 11:1468-1489, 2021.
PubMed
9) Miyawaki K, Kato K, Sugio T, et al:A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. Blood Adv 6:2388-2402, 2022.
PubMed
10) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
11) Kiyasu J, Miyoshi H, Hirata A, et al:Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193-2201, 2015.
PubMed
12) McCord R, Bolen CR, Koeppen H, et al:PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv 3:531-540, 2019.
PubMed
13) Griffin GK, Weirather JL, Roemer MGM, et al:Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood 137:1353-1364, 2021.
 
14) Sugio T, Miyawaki K, Kato K, et al:Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv 2:2242-2252, 2018.
PubMed
15) Fujisawa M, Nguyen TB, Abe Y, et al:Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood 140:1937-1950, 2022.
 

[III] 悪性リンパ腫の診断概論

P.126 掲載の参考文献
1) Swerdlow SH, Campo E, Arber DA, et al:Response to "The WHO classification of haematolymphoid tumours"(Editorial). Leukemia 36:2748-2749, 2022.
 
2) Cree IA:The WHO Classification of Haematolymphoid Tumours. Leukemia 36:1701-1702, 2022.
PubMed
3) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
4) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
5) Carlsen ED, Swerdlow SH, Cook JR, et al:Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases. Am J Surg Pathol 43:1403-1412, 2019.
PubMed
6) Willemze R, Cerroni L, Kempf W, et al:The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133:1703-1714, 2019.
PubMed
7) Maurus K, Appenzeller S, Roth S, et al:Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. J Invest Dermatol 138:1573-1581, 2018.
PubMed
8) Takeuchi K, Yokoyama M, Ishizawa S, et al:Lymphomatoid gastropathy:a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 116:5631-5637, 2010.
PubMed
9) Mansoor A, Pittaluga S, Beck PL, et al:NK-cell enteropathy:a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma:clinicopathologic features and follow-up in a unique caseseries. Blood 117:1447-1452, 2011.
 
10) Xiao W, Gupta GK, Yao J, et al:Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood 134:986-991, 2019.
PubMed
11) Asano N, Suzuki R, Kagami Y, et al:Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29:1284-1293, 2005.
PubMed
12) Takahashi E, Asano N, Li C, et al:Nodal T/NK-cell lymphoma of nasal type:a clinicopathological study of six cases. Histopathology 52:585-596, 2008.
PubMed
13) Kato S, Takahashi E, Asano N, et al:Nodal cytotoxic molecule(CM)-positive Epstein-Barr virus(EBV)-associated peripheral T cell lymphoma(PTCL):a clinicopathological study of 26 cases. Histopathology 61:186-199, 2012.
PubMed
14) Hori J, Yamaguchi T, Keino H, et al:Immune privilege in corneal transplantation. Prog Retin Eye Res 72:100758, 2019.
PubMed
15) Booman M, Douwes J, Legdeur MC, et al:From brain to testis:immune escape and clonal selection in a B cell lymphoma with selective outgrowth in two immune sanctuaries [correction of sanctuariesy]. Haematologica 92:e69-71, 2007.
 
16) Ascoli V, Lo Coco F, Torelli G, et al:Human herpesvirus 8-associated primary effusion lymphoma in HIV--patients:a clinicopidemiologic variant resembling classic Kaposi's sarcoma. Haematologica 87:339-343, 2002.
PubMed
17) Kaji D, Ota Y, Sato Y, et al:Primary human herpesvirus 8-negative effusion-based lymphoma:a large B-cell lymphoma with favorable prognosis. Blood Adv 4:4442-4450, 2020.
 
18) Marafioti T, Jones M, Facchetti F, et al:Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 102:2868-2876, 2003.
 
19) Traverse-Glehen A, Pittaluga S, Gaulard P, et al:Mediastinal gray zone lymphoma:the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29:1411-1421, 2005.
 
20) Sarkozy C, Hung SS, Chavez EA, et al:Mutational landscape of gray zone lymphoma. Blood 137:1765-1776, 2021.
PubMed
21) Ishigaki T, Isobe M, Kobayashi S, et al:Development of peripheral T-cell lymphoma not otherwise specified in an HTLV-1 carrier. Int J Hematol 97:667-672, 2013.
PubMed
22) Takatori M, Sakihama S, Miyara M, et al:A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia/lymphoma:combination of RNA in situ hybridization and quantitative PCR for HTLV-1. Mod Pathol 34:51-58, 2021.
PubMed
P.132 掲載の参考文献
1) 田丸淳一:病理診断. 日本内科学会雑誌 97:1537-1545, 2008.
 
2) 田丸淳一:リンパ節生検時期, 方法, 部位の選択. 日本臨牀 73:302-305, 2015.
 
3) ゲノム研究用病理組織検体取扱い規程(日本病理学会ゲノム病理組織取扱い規約委員会/ゲノム研究用試料に関する病理組織検体取扱いガイドライン審議会), 2016. [https://pathology.or.jp/genome/index.html]
 
4) Tamaru J, Hummel M, Zemlin M, et al:Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 84:708-715, 1994.
 
5) Adam P, Baumann R, Schmidt J, et al:The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade1/2 follicular lymphomas. Hum Pathol 44:1817-1826, 2013.
 
6) Mozos A, Royo C, Hartmann E, et al:SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94:1555-1562, 2009.
PubMed
7) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
8) Ventura RA, Martin-Subero JI, Jones M, et al:FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 8:141-151, 2006.
 
9) Riedell PA, Smith SM:Double hit and double expressors in lymphoma:Definition and treatment. Cancer 124:4622-4632, 2018.
PubMed
P.141 掲載の参考文献
1) Tsai AG, Engelhart AE, Hatmal MM, et al:Conformational variants of duplex DNA correlated with cytosine-rich chromosomal fragile sites. J Biol Chem 284:7157-7164, 2009.
 
2) Tsai AG, Lu H, Raghavan SC, et al:Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135:1130-1142, 2008.
 
3) Matsumoto Y, Nomura K, Matsumoto S, et al:Detection of t(14;18) in follicular lymphoma by dual-color fluorescence in situ hybridization on paraffin-embedded tissue sections. Cancer Genet Cytogenet 150:22-26, 2004.
PubMed
4) Raghavan SC, Chastain P, Lee JS, et al:Evidence for a triplex DNA conformation at the bcl-2 major breakpoint region of the t(14;18) translocation. J Biol Chem 280:22749-22760, 2005.
 
5) Nambiar M, Goldsmith G, Moorthy BT, et al:Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma. Nucleic Acids Res 39:936-948, 2011.
 
6) Javadekar SM, Yadav R, Raghavan SC:DNA structural basis for fragility at peak III of BCL2 majorbreakpoint region associated with t(14;18) translocation. Biochim Biophys Acta Gen Subj 1862:649-659, 2018.
 
7) Raghavan SC, Swanson PC, Wu X, et al:A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 428:88-93, 2004.
 
8) Nambiar M, Raghavan SC:Mechanism of fragility at BCL2 gene minor breakpoint cluster regionduring t(14;18) chromosomal translocation. J Biol Chem 287:8688-8701, 2012.
 
9) Duquette ML, Pham P, Goodman MF, et al:AID binds to transcription-induced structures in c-MYCthat map to regions associated with translocation and hypermutation. Oncogene 24:5791-5798, 2005.
 
10) Greisman HA, Lu Z, Tsai AG, et al:IgH partner breakpoint sequences provide evidence that AID initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt lymphomas. Blood 120:2864-2867, 2012.
 
11) Lieber MR:Mechanisms of human lymphoid chromosomal translocations. Nat Rev Cancer 16:387-398, 2016.
PubMed
12) Kirkham CM, Scott JNF, Wang X, et al:Cut-and-Run:A Distinct Mechanism by which V(D)J Recombination Causes Genome Instability. Mol Cell 74:584-597. e9, 2019.
 
13) Jager U, Bocskor S, Le T, et al:Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions:novel insights into the mechanism of t(14;18) translocation. Blood 95:3520-3529, 2000.
PubMed
14) Raghavan SC, Hsieh CL, Lieber MR:Both V(D)J coding ends but neither signal end can recombine at the bcl-2 major breakpoint region, and the rejoining is ligase IV dependent. Mol Cell Biol 25:6475-6484, 2005.
 
15) Zhu C, Mills KD, Ferguson DO, et al:Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109:811-821, 2002.
PubMed
P.148 掲載の参考文献
1) Flores-Montero J, Sanoja-Flores L, Paiva B, et al:Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31:2094-2103, 2017.
PubMed
2) 日本臨床検査標準協議会血液検査標準化検討委員会フローサイトメトリーワーキンググループ:フローサイトメトリーによる造血器腫瘍細胞表面抗原検査に関するガイドライン(JCCLS H2-P V1.0). 日本臨床検査標準協議会会誌 18:69-107, 2003.
 
3) Clinical and Laboratory Standards Institute:Clinical Flowcytometric Analysis of Neoplastic Hematolymphoid Cells;Approved Guideline-second edition(H43-A2), CLSI, Wayne PA, 2007.
 
4) van Dongen JJ, Lhermitte L, Bottcher S, et al:EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26:1908-1975, 2012.
PubMed
5) Inaba T, Nishimura H, Saito J, et al:A case of CD45-negative diffuse large B-cell lymphoma in thyroid gland. Lab Hematol 14:12-14, 2008.
 
6) Morisako T, Shishido-Hara Y, Inaba T, et al:Primary CNS CD45-Negative T-cell lymphoma:the first pathologically confirmed case. J Neuropathol Exp Neurol 79:817-820, 2020.
 
7) 稲葉 亨, 松本和道, 抱 章子, ほか:FCM検査の標準化 検査所見の付け方, 留意点. 日本検査血液学会雑誌 24:166-174, 2023.
 
8) 稲葉 亨, 松本和道, 塚本 拓:B細胞性腫瘍. 臨床病理 68:207-213, 2020.
Medical*Online
9) Inaba T, Shimazaki C, Sumikuma T, et al:T-cell associated antigen-positive B-cell lymphoma. Leuk Lymphoma 42:1161-1171, 2001.
 
10) Ravandi F, Kantarjian H, Jones D, et al:Mature T-cell leukemias. Cancer 104:1808-1818, 2005.
PubMed
11) Foucar K:Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sezary syndrome. Am J Clin Pathol 127:496-510, 2007.
PubMed
12) 石垣知寛, 小林誠一郎, 在家裕司, ほか:成人T細胞白血病(ATL)におけるフローサイトメトリー解析法の確立とその臨床応用～12カラーの病態解析から4カラーの臨床検査まで～. CytometryResearch 24:33-39, 2014.
 
13) 松下弘道, 有賀 祐, 池田千秋:マルチカラー解析の基礎. 日本検査血液学会雑誌 19:422-429, 2018.
 
14) 林田雅彦, 前川ふみよ, 本庄 原, ほか:悪性リンパ腫のマルチカラーフローサイトメトリー解析-炎症を背景にもつ MALT リンパ腫および AITL を中心に-. 日本検査血液学会雑誌 19:441-453, 2018.
 
15) Schuster SJ, Bishop MR, Tam CS, et al:Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380:45-56, 2019.
 
P.154 掲載の参考文献
1) Cheson BD, Fisher RI, Barrington SF, et al:Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification. J Clin Oncol32:3059-3068, 2014.
 
P.158 掲載の参考文献
1) Davis AR, Stone SL, Oran AR, et al:Targeted massively parallel sequencing of mature lymphoid neoplasms:assessment of empirical application and diagnostic utility in routine clinical practice. Mod Pathol 34:904-921, 2021.
PubMed
2) Yasuda T, Sanada M, Nishijima D, et al:Clinical utility of target capture-based panel sequencing in hematological malignancies:A multicenter feasibility study. Cancer Sci 111:3367-3378, 2020.
PubMed
3) Pastore A, Jurinovic V, Kridel R, et al:Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma:a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111-1122, 2015.
 
4) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
5) Morschhauser F, Tilly H, Chaidos A, et al:Tazemetostat for patients with relapsed or refractory follicular lymphoma:an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21:1433-1442, 2020.
PubMed
6) Lauer EM, Mutter J, Scherer F:Circulating tumor DNA in B-cell lymphoma:technical advances, clinical applications, and perspectives for translational research. Leukemia 36:2151-2164, 2022.
 
7) Kurtz DM, Scherer F, Jin MC, et al:Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 36:2845-2853, 2018.
PubMed
8) Shimada K, Yoshida K, Suzuki Y, et al:Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood 137:1491-1502, 2021.
 
9) Gupta M, Burns EJ, Georgantas NZ, et al:A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood 138:382-386, 2021.
PubMed
10) Bonzheim I, Giese S, Deuter C, et al:High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma:a valuable tool to improve diagnostic yield of vitreous aspirates. Blood 126:76-79, 2015
PubMed

[IV] 悪性リンパ腫の予後予測因子

P.167 掲載の参考文献
1) International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model foraggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
2) Sehn LH, Berry B, Chhanabhai M, et al:The revised International Prognostic Index(R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007.
 
3) Zhou Z, Sehn LH, Rademaker AW, et al:An enhanced International Prognostic Index(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837-842, 2014.
PubMed
4) Kobayashi T, Kuroda J, Yokota I, et al:The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer J 6:e383, 2016.
 
5) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
6) Wright GW, Huang DW, Phelan JD, et al:A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37:551-568. e14, 2020.
 
7) Solal-Celigny P, Roy P, Colombat P, et al:Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004.
PubMed
8) Federico M, Bellei M, Marcheselli L, et al:Follicular lymphoma international prognostic index 2:a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555-4562, 2009.
PubMed
9) Pastore A, Jurinovic V, Kridel R, et al:Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma:a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111-1122, 2015.
 
10) Bolen CR, Mattiello F, Herold M, et al:Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood 137:2704-2707, 2021.
PubMed
11) Mir F, Mattiello F, Grigg A, et al:Follicular Lymphoma Evaluation Index(FLEX):A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol 95:1503-1510, 2020.
 
12) Mondello P, Fama A, Larson MC, et al:Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J 11:130, 2021.
PubMed
13) Tsukamoto T, Nakano M, Sato R, et al:High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif. Sci Rep 7:14039, 2017.
PubMed
14) Hoster E, Dreyling M, Klapper W, et al:A new prognostic index(MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008.
PubMed
15) Thieblemont C, Cascione L, Conconi A, et al:A MALT lymphoma prognostic index. Blood 130:1409-1417, 2017.
PubMed
P.172 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition(ed by Swerdlow S, Campo E, Harris N, et al). IARC Press, Lyon, 2017.
 
2) Vose J, Armitage J, Weisenburger D, et al:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
PubMed
3) International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
 
4) Gallamini A, Stelitano C, Calvi R, et al:Peripheral T-cell lymphoma unspecified(PTCL-U):a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004.
 
5) Went P, Agostinelli, Gallamini A, et al:Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score. J Clin Oncol 24:2472-2479, 2006.
 
6) Federico M, Bellei M, Marcheselli L, et al:Peripheral T cell lymphoma, not otherwise specified(PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol 181:760-769, 2018.
 
7) Federico M, Rudiger T, Bellei A, et al:Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 31:240-246, 2013.
 
8) Tokunaga T, Shimada K, Yamamoto K, et al:Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma:a multicenter cooperative study in Japan. Blood 119:2837-2843, 2012.
PubMed
9) Vose JM:International Peripheral T-cell Lymphoma(PTCL) Clinical and Pathology Review Project:poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 106:811, 2005.
 
10) Savage KJ, Harris NL, Vose JM, et al:ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008.
 
11) Sibon D, Fournier M, Briere J, et al:Long-term outcome of adults with systemic anaplastic large cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 30:3939-3946, 2012.
 
12) Lee J, Suh C, Park YH, et al:Extranodal natural killer T-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006.
 
13) Kim TM, Park YH, Lee SY, et al:Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood106:3785-3790, 2005.
 
14) Kim SJ, Yoon DH, Jaccard A, et al:A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment:a multicentre, retrospective analysis. Lancet Oncol 17:389-400, 2016.
PubMed
15) Yamaguchi M, Suzuki R, Oguchi M, et al:Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013:A Cooperative Study in Japan. J Clin Oncol 35:32-39, 2017.
PubMed
16) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group(1984-87). Br J Haematol 79:428-437, 1991.
 
17) Katsuya H, Ishitsuka K, Utsunomiya A, et al:Treatment and survival among 1594 patients with ATL. Blood 126:2570-2577, 2015.
PubMed
18) Fukushima T, Nomura S, Shimoyama M, et al:Japan Clinical Oncology Group(JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma(JCOG0902A). Br J Haematol 166:739-748, 2014.
PubMed
19) Fuji S, Yamaguchi T, Inoue Y, et al:Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger:possible risk-adapted management strategies including allogeneic transplantation. Haematologica 102:1258-1265, 2017.
PubMed
20) Katsuya H, Shimokawa M, Ishitsuka K, et al:Prognostic index for chronic-and smoldering-type adult T-cell leukemia-lymphoma. Blood 130:39-47, 2017.
PubMed
21) de Baaij LR, Berkhof J, van de Water JM, et al:A New and Validated Clinical Prognostic Model(EPI) for Enteropathy-Associated T-cell Lymphoma. Clin Cancer Res 21:3013-3019, 2015.
PubMed
22) Mead M, Cederleuf H, Bjorklund M, et al:Impact of comorbidity in older patients with peripheral T-cell lymphoma:an international retrospective analysis of 891 patients. Blood Adv 6:2120-2128, 2022.
PubMed
23) El-Galaly TC, Pedersen MB, Hutchings M, et al:Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas:A review of 124 patients. Am J Hematol 90:975-980, 2015.
PubMed
24) Advani RH, Skrypets T, Civallero M, et al:Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma:final report from the international T-cell Project. Blood 138:213-220, 2021.
PubMed
P.178 掲載の参考文献
1) Makita S, Maruyama D, Miyagi Maeshima A, et al:Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol 104:236-244, 2016.
 
2) Armitage JO:Early-stage Hodgkin's lymphoma. N Engl J Med 363:653-662, 2010.
PubMed
3) Meyer RM, Gospodarowicz MK, Connors JM, et al:Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005.
 
4) ホジキンリンパ腫(HL). 造血器腫瘍診療ガイドライン2018年版補訂版(一般社団法人日本血液学会 編), p297, 金原出版, 2020.
 
5) Armitage JO:Early-stage Hodgkin's lymphoma. N Engl J Med 363:653-662, 2010.
PubMed
6) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998.
 
7) Moccia AA, Donaldson J, Chhanabhai M, et al:International Prognostic Score in advanced-stage Hodgkin's lymphoma:altered utility in the modern era. J Clin Oncol 30:3383-3388, 2012.
PubMed
8) Gallamini A, Hutchings M, Rigacci L, et al:Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:a report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007.
PubMed
9) Connors JM, Jurczak W, Straus DJ, et al:Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344, 2018.
PubMed
10) Rodday AM, Parsons SK, Upshaw JN, et al:The Advanced-Stage Hodgkin lymphoma International Prognostic Index:Development and validation of a clinical prediction model from the HoLISTIC consortium. J Clin Oncol, 2022.(DOI:10.1200/JCO. 22.02473)
 
11) Moskowitz CH, Nademanee A, Masszi T, et al:Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression(AETHERA):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853-1862, 2015.
 
12) Chan FC, Mottok A, Gerrie AS, et al:Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. J Clin Oncol 35:3722-3733, 2017.
PubMed
13) Spina V, Bruscaggin A, Cuccaro A, et al:Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 131:2413-2425, 2018.
PubMed
P.184 掲載の参考文献
1) Gleeson M, Counsell N, Cunningham D, et al:Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era:results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol 28:2511-2516, 2017.
PubMed
2) Schmitz N, Zeynalova S, Nickelsen M, et al:CNS International Prognostic Index:A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol 34:3150-3156, 2016.
 
3) El-Galaly TC, Villa D, Michaelsen TY, et al:The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma:An international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer75:195-203, 2017.
 
4) Kridel R, Telio D, Villa D, et al:Diffuse large B-cell lymphoma with testicular involvement:outcome and risk of CNS relapse in the rituximab era. Br J Haematol 176:210-221, 2017.
PubMed
5) Tomita N, Yokoyama M, Yamamoto W, et al:Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103:245-251, 2012.
PubMed
6) Klanova M, Sehn LH, Bence-Bruckler I, et al:Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood 133:919-926, 2019.
PubMed
7) Miyazaki K, Yamaguchi M, Suzuki R, et al:CD5-positive diffuse large B-cell lymphoma:a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22:1601-1607, 2011.
PubMed
8) Shimada K, Matsue K, Yamamoto K, et al:Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189-3195, 2008.
 
9) Eyre TA, Djebbari F, Kirkwood AA, et al:Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era:a systematic review. Haematologica 105:1914-1924, 2020.
 
10) Wilson MR, Eyre TA, Kirkwood AA, et al:Timing of high-dose methotrexate CNS prophylaxis in DLBCL:a multicenter international analysis of 1384 patients. Blood 139:2499-2511, 2022.
PubMed
11) Lin Z, Chen X, Liu L, et al:The role of central nervous system(CNS) prophylaxis in preventing DLBCL patients from CNS relapse:A network meta-analysis. Crit Rev Oncol Hematol 176:103756, 2022.
 
12) Miyazaki K, Asano N, Yamada T, et al:DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma:a single-arm, open-label, phase II study. Haematologica 105:2308-2315, 2020.
PubMed
13) Shimada K, Yamaguchi M, Atsuta Y, et al:Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma(PRIMEUR-IVL):a multicentre, single-arm, phase 2 trial. Lancet Oncol 21:593-602, 2020.
 
14) Zayac AS, Evens AM, Danilov A, et al:Outcomes of Burkitt lymphoma with central nervous system involvement:evidence from a large multicenter cohort study. Haematologica 106:1932-1942, 2021.
PubMed
15) Kim H, Jeong H, Yamaguchi M, et al:Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood 136:2548-2556, 2020.
 

[V] 病型各論 - 疾患概念・疫学・分類・臨床像・診断・治療・予後・話題 -

P.193 掲載の参考文献
1) Engert A, Plutschow A, Eich HT, et al:Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010.
PubMed
2) Eich HT, Diehl V, Gorgen H, et al:Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma:final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010.
 
3) Meyer RM, Gospodarowicz MK, Connors JM, et al:ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366:399-408, 2012.
PubMed
4) Borchmann P, Plutschow A, Kobe C, et al:PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma(GHSG HD17):a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:223-234, 2021.
PubMed
5) LaCasce AS, Dockter T, Ruppert AS, et al:Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma:CALGB 50801(Alliance). J Clin Oncol 41:1023-1034, 2023.
 
6) Johnson P, Federico M, Kirkwood A, et al:Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med 374:2419-2429, 2016.
PubMed
7) Andre MPE, Girinsky T, Federico M, et al:Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma:Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol 35:1786-1794, 2017.
 
8) Press OW, Li H, Schoder H, et al:US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging:Southwest Oncology Group S0816. J Clin Oncol 34:2020-2027, 2016.
 
9) Kusumoto S, Munakata W, Machida R, et al:Interim PET-guided ABVD or ABVD/escalated BEACOPP regimen for newly diagnosed advanced-stage classic Hodgkin lymphoma(JCOG1305, INNOVATE-HL study). Blood 14(Suppl 1):3718-3721, 2022.
 
10) Connors JM, Jurczak W, Straus DJ, et al:Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344, 2018.
PubMed
11) Ansell SM, Radford J, Connors JM, et al:Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med 387:310-320, 2022.
 
12) Longo DL, Armitage JO:A Better Treatment for Advanced-Stage Hodgkin's Lymphoma? N Engl JMed 387:370-372, 2022.
 
13) Evens AM, Connors JM, Younes A, et al:Older patients(aged360 years) with previously untreated advanced-stage classical Hodgkin lymphoma:a detailed analysis from the phase III ECHELON-1 study. Haematologica 107:1086-1094, 2022.
PubMed
14) Moskowitz CH, Nademanee A, Masszi T, et al:Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression(AETHERA):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853-1862, 2015.
 
15) Casadei B, Argnani L, Morigi A, et al:Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med 9:7830-7836, 2020.
PubMed
P.196 掲載の参考文献
1) Li W:Chapter 1. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors In:Leukemia [Internet](ed by Li W), Exon Publications, Brisbane, 2022 Oct 16.
 
2) Maitra A, McKenna RW, Weinberg AG, et al:Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pthol 115:868-875, 2001.
 
3) Coyaud E, Struski S, Prade N, et al:Wide diversity of PAX5 alterations in B-ALL:a Groupe Francophone de Cytogenetique Hematologique study. Blood 115:3089-3097, 2010.
 
4) Parker C, Krishnan S, Hamadeh L, et al:Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukameia with late bone marrow relapses:long-term follow-up of the ALLR3 open-label randomized trial. Lancet Haematol 6:e204-e216, 2019.
PubMed
5) Suzuki K, Okuno Y, Kawashima N, et al:MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. J Clin Oncol 34:3451-3459, 2016.
PubMed
6) Yasuda T, Tsuzuki S, Kawazu M, et al:Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 48:569-574, 2016.
 
7) Qian M, Zhang H, Kham SK, et al:Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res 27:185-195, 2017.
PubMed
8) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997.
 
9) Soslow RA, Baergen RN, Warnke RA:B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 85:2648-2654, 1999.
PubMed
10) 小児慢性特定疾患情報センター:Bリンパ芽球性リンパ腫. バージョン1.0 更新日:2014年10月1日(文責 日本小児血液・がん学会)[https://www.shouman.jp/disease/details/01_03_020/]
 
11) Lin P, Jones D, Dorman DM, et al:Precursor B-cell lymphoblastic lymphoma:a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol 24:1480-1490, 2000.
 
12) Sander CA, Jaffe ES, Gebhardt FC, et al:Mediastinal lymphoblastic lymphoma with an immature B-cell immunophenotype. Am J Surg Pathol 16:300-305, 1992.
PubMed
13) Anderson BP, Metz CM:B-cell lymphoblastic lymphoma of the Paranasal Sinuses:A Case Study of a Rare Clinical Entity. Cureus 14:e31565, 2022.
PubMed
14) Thomas DA, O'Brien S, Cortes J, et al:Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624-1630, 2004.
PubMed
P.203 掲載の参考文献
1) Campo E, et al:Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, Revised ed(ed by Swerdlow SH, Campo E, Harris NL, et al), p216-221, IARC Press, Lyon, 2017.
 
2) Hallek M, Cheson BD, Catovsky D, et al:iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745-2760, 2018.
PubMed
3) 造血器腫瘍診療ガイドライン2018年版補訂版(日本血液学会 編), p121-143, 金原出版, 2020.
 
4) Ruchlemer R, Polliack A:Geography, ethnicity and "roots" in chronic lymphocytic leuk emia. LeukLymphoma 54:1142-1150, 2013.
 
5) Redaelli A, Laskin BL, Stephens JM, et al:The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care(Engl) 13:279-287, 2004.
PubMed
6) Eichhorst B, Robak T, Montserrat E, et al:Chronic lymphocytic leukaemia:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v78-v84, 2015.
 
7) NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2, 2020.
PubMed
8) 瀧澤 淳:慢性リンパ性白血病-病態解明の進歩と治療の現在-. 臨床血液 58:471-479, 2017.
 
9) Yatabe Y, Suzuki R, Tobinai K, et al:Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000.
 
10) Dufresne SD, Felgar RE, Sargent RL, et al:Defining the borders of splenic marginal zone lymphoma:a multiparameter study. Hum Pathol 41:540-551, 2010.
PubMed
11) Thorns C, Kalies K, Fischer U, et al:Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology 50:716-719, 2007.
PubMed
12) Matutes E, Owusu-Ankomah K, Morilla R, et al:The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645, 1994.
PubMed
13) Rawstron AC, Kreuzer KA, Soosapilla A, et al:Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry:An European Research Initiative on CLL(ERIC) & European Society for Clinical Cell Analysis(ESCCA) Harmonisation project. Cytometry B Clin Cytom 94:121-128, 2018.
PubMed
14) Takizawa J, Izutsu K, Nagai H, et al:Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan:An Observational Database Research Study(CLIMBER-DBR). J Clin Exp Hematop 61:126-134, 2021.
PubMed
15) Parikh SA:Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J 8:93, 2018.
PubMed
16) Burger JA, Barr PM, Robak T, et al:Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL:5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34:787-798, 2020.
PubMed
17) Bewarder M, Stilgenbauer S, Thurner L, et al:Current Treatment Options in CLL. Cancers 13(Basel):2468, 2021.
PubMed
18) Byrd JC, Hillmen P, Ghia P, et al:Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia:Results of the First Randomized Phase III Trial. J Clin Oncol 39:3441-3452, 2021.
PubMed
19) Seymour JF, Kipps TJ, Eichhorst B, et al:Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 378:1107-1120, 2018.
 
20) Mukkamalla SKR, Taneja A, Malipeddi D, et al:Chronic Lymphocytic leukemia. StatPearls[Internet], NCBI Bookshelf, 2022.
 
21) Sharman JP, Egyed M, Jurczak W, et al:Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia(ELEVATE TN):a randomised, controlled, phase 3 trial. Lancet 395:1278-1291, 2020.
 
P.209 掲載の参考文献
1) Campo E, et al:B-cell prolymphocytic leukemia. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed,(ed by Swedlow SH, Campo E, Harris NL, et al), p183-184, IARC, Lyon, 2008.
 
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022
PubMed
4) Galton DA, Goldman JM, Wiltshaw E, et al:Prolymphocytic leukaemia. Brit J Haematol 27:7-23, 1974.
 
5) Melo JV, Catovsky D, Galton DA, et al:The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. 1. Clinical and laboratory features of 300 patients and characteriza-tion of an intermediate group. Brit J Haematol 63:377-387, 1986.
 
6) Schlette E, Bueso-Ramos C, Giles F, et al:Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 115:571-581, 2001.
PubMed
7) Ruchlemer R, Parry-Jones N, Brito-Babapulle V, et al:B-prolymphocytic leukaemia with t(11;14) revisited:a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol125:330-336, 2004.
 
8) Hoehn D, Miranda RN, Kanagal-Shamanna R, et al:Splenic B-cell lymphomas with more than 55% prolymphocytes in blood:evidence for prolymphocytoid transformation. Hum Pathol 43:1828-1838, 2012.
PubMed
9) Cai J, Qing X:Splenic marginal zone lymphoma with increased prolymphocytes. Blood 137:31502021.
 
10) Matutes E, Owusu-Ankomah K, Morilla R, et al:The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645, 1994.
PubMed
11) Cross M, Dearden C:B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol 32:217-228, 2019.
 
12) Chapiro E, Pramil E, Diop M, et al:Genetic characterization of B-cell prolymphocytic leukemia:a prognostic model involving MYC and TP53. Blood 134:1821-1831, 2019.
PubMed
13) Davi F, Maloum K, Michel A, et al:High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia. Blood 88:3953-3961, 1996.
PubMed
14) Del Giudice I, Davis Z, Matutes E, et al:IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia(B-PLL). Leukemia 20:1231-1237, 2006.
 
15) Del Giudice I, Osuji N, Dexter T, et al:B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia 23:2160-2167, 2009.
PubMed
16) van der Velden VH, Hoogeveen PG, de Ridder D, et al:B-cell prolymphocytic leukemia:a specific subgroup of mantle cell lymphoma. Blood 124:412-419, 2014.
PubMed
17) Dearden C:How I treat prolymphocytic leukemia. Blood 120:538-551, 2012.
 
18) Eyre TA, Fox CP, Boden A, et al:Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity:updated results of the UK-wide compassionate useprogramme. Br J Haematol 184:667-671, 2019.
PubMed
19) Gordon MJ, Raess PW, Young K, et al:Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. Br J Haematol 179:501-503, 2017.
PubMed
20) Patil N, Went RG:Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors. Br J Haematol 186:e80-e82, 2019.
 
21) Chen LY, Eyre TA:Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia. Eur J Haematol 109:590-592, 2022.
PubMed
22) Kalaycio ME, Kukreja M, Woolfrey AE, et al:Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant 16:543-547, 2010.
PubMed
P.214 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Swedlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th ed, International Agency for Research on Cancer, Lyon, 2017.
 
3) Sutcliffe MJ, Shuster JJ, Sather HN, et al:High concordance from independent studies by the Children's Cancer Group(CCG) and Pediatric Oncology Group(POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia:a Children's Oncology Group(COG) initiative. Leukemia 19:734-740, 2005.
 
4) Meyer JA, Zhou D, Mason CC, et al:Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer 64:e26363, 2017.
 
5) Holmfeldt L, Wei L, Diaz-Flores E, et al:The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45:242-252, 2013.
PubMed
6) Moorman AV, Ensor HM, Richards SM, et al:Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia:results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 11:429-438, 2010.
PubMed
7) Harrison CJ, Moorman AV, Schwab C, et al:An international study of intrachromosomal amplification of chromosome 21(iAMP21):cytogenetic characterization and outcome. Leukemia 28:1015-1021, 2014.
 
8) Yamada C, Shimomura Y, Kamijyo K, et al:BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy. Intern Med 60:3149-3153, 2021.
 
9) Tomii T, Imamura T, Tanaka K, et al:Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model. Leukemia 35:2092-2096, 2021.
 
10) Mayumi A, Tomii T, Kanayama T, et al:The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion. Cancer Gene Ther 29:1930-1938, 2022.
 
11) Isobe T, Takagi M, Sato-Otsubo A, et al:Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia. Nat Commun 13:4501, 2022.
PubMed
12) Mater DV, Goodman BK, Wang E, et al:MLL duplication in a pediatric patient with B-cell lymphoblastic lymphoma. J Pediatr Hematol Oncol 34:e120-e123, 2012.
 
13) Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, et al:Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun 7:11790, 2016.
PubMed
14) Fischer U, Forster M, Rinaldi A, et al:Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet47:1020-1029, 2015.
PubMed
15) Tomizawa D, Miyamura T, Imamura T, et al:A risk-stratified therapy for infants with acute lymphoblastic leukemia:a report from the JPLSG MLL-10 trial. Blood 136:1813-1823, 2020.
PubMed
P.220 掲載の参考文献
1) Bouroncle BA, Wiseman BK, Doan CA:Leukemic reticuloendotheliosis. Blood 13:609-630, 1958.
PubMed
2) Schrek R, Donnelly WJ:"Hairy" cells in blood in lymphoreticular neoplastic disease and "flagellated" cells of normal lymph nodes. Blood 27:199-211, 1966.
PubMed
3) Basso K, Liso A, Tiacci E, et al:Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med199:59-68, 2004.
 
4) Tiacci E, Trifonov V, Schiavoni G, et al:BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305-2315, 2011.
PubMed
5) Zhang X, Machii T, Matsumura I, et al:Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells. Int J Hematol 77:263-273, 2003.
PubMed
6) 柴山浩彦:ヘアリーセル白血病. 造血器腫瘍アトラス(第5版), p488-494, 日本医事新報社, 2016.
 
7) Matutes E, Wotherspoon A, Brito-Babapulle V, et al:The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 15:184-186, 2001.
PubMed
8) Machii T, Tokumine Y, Inoue R, et al:Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia 7:181-186, 1993.
PubMed
9) Maevis V, Mey U, Schmidt-Wolf G, et al:Hairy cell leukemia:short review, today's recommendations and outlook. Blood Cancer J 4:e184, 2014.
 
10) Grever M, Andritsos L, Banerji V, et al:Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia 35:1864-1872, 2021.
PubMed
11) Dietrich S, Glimm H, Andrulis M, et al:BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038-2040, 2012.
PubMed
12) Robak T, Wolska A, Robak P:Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opin Investig Drugs 24:1419-1431, 2015.
PubMed
13) Salam L, Abdel-Wahab O:Hairy cell leukemia:update and current therapeutic approach. Curr Opin Hematol 22:355-361, 2015.
 
14) NCCN Guidelines Version 1. 2023. Hairy Cell Leukemia. [https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf]
 
P.224 掲載の参考文献
1) Swerdlow SH, Cook JR, Sohani AR, et al:Lymphoplasmacytic lymphoma. In:World health Organization Classification of Tumour of Hematopoietic and Lymphoid Tissues 4th ed(ed by Swerdlow SH, Campo E, Harris NL, et al) p232-235, JARC Press, Lyon, 2017.
 
2) Sekiguchi N:Waldenstrom macroglobulinemia:Japanese perception. Rinsho Ketsueki 60:988-997, 2019.
PubMed
3) Treon SP, Xu L, Yang G, et al:MYD88 L265P somatic mutation in Waldenstrom's macroglobuline-mia. N Engl J Med 367:826-833, 2012.
 
4) Hunter ZR, Xu L, Yang G, et al:The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123:1637-1646, 2014.
 
5) Poulain S, Roumier C, Venet-Caillault A, et al:Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. Clin Cancer Res 22:1480-1488, 2016.
PubMed
6) Treon SP, Cao Y, Xu L, et al:Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123:2791-2796, 2014.
PubMed
7) Kofides A, Hunter ZR, Xu L, et al:Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265Pin Waldenstrom Macroglobulinemia. Hemasphere 5:e624, 2021.
PubMed
8) Gustine JN, Xu L, Yang G, et al:Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstrom macroglobulinaemia. Br J Haematol 194:730-733, 2021.
 
9) National Comprehensive Cancer Network:NCCN Clinical Practice Guidelines in Oncology. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 1.2023. [https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physi-cian_gls/pdf/waldenstroms]
 
10) リンパ形質細胞性リンパ腫/ワルデンシュトレームマクログロブリン血症(LPL/WM). 造血器腫瘍診療ガイドライン2018年版補訂版(日本血液学会 編), p208-214, 金原出版, 2020.
 
11) Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al:Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25:3344-3349, 2007.
PubMed
12) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
13) Treon SP, Ioakimidis L, Soumerai JD, et al:Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab:WMCTG clinical trial 05-180. J Clin Oncol 27:3830-3835, 2009.
PubMed
14) Treon SP, Tripsas CK, Meid K, et al:Ibrutinib in previously treated Waldenstrom's macroglobuline-mia. N Engl J Med 372:1430-1440, 2015.
 
15) Treon SP, Gustine J, Meid K, et al:Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia. J Clin Oncol 36:2755-2761, 2018.
PubMed
16) Dimopoulos MA, Tedeschi A, Trotman J, et al:Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med 378:2399-2410, 2018.
PubMed
17) Tam CS, Opat S, D'Sa S, et al:A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia:the ASPEN study. Blood 136:2038-2050, 2020.
PubMed
18) Owen RG, McCarthy H, Rule S, et al:Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia:a single-arm, multicentre, phase 2 study. Lancet Haematol 7:e112-e121, 2020.
PubMed
19) Sekiguchi N, Rai S, Munakata W, et al:A multicenter, open-label, phase II study of tirabrutinib(ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia. Cancer Sci 111:3327-3337, 2020.
PubMed
20) Sekiguchi N, Rai S, Munakata W, et al:Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia. Cancer Sci 113:2085-2096, 2022.
PubMed
21) Castillo JJ, Abeykoon JP, Gustine JN, et al:Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib. Br J Haematol 192:542-550, 2021.
PubMed
22) Abushukair H, Syaj S, Ababneh O, et al:First-versus second-generation Bruton tyrosine kinase inhibitors in Waldenstrom's Macroglobulinemia:A systematic review and meta-analysis. Am J Hematol 97:942-950, 2022.
PubMed
23) Abeykoon JP, Kumar S, Castillo JJ, et al:Bendamustine rituximab(BR) versus ibrutinib(Ibr) as primary therapy for Waldenstrom macroglobulinemia(WM):An international collaborative study. J Clin Oncol 16(Suppl):7566, 2022.
 
24) Deodato M, Frustaci AM, Zamprogna G, et al:Should Patients with Waldenstrom Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? Hemato 3:689-703, 2022.
 
25) Mato AR, Shah NN, Jurczak W, et al:Pirtobrutinib in relapsed or refractory B-cell malignancies(BRUIN):a phase 1/2 study. Lancet 397:892-901, 2021.
 
26) Castillo JJ, Allan JN, Siddiqi T, et al:Venetoclax in Previously Treated Waldenstrom Macroglobulinemia. J Clin Oncol 40:63-71, 2022.
PubMed
27) Treon SP, Buske C, Thomas S, et al:Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenstrom's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood 138(Suppl 1):1362, 2021.
 
28) Castillo JJ, Itchaki G, Paludo J, et al:Ibrutinib for the treatment of Bing-Neel syndrome:a multicenter study. Blood 133:299-305, 2019.
PubMed
29) Saburi M, Saburi Y, Kawano K, et al:Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome. Int J Hematol 115:585-589, 2022.
PubMed
30) Oyama T, Taoka K, Chiba A, et al:Bing-Neel Syndrome Successfully Treated with Tirabrutinib. Intern Med 61:3575-3579, 2022.
PubMed
31) Sekiguchi N:The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenstrom's Macroglobulinemia. Intern Med 61:3473-3474, 2022.
PubMed
P.231 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Cerhan JR, Habermann TM:Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma. 5:1, 2021(DOI:10.21037/aol-20-28).
 
3) Zucca E, Bertoni F, Vannata B, et al:Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res 20:5207-5216, 2014.
 
4) Rossi D, Bertoni F, Zucca E:Marginal-Zone Lymphomas. N Engl J Med 386:568-581, 2022.
PubMed
5) Thieblemont C, Cascione L, Conconi A, et al:A MALT lymphoma prognostic index. Blood 130:1409-1417, 2017.
PubMed
6) Conconi A, Thieblemont C, Cascione L, et al:Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica 105:2592-2597, 2020.
PubMed
7) Zucca E, Arcaini L, Buske C, et al:Marginal zone lymphomas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:17-29, 2020.
 
8) National Comprehensive Cancer Network:B-cell lymphomas(NCCN guidelines version 5. 2022). 2022.(https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf)
 
9) Wirth A, Gospodarowicz M, Aleman BM, et al:Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy:a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 24:1344-1351, 2013.
 
10) Arcaini L, Besson C, Frigeni M, et al:Interferon-free antiviral treatment in B-cell lymphoprolifera-tive disorders associated with hepatitis C virus infection. Blood 128:2527-2532, 2016.
 
11) Wirth A, Mikhaeel NG, Aleman BMP, et al:Involved Site Radiation Therapy in Adult Lymphomas:An Overview of International Lymphoma Radiation Oncology Group Guidelines. Int J Radiat Oncol Biol Phys 107:909-933, 2020.
PubMed
12) Ardeshna KM, Smith P, Norton A, et al:Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma:a randomised controlled trial. Lancet 362:516-522, 2003.
PubMed
13) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
14) Zucca E, Conconi A, Martinelli G, et al:Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma:Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol 35:1905-1912, 2017.
PubMed
P.236 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC, Lyon, 2008.
 
2) Nakamura S, Ponzoni M:Marginal zone B-cell lymphoma:lessons from Western and Eastern diagnostic approaches. Pathology 52:15-29, 2020.
PubMed
3) Alderuccio JP, Kahl BS:Current Treatments in Marginal Zone Lymphoma. Oncology(Williston Park) 36:206-215, 2022.
PubMed
4) Luminari S, Merli M, Rattotti S, et al:Early progression as a predictor of survival in marginal zone lymphomas:an analysis from the FIL-NF10 study. Blood 134:798-801, 2019.
PubMed
5) Zucca E, Arcaini L, Buske C, et al:Marginal zone lymphomas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:17-29, 2020.
 
6) Armand M, Besson C, Hermine O, et al:Hepatitis C virus-associated marginal zone lymphoma. Best Pract Res Clin Haematol 30:41-49, 2017.
PubMed
7) Rossi D, Bertoni F, Zucca E:Marginal-Zone Lymphomas. N Engl J Med 386:568-581, 2022.
PubMed
8) Kalpadakis C, Pangalis GA, Sachanas S, et al:Rituximab monotherapy in splenic marginal zone lymphoma:prolonged responses and potential benefit from maintenance. Blood 132:666-670, 2018.
PubMed
9) Iannitto E, Bellei M, Amorim S, et al:Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma:results from the phase II BRISMA/IELSG36 study. Br J Haematol 183:755-765, 2018.
PubMed
10) Salar A, Domingo-Domenech E, Panizo C, et al:Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood 130:1772-1774, 2017.
PubMed
11) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
12) Walewski J, Paszkiewicz-Kozik E, Michalski W, et al:First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol 188:898-906, 2020.
 
13) Herold M, Hoster E, Janssens A, et al:Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial. Hemasphere 6:e699, 2022.
PubMed
14) Leonard JP, Trneny M, Izutsu K, et al:AUGMENT:A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 37:1188-1199, 2019.
PubMed
15) Cheson BD, Chua N, Mayer J, et al:Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol 36:2259-2266, 2018.
PubMed
16) Conconi A, Thieblemont C, Cascione L, et al:Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica 105:2592-2597, 2020.
PubMed
P.243 掲載の参考文献
1) Batlevi CL, Sha F, Alperovich A, et al:Follicular lymphoma in the modern era:survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10:74, 2020.
PubMed
2) Sarkozy C, Maurer MJ, Link BK, et al:Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era:A Pooled Analysis of French and US Cohorts. J Clin Oncol 37:144-152, 2019.
 
3) Casulo C, Byrtek M, Dawson KL, et al:Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death:An Analysis From the National LymphoCare Study. J Clin Oncol 33:2516-2522, 2015.
PubMed
4) Huet S, Tesson B, Jais JP, et al:A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma:a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561, 2018.
 
5) Luminari S, Ferrari A, Manni M, et al:Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. J Clin Oncol 36:689-696, 2018.
PubMed
6) Rummel MJ, Niederle N, Maschmeyer G, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013.
PubMed
7) Salles G, Seymour JF, Offner F, et al:Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy(PRIMA):a phase 3, randomised controlled trial. Lancet 377:42-51, 2011.
 
8) Marcus R, Davies A, Ando K, et al:Obinutuzumab for the First-Line Treatment of Follicula Lymphoma. N Engl J Med 377:1331-1344, 2017.
 
9) Fujino T, Maruyama D, Maeshima AM, et al:The outcome of watchful waiting in patients with previously treated follicular lymphoma. Cancer Med 11:2106-2116, 2022.
PubMed
10) Sehn LH, Chua N, Mayer J, et al:Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma(GADOLIN):a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081-1093, 2016.
PubMed
11) Leonard JP, Trneny M, Izutsu K, et al:AUGMENT:A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 37:1188-1199, 2019.
PubMed
12) Morschhauser F, Tilly H, Chaidos A, et al:Tazemetostat for patients with relapsed or refractory follicular lymphoma:an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21:1433-1442, 2020.
PubMed
13) Fowler NH, Dickinson M, Dreyling M, et al:Tisagenlecleucel in adult relapsed or refractory follicular lymphoma:the phase 2 ELARA trial. Nat Med 28:325-332, 2022.
 
14) Budde LE, Sehn LH, Matasar M, et al:Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma:a single-arm, multicentre, phase 2 study. Lancet Oncol 23:1055-1065, 2022.
 
15) Richardson NC, Kasamon Y, Pazdur R, et al:The saga of PI3K inhibitors in haematological malignancies:survival is the ultimate safety endpoint. Lancet Oncol 23:563-566, 2022.
PubMed
P.249 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(Revised 4th edition), WHO, Lyon, 2017.
 
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) 日本血液学会:造血器腫瘍診療ガイドライン2018年版補訂版, 2020.
 
4) Armitage JO, Longo DL:Mantle-Cell Lymphoma. N Engl J Med 386:2495-2506, 2022.
PubMed
5) Ferrero S, Grimaldi D, Dreyling M, et al:Tailored treatment in mantle cell lymphoma. Ann Lymphoma 4:12, 2020.
 
6) Eyre TA, Cheah CY, Wang ML:Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood 139:666-677, 2022.
PubMed
7) Ferrero S, Rossi D, Rinaldi A, et al:KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy:a FIL study. Haematologica 105:1604-1612, 2020.
PubMed
8) Leitch HA, Gascoyne RD, Chhanabhai M, et al:Limited-stage mantle-cell lymphoma. Ann Oncol 14:1555-1561, 2003.
PubMed
9) Schulz H, Bohlius JF, Trelle S, et al:Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma:a systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007.
PubMed
10) Geisler CH, Kolstad A, Laurell A, et al:Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693, 2008.
 
11) Chihara D, Cheah CY, Westin JR, et al:Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma:15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172:80-88, 2016.
 
12) Chen RW, Li H, Bernstein SH, et al:RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL:results of SWOG Study S1106. Br J Haematol 176:759-769, 2017.
 
13) Merryman RW, Edwin N, Redd R, et al:Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv 4:858-867, 2020.
PubMed
14) Zoellner AK, Unterhalt M, Stilgenbauer S, et al:Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission:a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 8:e648-e657, 2021.
PubMed
15) Le Gouill S, Thieblemont C, Oberic L, et al:Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med 377:1250-1260, 2017.
PubMed
16) Kluin-Nelemans HC, Hoster E, Hermine O, et al:Treatment of Older Patients With Mantle Cell Lymphoma(MCL):Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 38:248-256, 2020.
 
17) Robak T, Jin J, Pylypenko H, et al:Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone(VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone(R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma:final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 19:1449-1458, 2018.
 
18) Flinn IW, van der Jagt R, Kahl BS, et al:Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL:the BRIGHT study. Blood 123:2944-2952, 2014.
 
19) Wang ML, Jurczak W, Jerkeman M, et al:Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med 386:2482-2494, 2022.
PubMed
20) Visco C, Di Rocco A, Evangelista A, et al:Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma:results from the MANTLE-FIRST study. Leukemia 35:787-795, 2021.
PubMed
21) Munshi PN, Hamadani M, Kumar A, et al:ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant 56:2911-2921, 2021.
PubMed
P.256 掲載の参考文献
1) Coiffier B, Lepage E, Briere J, et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.
PubMed
2) Pfreundschuh M, Trumper L, Osterborg A, et al:CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma:a randomised controlled trial by the MabThera International Trial(MInT) Group. Lancet Oncol 7:379-391, 2006.
PubMed
3) Pfreundschuh M, Schubert J, Ziepert M, et al:Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:a randomised controlled trial(RICOVER-60). Lancet Oncol 9:105-116, 2008.
PubMed
4) Vitolo U, Trneny M, Belada D, et al:Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol 35:3529-3537, 2017.
 
5) Sehn LH, Salles G:Diffuse Large B-Cell Lymphoma. N Engl J Med 384:842-858, 2021.
PubMed
6) Stephens DM, Li H, LeBlanc ML, et al:Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma:Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004, 2016.
 
7) Poeschel V, Held G, Ziepert M, et al:Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis(FLYER):a randomised, phase 3, non-inferiority trial. Lancet 394:2271-2281, 2019.
 
8) Persky DO, Li H, Stephens DM, et al:Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma:Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol 38:3003-3011, 2020.
PubMed
9) Lamy T, Damaj G, Soubeyran P, et al:R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 131:174-181, 2018.
PubMed
10) Tilly H, Morschhauser F, Sehn LH, et al:Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386:351-363, 2022.
PubMed
11) Roschewski M, Staudt LM, Wilson WH:Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11:12-23, 2014.
PubMed
12) Younes A, Sehn LH, Johnson P, et al:Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol 37:1285-1295, 2019.
PubMed
13) Nowakowski GS, Chiappella A, Gascoyne RD, et al:ROBUST:A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol 39:1317-1328, 2021.
 
14) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
15) Sehn LH, Herrera AF, Flowers CR, et al:Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 38:155-165, 2020.
 
P.263 掲載の参考文献
1) Kluin PM, Harris NL, Stein H, et al:High-grade B-cell lymphoma. In:WHO Classfication of Tumours of Hematopoietic and Lymphoid Tissues, Revised Fourth Edition(ed by Swerdlow SH, Campo E, Harris NL, et al), p335-341, IARC Press, Lyon, 2017.
 
2) Kluin PM, Harris NL, Stein H, et al:B-cell lymphoma, unclassfiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In:WHO Classfication of Tumours of Hematopoietic and Lymphoid Tissues, Fourth Edition(ed by Swerdlow SH, Campo E, Harris NL, et al), p265-266, IARC Press, Lyon, 2008.
 
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
5) Oki Y, Noorani M, Lin P, et al:Double hit lymphoma:the MD Anderson Cancer Center clinical experience. Br J Haematol 166:891-901, 2014.
 
6) Petrich AM, Gandhi M, Jovanovic B, et al:Impact of induction regimen and stem cell transplantationon outcomes in double-hit lymphoma:a multicenter retrospective analysis. Blood 124:2354-2361, 2014.
PubMed
7) Landsburg DJ, Falkiewicz MK, Maly J, et al:Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol 35:2260-2267, 2017.
PubMed
8) Olszewski AJ, Kurt H, Evens AM:Defining and treating high-grade B-cell lymphoma, NOS. Blood 140:943-954, 2022.
PubMed
9) Abramson JS, Ruppert AS, Giri S, et al:Randomized phase II/III study of DA-EPOCH-R +/- venetoclax in previously untreated double hit lymphoma:initial results from Alliance A051701, Blood 138(Suppl):523, 2021.
 
10) Bishop MR, Dickinson M, Purtill D, et al:Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 386:629-639, 2022.
PubMed
11) Kamdar M, Solomon SR, Arnason J, et al:Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma(TRANSFORM):results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:2294-2308, 2022.
PubMed
12) Locke FL, Miklos DB, Jacobson CA, et al:Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386:640-654, 2022.
 
13) Neelapu SS, Dickinson M, Munoz J, et al:Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma:the phase 2 ZUMA-12 trial. Nat Med 28:735-742, 2022.
 
14) Ennishi D, Jiang A, Boyle M, et al:Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 37:190-201, 2019.
PubMed
15) Sha C, Barrans S, Cucco F, et al:Molecular High-Grade B-Cell Lymphoma:Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol 37:202-212, 2019.
PubMed
P.268 掲載の参考文献
1) Rudiger T, Jaffe ES, Delsol G, et al:Workshop report on Hodgkin's disease and related diseases('grey zone' lymphoma). Ann Oncol 9(Suppl 5):S31-38, 1998.
 
2) Swerdlow S, Campo E, Harris N, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008.
 
3) Wilson WH, Pittaluga S, Nicolae A, et al:A prospective study of mediastinal gray-zone lymphoma. Blood 124:1563-1569, 2014.
PubMed
4) Evens AM, Kanakry JA, Sehn LH, et al:Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma:characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 90:778-783, 2015.
PubMed
5) Hasserjian R, Le Beau M, List A, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. revised 4th ed, IARC, Lyon, 2017.
 
6) Tanaka Y, Maeshima AM, Nomoto J, et al:Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol 100:511-517, 2018.
 
7) Sarkozy C, Chong L, Takata K, et al:Gene expression profiling of gray zone lymphoma. Blood Adv 4:2523-2535, 2020.
PubMed
8) Pilichowska M, Pittaluga S, Ferry JA, et al:Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv 1:2600-2609, 2017.
PubMed
9) Sarkozy C, Copie-Bergman C, Damotte D, et al:Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma:A Histopathologic Series From the LYSA. Am J Surg Pathol 43:341-351, 2019.
 
10) Green MR, Monti S, Rodig SJ, et al:Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010.
 
11) Kritharis A, Pilichowska M, Evens AM:How I manage patients with grey zone lymphoma. Br J Haematol 174:345-350, 2016.
 
12) Eberle FC, Rodriguez-Canales J, Wei L, et al:Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558-566, 2011.
 
13) Sarkozy C, Hung SS, Chavez EA, et al:Mutational landscape of gray zone lymphoma. Blood 137:1765-1776, 2021.
PubMed
14) Armand P, Rodig S, Melnichenko V, et al:Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 37:3291-3299, 2019.
PubMed
15) Armand P, Engert A, Younes A, et al:Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation:Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 36:1428-1439, 2018.
 
16) Melani C, Major A, Schowinsky J, et al:PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med 377:89-91, 2017.
PubMed
17) Jacobsen ED, Sharman JP, Oki Y, et al:Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 125:1394-1402, 2015.
 
P.273 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008.
 
2) Savage KJ:Primary mediastinal large B-cell lymphoma. Blood 140:955-970, 2022.
 
3) Barth TF, Leithauser F, Joos S, et al:Mediastinal(thymic) large B-cell lymphoma:where do we stand? Lancet Oncol 3:229-234, 2002.
 
4) Cazals-Hatem D, Lepage E, Brice P, et al:Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol 20:877-888, 1996.
 
5) Lazzarino M, Orlandi E, Paulli M, et al:Treatment outcome and prognostic factors for primary mediastinal(thymic) B-cell lymphoma:a multicenter study of 106 patients. J Clin Oncol 15:1646-1653, 1997.
PubMed
6) Sarkozy C, Hung SS, Chavez EA, et al:Mutational landscape of gray zone lymphoma. Blood 137:1765-1776, 2021.
PubMed
7) Gunawardana J, Chan FC, Telenius A, et al:Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 46:329-335, 2014.
PubMed
8) Steidl C, Shah SP, Woolcock BW, et al:MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471:377-381, 2011.
PubMed
9) Mottok A, Wright G, Rosenwald A, et al:Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood 132:2401-2405, 2018.
 
10) Duns G, Vigano E, Ennishi D, et al:Characterization of DLBCL with a PMBL gene expression signature. Blood 138:136-148, 2021.
PubMed
11) Paulli M, Strater J, Gianelli U, et al:Mediastinal B-cell lymphoma:a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 30:178-187, 1999.
PubMed
12) Pileri SA, Gaidano G, Zinzani PL, et al:Primary mediastinal B-cell lymphoma:high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB. 1, and PU. 1 in the absence of immunoglobulins. Am J Pathol 162:243-253, 2003.
PubMed
13) Pileri SA, Zinzani PL, Gaidano G, et al:Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma 44(Suppl 3):S21-S26, 2003.
 
14) Traverse-Glehen A, Pittaluga S, Gaulard P, et al:Mediastinal gray zone lymphoma:the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 29:1411-1421, 2005.
 
15) Rosenwald A, Wright G, Leroy K, et al:Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003.
PubMed
16) Eberle FC, Rodriguez-Canales J, Wei L, et al:Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558-566, 2011.
 
17) Savage KJ, Monti S, Kutok JL, et al:The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003.
 
18) Gentry M, Bodo J, Durkin L, et al:Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma. Am J Surg Pathol 41:189-194, 2017.
 
19) Dunleavy K, Pittaluga S, Maeda LS, et al:Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408-1416, 2013.
PubMed
20) Shah NN, Szabo A, Huntington SF, et al:R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma:a multi-centre analysis. Br J Haematol 180:534-544, 2018.
PubMed
21) Malenda A, Kolkowska-Lesniak A, Pula B, et al:Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol 104:59-66, 2020.
PubMed
22) Bartlett NL, Wilson WH, Jung SH, et al:Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma:Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol 37:1790-1799, 2019.
 
23) Aoki T, Shimada K, Suzuki R, et al:High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J 5:e372, 2015.
 
24) Zinzani PL, Pellegrini C, Chiappella A, et al:Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma:results from a phase 2 clinical trial. Blood 129:2328-2330, 2017.
 
25) Kim SJ, Yoon DH, Kang HJ, et al:Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer 19:1080, 2019.
PubMed
26) Zinzani PL, Ribrag V, Moskowitz CH, et al:Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130:267-270, 2017.
 
27) Armand P, Rodig S, Melnichenko V, et al:Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 37:3291-3299, 2019.
PubMed
28) Zinzani PL, Santoro A, Gritti G, et al:Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma:Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol 37:3081-3089, 2019
 
P.281 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) Geer M, Roberts E, Shango M, et al:Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol 186:255-262, 2019.
 
3) Shimada K, Kinoshita T, Naoe T, et al:Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10:895-902, 2009.
 
4) Enzan N, Kitadate A, Tanaka A, et al:Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma:a clinicopathological study of 25 patients. Br J Dermatol 181:200-201, 2019.
 
5) Matsue K, Abe Y, Kitadate A, et al:Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood 133:1257-1259, 2019.
 
6) Abe Y, Narita K, Kobayashi H, et al:Clinical value of abnormal findings on brain magnetic resonance imaging in patients with intravascular large B-cell lymphoma. Ann Hematol 97:2345-2352, 2018.
 
7) Shimada K, Matsue K, Yamamoto K, et al:Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:3189-3195, 2008.
 
8) Shimada K, Murase T, Matsue K, et al:Central nervous system involvement in intravascular large B-cell lymphoma:a retrospective analysis of 109 patients. Cancer Sci 101:1480-1486, 2010.
 
9) Shimada K, Yamaguchi M, Atsuta Y, et al:Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma(PRIMEUR-IVL):a multicentre, single-arm, phase 2 trial. Lancet Oncol 21:593-602, 2020.
 
10) Kato K, Mori T, Kim SW, et al:Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma:Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant 54:1515-1517, 2019.
 
11) Hill BT, Roth CJ, Kositsky R, et al:Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor(CAR) T-Cell Therapy Blood 138(Suppl 1):165, 2021.
 
12) Shimada K, Yoshida K, Suzuki Y, et al:Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood 137:1491-1502, 2021.
 
13) Tilly H, Morschhauser F, Sehn LH, et al:Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386:351-363, 2022.
PubMed
P.287 掲載の参考文献
1) Bailly J, Jenkins N, Chetty D, et al:Plasmablastic lymphoma:An update. Int J Lab Hematol 44(Suppl 1):54-63, 2022.
 
2) Castillo JJ, Bibas M, Miranda RN:The biology and treatment of plasmablastic lymphoma. Blood 125:2323-2330, 2015.
PubMed
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Zarifi C, Deutsch S, Dullet N, et al:An enlarging pacemaker pocket:A case report of a plasmablastic lymphoma arising as a primary tumor around a cardiac pacemaker and systematic literature review of various malignancies arising at the pacemaker pocket. J Cardiol Cases 17:41-43, 2018.
PubMed
5) Frontzek F, Staiger AM, Zapukhlyak M, et al:Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun 12:5183, 2021.
PubMed
6) Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al:Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica 106:1120-1128, 2021.
PubMed
7) Zhou T, Cheng J, Karrs J, et al:Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma. Am J Surg Pathol 46:1364-1379, 2022.
 
8) Mori H, Fukatsu M, Ohkawara H, et al:Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm:a scoping review. Int J Hematol 114:639-652, 2021.
PubMed
9) Makady NF, Ramzy D, Ghaly R, et al:The Emerging Treatment Options of Plasmablastic Lymphoma:Analysis of 173 Individual Patient Outcomes. Clin Lymphoma Myeloma Leuk 21:e255-e263, 2021.
PubMed
10) Castillo JJ, Guerrero-Garcia T, Baldini F, et al:Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol 184:679-682, 2019.
PubMed
11) Jessa R, Chien N, Villa D, et al:Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. Br J Haematol 199:230-238, 2022.
PubMed
12) Cattaneo C, Finel H, McQuaker G, et al:Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma:the European Society for Blood and Marrow Transplantation experience. Biol Blood Marrow Transplant 21:1146-1147, 2015.
PubMed
13) Ryu YK, Ricker EC, Soderquist CR, et al:Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. J Clin Med 11:49282022.
 
14) Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al:Plasmablastic lymphomas of the oral cavity:a new entity associated with the human immunodeficiency virus infection. Blood 89:1413-1420, 1997.
PubMed
15) Vega F, Chang CC, Medeiros LJ, et al:Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18:806-815, 2005.
PubMed
16) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
17) Harris NL, Jaffe ES, Stein H, et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
 
18) Green TL, Eversole LR:Oral lymphomas in HIV-infected patients:association with Epstein-Barr virus DNA. Oral Surg Oral Med Oral Pathol 67:437-442, 1989.
PubMed
19) Kochling G, Ochs A, Hauke G, et al:Plasmablastic immunoglobulin-secreting lymphoma. Report of acase and a glimpse at the prognosis. Klin Wochenschr 66:990-994, 1988.
 
P.292 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition, Volume 2, The International Agency for Research on Cancer, Lyon, 2017.
 
2) Cesarman E, Chang Y, Moore PS, et al:Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191, 1995.
PubMed
3) Kaji D, Ota Y, Sato Y, et al:Primary human herpesvirus 8-negative effusion-based lymphoma:a large B-cell lymphoma with favorable prognosis. Blood Adv 4:4442-4450, 2020.
 
4) Katano H, Sata T:Human herpesvirus 8 virology, epidemiology and related diseases. Jpn J Infect Dis 53:137-155, 2000.
PubMed
5) Said JW, Tasaka T, Takeuchi S, et al:Primary effusion lymphoma in women:report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 88:3124-3128, 1996.
PubMed
6) Klein U, Gloghini A, Gaidano G, et al:Gene expression profile analysis of AIDS-related primary effusion lymphoma(PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101:4115-4121, 2003.
PubMed
7) Tolani B, Gopalakrishnan R, Punj V, et al:Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 33:2928-2937, 2014.
PubMed
8) Gathers DA, Galloway E, Kelemen K, et al:Primary Effusion Lymphoma:A Clinicopathologic Perspective. Cancers(Basel) 14:722, 2022.
PubMed
9) Shimada K, Hayakawa F, Kiyoi H:Biology and management of primary effusion lymphoma. Blood 132:1879-1888, 2018.
PubMed
10) Won JH, Han SH, Bae SB, et al:Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 83:328-330, 2006.
 
11) Bryant A, Milliken S:Successful reduced intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant 14:601-602, 2008.
PubMed
12) Shah NN, Singavi AK, Harrington A:Daratumumab in Primary Effusion Lymphoma:N Engl J Med 379:689-690, 2018.
PubMed
13) Lurain K, Ramaswami R, Widell A, et al:Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab(DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV. Blood 134(Suppl 1):4096, 2019.
 
P.296 掲載の参考文献
1) Boshoff C, Chang Y:Kaposi's sarcoma-associated herpesvirus:a new DNA tumor virus. Annu Rev Med 52:453-470, 2001.
PubMed
2) Simpson GR, Schulz TF, Whitby D, et al:Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 348:1133-1138, 1996.
PubMed
3) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
4) Foster WR, Bischin A, Dorer R, et al:Human Herpesvirus Type 8-associated Large B-cell Lymphoma:A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man:A Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk 16:311-321, 2016.
 
5) Dupin N, Diss TL, Kellam P, et al:HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412, 2000.
PubMed
6) Oksenhendler E, Boulanger E, Galicier L, et al:High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331-2336, 2002.
PubMed
7) Ghoneima A, Cooke J, Shaw E, et al:Human herpes virus 8-positive germinotropic lymphoprolifera-tive disorder:first case diagnosed in the UK, literature review and discussion of treatment options. BMJ Case Rep 13:e231640, 2020.
PubMed
8) Zanelli M, Zizzo M, Bisagni A, et al:Germinotropic lymphoproliferative disorder:a systematic review. Ann Hematol 99:2243-2253, 2020.
PubMed
9) Du MQ, Diss TC, Liu H, et al:KSHV-and EBV-associated germinotropic lymphoproliferative disorder. Blood 100:3415-3418, 2002.
PubMed
10) Said J IP, Campo E, Harris NL:HHV8-associated lymphoproliferative disorders. In:WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues, Revised 4th ed(ed by Swerdlow SH, Campo E, Harris NL et al), International Agency for Research on Cancer(IARC), Lyon, 325-329, 2017.
 
11) Suda T, Katano H, Delsol G, et al:HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 51:671-679, 2001.
PubMed
12) Rehman MEU, Chattaraj A, Neupane K, et al:Efficacy and safety of regimens used for the treatment of multicentric Castleman disease:A systematic review. Eur J Haematol 109:309-320, 2022.
PubMed
13) Katano H, Sato Y, Kurata T, et al:Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 269:335-344, 2000.
PubMed
P.302 掲載の参考文献
1) WHO Classification of Tumours, Revised 4th ed, Vol 2, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(ed by Swerdlow SH, Campo E, Harris NL, et al), IARC, Lyon, 2017.
 
2) Crombie J, LaCasce A:The treatment of Burkitt lymphoma in adults. Blood 137:743-750, 2021.
PubMed
3) Katsushima H, Fukuhara N, Ichikawa S, et al:Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years:a first representative index of Japan from an epidemiologically stable Miyagi Prefecture. Leuk Lymphoma 58:80-88, 2017.
 
4) Kojima Y, Hagiwara S, Uehira T, et al:Clinical outcomes of AIDS-related Burkitt lymphoma:a multi-institution retrospective survey in Japan. Jpn J Clin Oncol 44:318-323, 2014.
PubMed
5) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
6) Magrath I, Adde M, Shad A, et al:Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
PubMed
7) Mead GM, Sydes MR, Walewski J, et al:An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma:results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274, 2002.
PubMed
8) Mead GM, Barrans SL, Qian W, et al:A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria(MRC/NCRI LY10 trial). Blood 112:2248-2260, 2008.
PubMed
9) Maruyama D, Watanabe T, Maeshima AM, et al:Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate(CODOX-M)/ifosfamide, etoposide, and cytarabine(IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma(BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 92:732-743, 2010.
PubMed
10) Zhu KY, Song KW, Connors JM, et al:Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. Br J Haematol 181:782-790, 2018.
PubMed
11) Thomas DA, Faderl S, O'Brien S, et al:Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
PubMed
12) Dunleavy K, Pittaluga S, Shovlin M, et al:Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 369:1915-1925, 2013.
PubMed
13) Roschewski M, Dunleavy K, Abramson JS, et al:Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol 38:2519-2529, 2020.
PubMed
14) Zayac AS, Evens AM, Danilov A, et al:Outcomes of Burkitt lymphoma with central nervous system involvement:evidence from a large multicenter cohort study. Haematologica 106:1932-1942, 2021.
PubMed
15) Dunleavy K:Approach to the Diagnosis and Treatment of Adult Burkitt's Lymphoma. J Oncol Pract 14:665-671, 2018.
 
P.307 掲載の参考文献
1) Van Vlierberghe P, Ferrando A:The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 122:3398-3406, 2012.
PubMed
2) Van Vlierberghe P, Pieters R, Beverloo HB, et al:Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol 143:153-168, 2008.
PubMed
3) Basso K, Mussolin L, Lettieri A, et al:T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Caner 50:1063-1075, 2011.
 
4) Burkhardt B, Hermiston ML:Lymphoblastic lymphoma in children and adolescents:review of current challenges and future opportunities. Br J Haematol 185:1158-1170, 2019.
PubMed
5) Coustan-Smith E, Mullighan CG, Onciu M, et al:Early T-cell precursor leukaemia:a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147-156, 2009.
 
6) Conter V, Valsecchi MG, Buldini B, et al:Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols:a retrospective analysis. Lancet Haematol 3:e80-e86, 2016.
 
7) Liu Y, Easton J, Shao Y, et al:The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 49:1211-1218, 2017.
 
8) Summers RJ, Teachey DT:SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma. Clin Lymphoma Myeloma Leuk 22:718-725, 2022.
 
9) Seki M, Kimura S, Isobe T, et al:Recurrent SPI1(PU. 1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 49:1274-1281, 2017.
PubMed
10) Schrappe M, Valsecchi MG, Bartram CR, et al:Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL:results of the AIEOP-BFM-ALL 2000 study. Blood 118:2077-2084, 2011.
PubMed
11) Sato A, Hatta Y, Imai C, et al:Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia:Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group. Blood 138(Suppl 1):3393, 2021.
 
12) Dunsmore KP, Winter SS, Devidas M, et al:Children's Oncology Group AALL0434:A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 38:3282-3293, 2020.
 
13) Teachey DT, Devidas M, Wood BL, et al:Children's Oncology Group Trial AALL1231:A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol 40:2106-2118, 2022.
 
14) Balbach ST, Makarova O, Bonn BR, et al:Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia 30:970-973, 2016.
PubMed
15) Sunami S, Sekimizu M, Takimoto T, et al:Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma:A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer 63:451-457, 2016.
 
P.312 掲載の参考文献
1) Herling M, Khoury JD, Washington LT, et al:A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104:328-335, 2004.
PubMed
2) Jain P, Aoki E, Keating M, et al:Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia(T-PLL). Ann Oncol 28:1554-1559, 2017.
 
3) Taylor AM, Metcalfe JA, Thick J, et al:Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-438, 1996.
PubMed
4) Yamasaki S, Nitta H, Kondo E, et al:Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia:a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. Ann Hematol 98:2213-2220, 2019.
 
5) Staber PB, Herling M, Bellido M, et al:Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 134:1132-1143, 2019.
PubMed
6) Hu Z, Medeiros LJ, Fang L, et al:Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol 92:441-447, 2017.
 
7) Lopez C, Bergmann AK, Paul U, et al:Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol 173:265-273, 2016.
PubMed
8) Herling M, Patel KA, Teitell MA, et al:High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111:328-337, 2008.
PubMed
9) Murthy HS, Ahn KW, Estrada-Merly N, et al:Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia:A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther 28:187. e1-187. e10, 2022.
 
10) Boidol B, Kornauth C, van der Kouwe E, et al:First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood 130:2499-2503, 2017.
 
11) Herbaux C, Kornauth C, Poulain S, et al:BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood 137:3495-3506, 2021.
 
12) Niemann CU, Levin MD, Dubois J, et al:Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Blood 137:1117-1120, 2021.
PubMed
13) Vivekanandarajah A, Atallah JP, Gupta S:T-cell prolymphocytic leukaemia(T-PLL):a rare disease with a grave prognosis. BMJ Case Rep 2013:bcr2013009808, 2013.
 
14) Laribi K, Lemaire P, Sandrini J, et al:Advances in the understanding and management of T-cell prolymphocytic leukemia. Oncotarget 8:104664-104686, 2017.
PubMed
15) Kiel MJ, Velusamy T, Rolland D, et al:Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124:1460-1472, 2014.
PubMed
P.319 掲載の参考文献
1) Loughran TP Jr:Clonal diseases of large granular lymphocytes. Blood 82:1-14, 1993.
PubMed
2) Lamy T, Moignet A, Loughran TP:LGL leukemia:from pathogenesis to treatment. Blood 129:1082-1094, 2017.
PubMed
3) Tanahashi T, Sekiguchi N, Matsuda K, et al:A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte(LGL) leukemia. Int J Hematol 105:87-91, 2017.
PubMed
4) Teramo A, Gattazzo C, Passeri F, et al:Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood 121:3843-3854, S1, 2013.
 
5) Koskela HL, Eldfors S, Ellonen P, et al:Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366:1905-1913, 2012.
PubMed
6) Andersson EI, Tanahashi T, Sekiguchi N, et al:High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood 128:2465-2468, 2016.
PubMed
7) Cheon H, Xing JC, Moosic KB, et al:Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia. Blood 139:3058-3072, 2022.
 
8) Giudice V, D'Addona M, Montuori N, et al:The Value of Flow Cytometry Clonality in Large Granular Lymphocyte Leukemia. Cancers(Basel) 13:4513, 2021.
PubMed
9) Huuhtanen J, Bhattacharya D, Lonnberg T, et al:Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nat Commun 13:1981, 2022.
PubMed
10) Kim D, Park G, Huuhtanen J, et al:STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. Leukemia 35:3430-3443, 2021.
PubMed
11) Ishida F, Matsuda K, Sekiguchi N, et al:STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci 105:342-346, 2014.
PubMed
12) Tanahashi T, Sekiguchi N, Matsuda K, et al:Cell size variations of large granular lymphocyte leukemia:Implication of a small cell subtype of granular lymphocyte leukemia with STAT3 mutations. Leuk Res 45:8-13, 2016.
PubMed
13) Loughran TP Jr, Zickl L, Olson TL, et al:Immunosuppressive therapy of LGL leukemia:prospective multicenter phase II study by the Eastern Cooperative Oncology Group(E5998). Leukemia 29:886-894, 2015.
PubMed
14) Hirokawa M, Sawada K, Fujishima N, et al:Long-term outcome of patients with acquired chronic pure red cell aplasia(PRCA) following immunosuppressive therapy:a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol 169:879-886, 2015.
 
15) Marchand T, Lamy T, Finel H, et al:Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia:a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia 30:1201-1204, 2016.
 
P.328 掲載の参考文献
1) Fernandez LA, Pope B, Lee C, et al:Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood 67:925-930, 1986.
 
2) Khoury JD, Solary E, Abla O, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36:1703-1719, 2022.
PubMed
3) Suzuki R, Suzumiya J, Nakamura S, et al:Aggressive natural killer-cell leukemia revisited:large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 18:763-770, 2004.
PubMed
4) Ishida F, Ko YH, Kim WS, et al:Aggressive natural killer cell leukemia:therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci 103:1079-1083, 2012.
PubMed
5) Nakashima Y, Tagawa H, Suzuki R, et al:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 44:247-255, 2005.
PubMed
6) Dufva O, Kankainen M, Kelkka T, et al:Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun 9:1567, 2018.
 
7) Caligiuri MA:Human natural killer cells. Blood 112:461-469, 2008.
PubMed
8) Bjorkstrom NK, Strunz B, Ljunggren HG:Natural killer cells in antiviral immunity. Nat Rev Immunol 22:112-123, 2022.
PubMed
9) Kimura H, Ito Y, Kawabe S, et al:EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts:prospective analysis of 108 cases. Blood 119:673-686, 2012.
PubMed
10) Fujimoto A, Ishida F, Izutsu K, et al:Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant 56:347-356, 2021.
PubMed
11) Tang YT, Wang D, Luo H, et al:Aggressive NK-cell leukemia:clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J 7:660, 2017.
PubMed
12) Wong KF, Chan JK, Kwong YL:Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. Br J Haematol 98:922-926, 1997.
PubMed
13) Kataoka K, Miyoshi H, Sakata S, et al:Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 33:1687-1699, 2019.
PubMed
14) Suzuki R, Suzumiya J, Yamaguchi M, et al:Prognostic factors for mature natural killer(NK) cell neoplasms:aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21:1032-1040, 2010.
PubMed
15) Ando M, Sugimoto K, Kitoh T, et al:Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130:860-868, 2005.
PubMed
16) Hamadani M, Kanate AS, DiGilio A, et al:Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 23:853-856, 2017.
PubMed
17) Jeong SH, Song HN, Park JS, et al:Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy:A Multicenter Analysis Comparing Upfront and Salvage Transplantation. Biol Blood Marrow Transplant 24:2471-2478, 2018.
PubMed
P.335 掲載の参考文献
1) Ishitsuka K, Tamura K:Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 15:e517-e526, 2014.
PubMed
2) Katsuya H, Ishitsuka K, Utsunomiya A, et al:Treatment and survival among 1594 patients with ATL. Blood 126:2570-2577, 2015.
PubMed
3) Katsuya H, Yamanaka T, Ishitsuka K, et al:Prognostic index for acute-and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 30:1635-1640, 2012.
PubMed
4) Katsuya H, Shimokawa M, Ishitsuka K, et al:Prognostic index for chronic and smoldering types adult T-cell leukemia/lymphoma. Blood 130:39-47, 2017.
 
5) Fukushima T, Nomura S, Shimoyama M, et al:Japan Clinical Oncology Group(JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma(JCOG0902A). Br J Haematol 166:739-748, 2014.
PubMed
6) Kataoka K, Iwanaga M, Yasunaga JI, et al:Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood 131:215-225, 2018.
PubMed
7) Tsukasaki K, Utsunomiya A, Fukuda H, et al:VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458-5464, 2007.
 
8) Toyoda K, Tsukasaki K, Machida R, et al:Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma(ATL) based on the ATL prognostic index:a supplementary analysis of the JCOG9801. Br J Haematol 186:440-447, 2019.
PubMed
9) Ishida T, Jo T, Takemoto S, et al:Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma:a randomized phase II study. Br J Haematol 169:672-682, 2015.
PubMed
10) Ishida T, Jo T, Takemoto S, et al:Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma:impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol, 184:479-483, 2019.
PubMed
11) Sakamoto Y, Ishida T, Masaki A, et al:CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood 132:758-761, 2018.
PubMed
12) Ishitsuka K, Yurimoto S, Tsuji Y, et al:Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol 102:407-415, 2019.
 
13) Horwitz S, O'Connor OA, Pro B, et al:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma(ECHELON-2):a global, double-blind, randomised, phase 3 trial. Lancet 393:229-240, 2019.
PubMed
14) Cook LB, Fuji S, Hermine O, et al:Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 37:677-687, 2019.
PubMed
15) Fuji S, Inoue Y, Utsunomiya A, et al:Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol 34:3426-3433, 2016.
PubMed
16) Ishida T, Fujiwara H, Nosaka K, et a:Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma:ATLL-002. J Clin Oncol 34:4086-4093, 2016.
PubMed
17) Utsunomiya A, Izutsu K, Jo T, et al:Oral histone deacetylase inhibitor tucidinostat(HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma:Phase IIb results. Cancer Sci 113:2778-2787, 2022.
PubMed
18) Izutsu K, Makita S, Nosaka K, et al:An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood 10. 1182/blood. 2022016862, 2022.
PubMed
P.340 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
2) 直江知樹, 小松則夫, 宮崎泰司, ほか編:WHO血液腫瘍分類WHO分類2017をうまく活用するために(改訂版), p358-365, 医薬ジャーナル社, 2018.
 
3) Swerdlow SH, Campo E, Harris NL, et al(ed):WHO Classification of Tumor, Tumours of Hematopoietic and Lymphoid Tissues, 4th ed 413-418, International Agency for Research on Cancer, Lyon, 2017.
 
4) Chiarle R, Simmons WJ, Cai H, et al:Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623-629, 2005.
PubMed
5) Stein H, Foss HD, Durkop H, et al:CD30(+) anaplastic large cell lymphoma:a review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695, 2000.
PubMed
6) Falini B, Pileri S, Zinzani PL, et al:ALK+ lymphoma:clinico-pathological findings and outcome. Blood 93:2697-2706, 1999.
PubMed
7) Vose J, Armitage J, Weisenburger D, et al:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
PubMed
8) Savage KJ, Harris NL, Vose JM, et al:ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008.
 
9) Sibon D, Nguyen DP, Schmitz N, et al:ALK-positive anaplastic large-cell lymphoma in adults:an individual patient data pooled analysis of 263 patients. Haematologica 104:e562-e565, 2019.
PubMed
10) Lobello C, Tichy B, Bystry V, et al:STAT3 and TP53 mutations associate with poor prognosis inanaplastic large cell lymphoma. Leukemia 35:1500-1505, 2021.
PubMed
11) Horwitz S, O'Connor OA, Pro B, et al:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma(ECHELON-2):a global, double-blind, randomised, phase 3 trial. Lancet 393:229-240, 2019.
PubMed
12) Fukano R, Mori T, Sekimizu M, et al:Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma:An open-label phase II trial. Cancer Sci 111:4540-4547, 2020.
PubMed
13) Hapgood G, Savage KJ:The biology and management of systemic anaplastic large cell lymphoma. Blood 126:17-25, 2015.
PubMed
14) Crescenzo R, Abate F, Lasorsa E, et al:Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27:516-532, 2015.
PubMed
15) Parrilla Castellar ER, Jaffe ES, Said JW, et al:ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473-1480, 2014.
PubMed
16) Ohishi Y, Mitsuda A, Ejima K, et al:Breast implant-associated anaplastic large-cell lymphoma:first case detected in a Japanese breast cancer patient. Breast Cancer 27:499-504, 2020.
 
17) Miranda RN, Aladily TN, Prince HM, et al:Breast implant-associated anaplastic large-cell lymphoma:long-term follow-up of 60 patients. J Clin Oncol 32:114-120, 2014.
PubMed
P.345 掲載の参考文献
1) Sakata-Yanagimoto M, Enami T, Yoshida K, et al:Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171-175, 2014.
PubMed
2) Advani RH, Skrypets T, Civallero M, et al:Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma:final report from the international T-cell Project. Blood 138:213-220, 2021.
PubMed
3) Tokunaga T, Shimada K, Yamamoto K, et al:Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma:a multicenter cooperative study in Japan. Blood 119:2837-2843, 2012.
PubMed
4) Bachy E, Camus V, Thieblemont C, et al:Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma:Results of the Ro-CHOP Phase III Study(Conducted by LYSA). J Clin Oncol 40:242-251, 2022.
PubMed
5) Horwitz S, O'Connor OA, Pro B, et al:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma(ECHELON-2):a global, double-blind, randomised, phase 3 trial. Lancet393:229-240, 2019.
PubMed
6) d'Amore F, Relander T, Lauritzsen GF, et al:Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma:NLG-T-01. J Clin Oncol 30:3093-3099, 2012.
PubMed
7) Kyriakou C, Canals C, Goldstone A, et al:High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma:complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218-224, 2008.
 
8) Fossard G, Broussais F, Coelho I, et al:Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction:an analysis of patients from LYSA centers. Ann Oncol 29:715-723, 2018.
 
9) Mak V, Hamm J, Chhanabhai M, et al:Survival of patients with peripheral T-cell lymphoma after first relapse or progression:spectrum of disease and rare long-term survivors. J Clin Oncol 31:1970-1976, 2013.
PubMed
10) Jagasia M, Morgan D, Goodman S, et al:Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45:2261-2267, 2004.
PubMed
11) Kyriakou C, Canals C, Finke J, et al:Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma:a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27:3951-3958, 2009.
 
12) Alonso-Castro AJ, Zapata-Morales JR, Arana-Argaez V, et al:Pharmacological and toxicological study of a chemical-standardized ethanol extract of the branches and leaves from Eysenhardtia polystachya(Ortega) Sarg.(Fabaceae). J Ethnopharmacol 224:314-322, 2018.
PubMed
13) Lemonnier F, Dupuis J, Sujobert P, et al:Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood 132:2305-2309, 2018.
PubMed
14) Falchi L, Ma H, Klein S, et al:Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL:a multicenter phase 2 study. Blood 137:2161-2170, 2021.
PubMed
15) O'Connor OA, Pro B, Pinter-Brown L, et al:Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma:results from the pivotal PROPEL study. J Clin Oncol 29:1182-1189, 2011.
 
P.351 掲載の参考文献
1) Yamaguchi M, Suzuki R, Oguchi M, et al:Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013:A Cooperative Study in Japan. J Clin Oncol 35:32-39, 2017.
PubMed
2) Kim SJ, Yoon DH, Jaccard A, et al:A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment:a multicentre, retrospective analysis. Lancet Oncol 17:389-400, 2016.
PubMed
3) 造血器腫瘍診療ガイドライン2018年版補訂版(一般社団法人日本血液学会 編), 金原出版, 2020.
 
4) Yamaguchi M, Tobinai K, Oguchi M, et al:Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol 30:4044-4046, 2012.
 
5) Huang Y, Yang J, Liu P, et al:Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol 96:1477-1483, 2017.
 
6) Kim SJ, Yang DH, Kim JS, et al:Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma:CISL08-01 phase II study. Ann Hematol 93:1895-1901, 2014.
PubMed
7) Qi S, Yahalom J, Hsu M, et al:Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leuk Lymphoma 57:2575-2583, 2016.
 
8) Zhang Y, Ma S, Cai J, et al:Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma:A multicenter study. Am J Hematol 96:1481-1490, 2021.
PubMed
9) Yamaguchi M, Kwong YL, Kim WS, et al:Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer(NK)/T-cell lymphoma, nasal type:the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410-4416, 2011.
PubMed
10) Yamaguchi M, Suzuki R, Miyazaki K, et al:Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. Ann Hematol 98:1647-1655, 2019.
 
11) Song GY, Yoon DH, Suh C, et al:Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Bone Marrow Transplant 56:1205-1208, 2021.
PubMed
12) Kim H, Jeong H, Yamaguchi M, et al:Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood 136:2548-2556, 2020.
 
13) Kharfan-Dabaja MA, Kumar A, Ayala E, et al:Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas:An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 23:1826-1838, 2017.
 
14) Ahn HK, Suh C, Chuang SS, et al:Extranodal natural killer/T-cell lymphoma from skin or soft tissue:suggestion of treatment from multinational retrospective analysis. Ann Oncol 23:2703-2707, 2012.
PubMed
15) Kim SJ, Choi JY, Hyun SH, et al:Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type:a multicentre, retrospective analysis. Lancet Haematol 2:e66-e74, 2015.
PubMed
16) Kim SJ, Hyeon J, Cho I, et al:Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas. Cancer Res Treat 51:611-622, 2019.
PubMed
P.356 掲載の参考文献
1) O'Farrelly C, Feighery C, O'Briain DS, et al:Humoral response to wheat protein in patients with coeliac disease and enteropathy associated T cell lymphoma. Br Med J(Clin Res Ed) 293:908-910, 1986.
PubMed
2) Campo E, Swerdlow SH, Harris NL, et al:The 2008 WHO classification of lymphoid neoplasms and beyond:evolving concepts and practical applications. Blood 117:5019-5032, 2011.
PubMed
3) Swerdlow SH, Campo E, Pileri SA, et al:The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016.
PubMed
4) Takeuchi K, Yokoyama M, Ishizawa S, et al:Lymphomatoid gastropathy:a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 116:5631-5637, 2010.
PubMed
5) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
6) The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50:696-702, 2000.
 
7) Green PHR, Cellier C:Celiac disease. N Engl J Med 357:1731-1743, 2007.
PubMed
8) Cellier C, Delabesse E, Helmer C, et al:Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 356:203-208, 2000.
 
9) Malamut G, Chandesris O, Verkarre V, et al:Enteropathy associated T cell lymphoma in celiac disease:a large retrospective study. Dig Liver Dis 45:377-384, 2013.
PubMed
10) Chan JK, Chan AC, Cheuk W, et al:Type II enteropathy-associated T-cell lymphoma:a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol 35:1557-1569, 2011.
 
11) Zettl A, Ott G, Makulik A, et al:Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 161:1635-1645, 2002.
PubMed
12) Deleeuw RJ, Zettl A, Klinker E, et al:Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 132:1902-1911, 2007.
PubMed
13) Nairismagi ML, Tan J, Lim JQ, et al:JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia 30:1311-1319, 2016.
 
14) Sieniawski M, Angamuthu N, Boyd K, et al:Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 115:3664-3670, 2010.
PubMed
15) Horwitz S, O'Connor OA, Pro B, et al:The ECHELON-2 Trial:5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33:288-298, 2022.
PubMed
P.360 掲載の参考文献
1) Gaulard P, Jaffe ES, Krenacs L, et al:Hepatosplenic T-cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(ed by Swerdlow SH, Campo E, Harris NK, et al), p381-382, IARC Press, Lyon, 2017.
 
2) Foss FM, Horwitz SM, Civallero M, et al:Incidence and outcomes of rare T cell lymphomas from the T Cell Project:hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol 95:151-155, 2020.
 
3) Yabe M, Miranda RN, Medeiros LJ:Hepatosplenic T-cell Lymphoma:a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol 74:5-16, 2018.
PubMed
4) Pro B, Allen P, Behdad A:Hepatosplenic T-cell lymphoma:a rare but challenging entity. Blood 136:2018-2026, 2020.
PubMed
5) Macon WR, Levy NB, Kurtin PJ, et al:Hepatosplenic αβ T-cell lymphomas:a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 25:285-296, 2001.
 
6) Roelandt PR, Maertens J, Vandenberghe P, et al:Hepatosplenic γδ T-cell lymphoma after liver transplantation:report of the first 2 cases and review of the literature. Liver Transpl 15:686-692, 2009.
 
7) Yabe M, Medeiros LJ, Wang SA, et al:Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia:A Clinicopathologic, Immunophenotypic, and Molecular Analysis. Am J Surg Pathol 41:82-93, 2017.
 
8) Sallah S, Smith SV, Lony LC, et al:Gamma/delta T-cell hepatosplenic lymphoma:review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann Hematol 74:139-142, 1997.
PubMed
9) Belhadj K, Reyes F, Farcet JP, et al:Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome:report on a series of 21 patients. Blood 102:4261-4269, 2003.
 
10) Falchook GS, Vega F, Dang NH, et al:Hepatosplenic gamma-delta T-cell lymphoma:clinicopathologi-cal features and treatment. Ann Oncol 20:1080-1085, 2009.
 
11) Voss MH, Lunning MA, Maragulia JC, et al:Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome fo rpatients with hepatosplenic T-cell lymphoma:a single institution experience. Clin Lymphoma Myeloma Leuk 13:8-14, 2013.
 
12) Tanase A, Schmitz N, Stein H, et al:Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma:a retrospective study of the EBMT Lymphoma Working Party. Leukemia 29:686-688, 2015.
PubMed
13) Rashidi A, Cashen AF:Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J 5:e318, 2015.
PubMed
14) Jaeger G, Bauer F, Brezinschek R, et al:Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 19:1025-1026, 2008.
 
15) Amengual JE, Lichtenstein R, Lue J, et al:A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 131:397-407, 2018.
 
P.365 掲載の参考文献
1) Jaffe ES, Gaulard P, Cerroni L:Subcutaneous panniculitis-like T-cell lymphoma. In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed(Swerdlow SH, Campo E, Harris NL, et al), p383-385, IARC Press, Lyon, 2017.
 
2) Willemze R, Jaffe ES, Burg G, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005.
PubMed
3) Hamada T, Iwatsuki K:Cutaneous lymphoma in Japan:a nationwide study of 1733 patients. J Dermatol 41:3-10, 2014.
PubMed
4) Ohtsuka M, Miura T, Yamamoto T:Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma:a literature review of published Japanese cases. Eur J Dermatol 27:34-41, 2017.
PubMed
5) LeBlanc RE, Tavallaee M, Kim YH, et al:Useful Parameters for Distinguishing Subcutaneous Panniculitis-like T-Cell Lymphoma From Lupus Erythematosus Panniculitis. Am J Surg Pathol 40:745-754, 2016.
PubMed
6) Willemze R, Jansen PM, Cerroni L, et al:Subcutaneous panniculitis-like T-cell lymphoma:definition, classification, and prognostic factors:an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111:838-845, 2008.
 
7) Mizutani S, Kuroda J, Shimura Y, et al:Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematol 126:8-12, 2011.
PubMed
8) 大塚幹夫, 伊豆津宏二, 大熊加惠, ほか:皮膚悪性腫瘍ガイドライン第3版皮膚リンパ腫診療ガイドライン2020. 日本皮膚科学会雑誌 130:1347-1423, 2020.
 
9) Gilson D, Whittaker SJ, Child FJ, et al:British Association of Dermatologists and U. K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 180:496-526, 2019.
 
10) Willemze R, Hodak E, Zinzani PL, et al:Primary cutaneous lymphomas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv30-iv40, 2018.
PubMed
11) Go RS, Wester SM:Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma:a systematic analysis of 156 patients reported in the literature. Cancer 101:1404-1413, 2004.
PubMed
P.370 掲載の参考文献
1) Campbell JJ, Clark RA, Watanabe R, et al:Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets:a biologic rationale for their distinct clinical behaviors. Blood 116:767-771, 2010.
PubMed
2) Bradford PT, Devesa SS, Anderson WF, et al:Cutaneous lymphoma incidence patterns in the United States:a population-based study of 3884 cases. Blood 113:5064-5073, 2009.
PubMed
3) Olsen E, Vonderheid E, Pimpinelli N, et al:Revisions to the staging and classification of mycosis fungoides and Sezary syndrome:a proposal of the International Society for Cutaneous Lymphomas(ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer(EORTC). Blood 110:1713-1722, 2007.
 
4) Agar NS, Wedgeworth E, Crichton S, et al:Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome:validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:4730-4739, 2010.
PubMed
5) Scarisbrick JJ, Prince HM, Vermeer MH, et al:Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome:Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33:3766-3773, 2015.
 
6) Gilson D, Whittaker SJ, Child FJ, et al:British Association of Dermatologists and U. K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 180:496-526, 2019.
 
7) Trautinger F, Eder J, Assaf C, et al:European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome-Update 2017. Eur J Cancer 77:57-74, 2017.
PubMed
8) NCCN clinical practice in oncology(NCCN guidelines), Primary cutaneous lymphoma, Version 2.2022, Jun 9, 2022.
 
9) 大塚幹夫, 伊豆津宏二, 大熊加惠, ほか:皮膚悪性腫瘍ガイドライン第3版 皮膚リンパ腫診療ガイドライン2020. 日本皮膚科学会雑誌 130:1347-1423, 2020.
 
10) Sugaya M, Tokura Y, Hamada T, et al:Phase II study of i. v. interferon-gamma in Japanese patients with mycosis fungoides. J Dermatol 41:50-56, 2014.
 
11) Hamada T, Tokura Y, Sugaya M, et al:Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma:The results of a phase 2 study(B-1201). J Dermatol 46:557-563, 2019.
PubMed
12) Olsen EA, Kim YH, Kuzel TM, et al:Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115, 2007.
PubMed
13) Kim YH, Bagot M, Pinter-Brown L, et al:Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma(MAVORIC):an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19:1192-1204, 2018.
 
14) Kawai H, Ando K, Maruyama D, et al:Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci 112:2426-2435, 2021.
PubMed
15) Prince HM, Kim YH, Horwitz SM, et al:Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma(ALCANZA):an international, open-label, randomised, phase 3, multicentre trial. Lancet 390:555-566, 2017.
 
P.375 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed, Vol2(ed by Swerdlow SH, Campo E, Harris NL, et al), IARC, Lyon, 2008.
 
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) Weisenburger DD, Savage KJ, Harris NL, et al:Peripheral T-cell lymphoma, not otherwise specified:a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402-3408, 2011.
 
4) Asano N, Suzuki R, Kagami Y, et al:Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29:1284-1293, 2005.
PubMed
5) Vose J, Armitage J, Weisenburger D, et al:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
PubMed
6) Laurent C, Baron M, Amara N, et al:Impact of Expert Pathologic Review of Lymphoma Diagnosis:Study of Patients From the French Lymphopath Network. J Clin Oncol 35:2008-2017, 2017.
PubMed
7) Bellei M, Sabattini E, Pesce EA, et al:Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas:results of the central review of 573 cases from the T-Cell Project, an international, cooperative study. Hematol Oncol 35:630-636, 2017.
 
8) Iqbal J, Wright G, Wang C, et al:Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915-2923, 2014.
PubMed
9) Amador C, Greiner TC, Heavican TB, et al:Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 134:2159-2170, 2019.
PubMed
10) Menon MP, Nicolae A, Meeker H, et al:Primary CNS T-cell Lymphomas:A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. Am J Surg Pathol 39:1719-1729, 2015.
PubMed
11) Horwitz S, O'Connor OA, Pro B, et al:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma(ECHELON-2):a global, double-blind, randomised, phase 3 trial. Lancet 393:229-240, 2019.
PubMed
12) Horwitz S, O'Connor OA, Pro B, et al:The ECHELON-2 Trial:5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33:288-298, 2022.
PubMed
13) Horwitz SM, Advani RH, Bartlett NL, et al:Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095-3100, 2014.
PubMed
P.380 掲載の参考文献
1) CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises:Case 40011. N Engl J Med 250:26-30, 1954.
PubMed
2) Castleman B, Iverson L, Menendez VP:Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9:822-830, 1956.
PubMed
3) Keller AR, Hochholzer L, Castleman B:Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670-683, 1972.
PubMed
4) Dupin N, Diss TL, Kellam P, et al:HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412, 2000.
PubMed
5) Fajgenbaum DC, Uldrick TS, Bagg A, et al:International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646-1657, 2017.
PubMed
6) キャッスルマン病診療ガイドライン統括委員会, キャッスルマン病診療ガイドライン作成ワーキンググループ:キャッスルマン病診療ガイドライン(令和2年度初版), 2020. [https://castleman.jp/index.html]
 
7) Dispenzieri A, Fajgenbaum DC:Overview of Castleman disease. Blood 135:1353-1364, 2020.
PubMed
8) Talat N, Schulte KM:Castleman's disease:systematic analysis of 416 patients from the literature. Oncologist 16:1316-1324, 2011.
PubMed
9) Liu W, Cai Q, Yu T, et al:Clinical characteristics and outcomes of Castleman disease:a multicenter Consortium study of 428 patients with 15-year follow-up. Am J Cancer Res 12:4227-4240, 2022.
 
10) Din F, Mellor F, Millard T, et al:Radiology of Castleman disease:the pivotal role of imaging in diagnosis, staging, and response assessment of this rare entity. Clin Radiol 77:399-408, 2022.
PubMed
11) He L, Chen Y, Tan X, et al:18F-FDG PET/CT and contrast-enhanced CT in the diagnosis of Castleman disease. Jpn J Radiol 4:98-107, 2023.
PubMed
12) Nishimura MF, Nishimura Y, Nishioki A, et al:Clinical and Pathological Characteristics of Hyaline-Vascular Type Unicentric Castleman Disease:A 20-Year Retrospective analysis. Diagnostics(Basel) 11:2008, 2021.
 
13) Barry KK, Plumptre I, Bazewicz CG, et al:Paraneoplastic pemphigus associated with Castleman disease:A multicenter case series. Pediatr Dermatol 40:90-95, 2022.
PubMed
14) Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, et al:Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells:molecular evidence of mesenchymal tumorigene-sis. Am J Surg Pathol 26:662-669, 2002.
 
15) Chang KC, Wang YC, Hung LY, et al:Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. Mod Pathol 27:823-831, 2014.
PubMed
16) Li Z, Lan X, Li C, et al:Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia 33:1035-1038, 2019.
PubMed
17) 日本血液学会(編):造血器腫瘍診療ガイドライン2018年版, 金原出版, 2018.
 
18) Dispenzieri A:POEMS syndrome:2021 Update on diagnosis, risk-stratification, and management. Am J Hematol 96:872-888, 2021.
PubMed
19) Abdallah NH, Habermann T, Buadi FK, et al:Multicentric Castleman disease:A single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol 97:401-410, 2022.
PubMed
20) Suichi T, Misawa S, Sekiguchi Y, et al:Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease. J Neurol Sci 413:116771, 2020.
PubMed
21) Parravicini C, Corbellino M, Paulli M, et al:Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 151:1517-1522, 1997.
PubMed
22) Du MQ, Liu H, Diss TC, et al:Kaposi sarcoma-associated herpesvirus infects monotypic(IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130-2136, 2001.
PubMed
23) Mori Y, Nishimoto N, Ohno M, et al:Human herpesvirus 8-encoded interleukin-6 homologue(viral IL-6) induces endogenous human IL-6 secretion. J Med Virol 61:332-335, 2000.
PubMed
24) Oksenhendler E, Carcelain G, Aoki Y, et al:High levels of human herpesvirus 8 viral load, humaninterleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentriccastleman disease in HIV-infected patients. Blood 96:2069-2073, 2000.
 
25) Uldrick TS, Polizzotto MN, Yarchoan R:Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol 24:495-505, 2012.
PubMed
26) Uldrick TS, Polizzotto MN, Aleman K, et al:Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood 124:3544-3552, 2014.
PubMed
27) Song SN, Tomosugi N, Kawabata H, et al:Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody(tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116:3627-3634, 2010.
 
28) Iwaki N, Gion Y, Kondo E, et al:Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep 7:42316, 2017.
 
29) Mizuno H, Sawa N, Watanabe S, et al:The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome. Kidney Int Rep 5:1172-1179, 2020.
PubMed
30) Arenas DJ, Floess K, Kobrin D, et al:Increased mTOR activation in idiopathic multicentric Castleman disease. Blood 135:1673-1684, 2020.
PubMed
31) Fujimoto S, Kawabata H, Sakai T, et al:Optimal treatments for TAFRO syndrome:a retrospective surveillance study in Japan. Int J Hematol 113:73-80, 2021.
PubMed
32) Yoshizaki K, Matsuda T, Nishimoto N, et al:Pathogenic significance of interleukin-6(IL-6/BSF-2) in Castleman's disease. Blood 74:1360-1367, 1989.
PubMed
33) Nishimoto N, Kanakura Y, Aozasa K, et al:Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627-2632, 2005.
PubMed
34) Goodman AM, Jeong AR, Phillips A, et al:Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. Eur J Haematol 107:642-649, 2021.
PubMed
35) 森 茂郎, 毛利 昇, 内田俊和, ほか:著しい多クローン性高免疫グロブリン血症と全身リンパ節の形質細胞増生を呈する症候群. 日本網内系学会会誌 20 suppl:85-94, 1981.
 
36) Nishikori A, Nishimura MF, Nishimura Y, et al:Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. Int J Mol Sci 23:10301, 2022.
PubMed
37) van Rhee F, Wong RS, Munshi N, et al:Siltuximab for multicentric Castleman's disease:a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15:966-974, 2014.
PubMed
38) Fujimoto S, Sakai T, Kawabata H, et al:Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94:975-983, 2019.
PubMed
39) Carbone A, Borok M, Damania B, et al:Castleman disease. Nat Rev Dis Primers 7:84, 2021.
PubMed
P.386 掲載の参考文献
1) Masaki Y, Ueda Y, Yanagisawa H, et al:TAFRO Syndrome:A Disease Requiring Immediate Medical Attention. Intern Med 62:27-32 2023.
PubMed
2) 高井和江, 新國公司, 渋谷宏行, ほか:発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51:320-325, 2010.
 
3) Masaki Y, Kawabata H, Fujimoto S, et al:Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop 59:175-178, 2019.
PubMed
4) Fujimoto S, Sakai T, Kawabata H, et al:Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94:975-983, 2019.
PubMed
5) Masaki Y, Arita K, Sakai T, et al:Castleman disease and TAFRO syndrome. Ann Hematol 101:485-490, 2022.
PubMed
6) Masaki Y, Kawabata H, Takai K, et al:Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103:686-692, 2016.
PubMed
7) Masaki Y, Kawabata H, Takai K, et al:2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111:155-158, 2020.
PubMed
8) Iwaki N, Fajgenbaum DC, Nabel CS, et al:Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220-226, 2016.
PubMed
9) Fujimoto S, Kawabata H, Sakai T, et al:Optimal treatments for TAFRO syndrome:a retrospective surveillance study in Japan. Int J Hematol 113:73-80, 2021.
PubMed
10) Kawabata H, Fujimoto S, Sakai T, et al:Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol 114:179-188, 2021.
 
11) Fajgenbaum DC, Uldrick TS, Bagg A, et al:International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646-1657, 2017.
PubMed
12) Fajgenbaum DC, van Rhee F, Nabel CS:HHV-8-negative, idiopathic multicentric Castleman disease:novel insights into biology, pathogenesis, and therapy. Blood 123:2924-2933, 2014.
PubMed

[VI] 節外リンパ腫の臓器別特徴に基づく診断と治療

P.395 掲載の参考文献
1) Grommes C, DeAngelis LM:Primary CNS Lymphoma. J Clin Oncol 35:2410-2418, 2017.
PubMed
2) Weller M, Martus P, Roth P, et al:Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14:1481-1484, 2012.
PubMed
3) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
4) Morris PG, Correa DD, Yahalom J, et al:Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma:final results and long-term outcome. J Clin Oncol 31:3971-3979, 2013.
PubMed
5) Omuro A, Correa DD, DeAngelis LM, et al:R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125:1403-1410, 2015.
PubMed
6) Kondo E, Ikeda T, Izutsu K, et al:High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma:Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant 25:899-905, 2019.
PubMed
7) Houillier C, Taillandier L, Dureau S, et al:Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger:Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol 37:823-833, 2019.
 
8) Kondo E, Ikeda T, Goto H, et al:Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma. Cancer Chemother Pharmacol 84:849-860, 2019.
PubMed
9) Nishikori M, Masaki Y, Fujii N, et al:An expanded-access clinical study of thiotepa(DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol 115:391-398, 2022.
PubMed
10) Schorb E, Kasenda B, Ihorst G, et al:High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma:a pilot study. Blood Adv 4:3378-3381, 2020.
PubMed
11) Thiel E, Korfel A, Martus P, et al:High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma(G-PCNSL-SG-1):a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036-1047, 2010.
 
12) Wilson WH, Bromberg JE, Stetler-Stevenson M, et al:Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 99:1228-1235, 2014.
PubMed
13) Schmitz N, Frontzek F:CNS prophylaxis in DLBCL:time to say goodbye? Blood 139:315-317, 2022.
PubMed
14) Batchelor T, Carson K, O'Neill A, et al:Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy:a report of NABTT 96-07. J Clin Oncol 21:1044-1049, 2003.
PubMed
15) Ferreri AJ, Reni M, Foppoli M, et al:High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma:a randomised phase 2 trial. Lancet 374:1512-1520, 2009.
PubMed
16) Ferreri AJ, Cwynarski K, Pulczynski E, et al:Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab(MATRix regimen) in patients with primary CNS lymphoma:results of the first randomisation of the International Extranodal Lymphoma Study Group-32(IELSG32) phase 2 trial. Lancet Haematol 3:e217-e227, 2016.
 
17) Rubenstein JL, Combs D, Rosenberg J, et al:Rituximab therapy for CNS lymphomas:targeting the leptomeningeal compartment. Blood 101:466-468, 2003.
PubMed
18) Schmitt AM, Herbrand AK, Fox CP, et al:Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. Hematol Oncol 37:548-557, 2019.
PubMed
P.405 掲載の参考文献
1) Willemze R:Primary cutaneous lymphoma:the 2018 update of the WHO-EORTC classification. Presse Med 51:104126, 2022.
PubMed
2) Fujii K, Hamada T, Shimauchi T, et al:Cutaneous lymphoma in Japan, 2012-2017:A nationwide study. J Dermatol Sci 97:187-193, 2020.
PubMed
3) Higashi Y, Kawai K, Yonekura K, et al:Indication for random skin biopsy for the diagnosis of intravascular large B cell lymphoma. Dermatology 224:46-50, 2012.
 
4) Yonekura K:Current treatment strategies and emerging therapies for cutaneous lymphoma. J Dermatol 49:223-231, 2022.
PubMed
5) Hamada T, Sugaya M, Tokura Y, et al:Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. J Dermatol 44:135-142, 2017.
PubMed
6) Wada H, Tsuboi R, Kato Y, et al:Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. J Dermatol 39:823-828, 2012.
PubMed
7) Whittaker SJ, Demierre MF, Kim EJ, et al:Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28:4485-4491, 2010.
PubMed
8) Utsunomiya A, Izutsu K, Jo T, et al:Oral histone deacetylase inhibitor tucidinostat(HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma:Phase IIb results. Cancer Sci 113:2778-2787, 2022.
PubMed
9) Kim YH, Bagot M, Pinter-Brown L, et al:Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma(MAVORIC):an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19:1192-1204, 2018.
 
10) Prince HM, Kim YH, Horwitz SM, et al:Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma(ALCANZA):an international, open-label, randomised, phase 3, multicentre trial. Lancet 390:555-566, 2017.
 
11) Kawai H, Ando K, Maruyama D, et al:Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci 112:2426-2435, 2021.
PubMed
P.410 掲載の参考文献
1) Freeman C, Berg JW, Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260, 1972.
PubMed
2) Mannami T, Yoshino T, Oshima K, et al:Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders:characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol 14:641-649, 2001.
PubMed
3) Cho EY, Han JJ, Ree HJ, et al:Clinicopathologic analysis of ocular adnexal lymphomas:extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol 73:87-96, 2003.
PubMed
4) Olsen TG, Holm F, Mikkelsen LH, et al:Orbital Lymphoma-An International Multicenter Retrospective Study. Am J Ophthalmol 199:44-57, 2019.
PubMed
5) Desai A, Joag MG, Lekakis L, et al:Long-term course of patients with primary ocular adnexal MALT lymphoma:a large single-institution cohort study. Blood 129:324-332, 2017.
PubMed
6) Ferreri AJ, Guidoboni M, Ponzoni M, et al:Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96:586-594, 2004.
PubMed
7) Travaglino A, Pace M, Varricchio S, et al:Prevalence of Chlamydia psittaci, Chlamydia pneumoniae, and Chlamydia trachomatis Determined by Molecular Testing in Ocular Adnexa Lymphoma Specimens. Am J Clin Pathol 153:427-434, 2020.
PubMed
8) Wohrer S, Troch M, Streubel B, et al:MALT lymphoma in patients with autoimmune diseases:a comparative analysis of characteristics and clinical course. Leukemia 21:1812-1818, 2007.
PubMed
9) Nishida K, Sogabe Y, Makihara A, et al:Ocular adnexal marginal zone lymphoma arising in a patient with IgG4-related ophthalmic disease. Mod Rheumatol 29:383-387, 2019.
 
10) Graue GF, Finger PT, Maher E, et al:Ocular adnexal lymphoma staging and treatment:American Joint Committee on Cancer versus Ann Arbor. Eur J Ophthalmol 23:344-355, 2013.
 
11) Lee J, Yoon JS, Kim JS, et al:Long-term outcome, relapse patterns, and toxicity after radiotherapy for orbital mucosa-associated lymphoid tissue lymphoma:implications for radiotherapy optimization. Jpn J Clin Oncol 49:664-670, 2019.
 
12) Tanimoto K, Kaneko A, Suzuki S, et al:Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 17:135-140, 2006.
PubMed
13) Mizuhara K, Kobayashi T, Nakao M, et al:Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma:A retrospec-tive study. Cancer Med. [Epub ahead of print], 2022.
 
14) Ferreri AJ, Ponzoni M, Martinelli G, et al:Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 90:1578-1579, 2005.
PubMed
15) Ferreri AJ, Ponzoni M, Guidoboni M, et al:Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 23:5067-5073, 2005.
PubMed
P.415 掲載の参考文献
1) Grimm SA, McCannel CA, Omuro AM, et al:Primary CNS lymphoma with intraocular involvement:International PCNSL Collaborative Group Report. Neurology 71:1355-1360, 2008.
 
2) Grimm SA, Pulido JS, Jahnke K, et al:Primary intraocular lymphoma:an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 18:1851-1855, 2007.
 
3) Sonoda KH, Hasegawa E, Namba K, et al:Epidemiology of uveitis in Japan:a 2016 retrospective nationwide survey. Jpn J Ophthalmol 65:184-190, 2021.
PubMed
4) Kimura K, Usui Y, Goto H:Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol 56:383-389, 2012.
PubMed
5) Frenkel S, Hendler K, Siegal T, et al:Intravitreal methotrexate for treating vitreoretinal lymphoma:10 years of experience. Br J Ophthalmol 92:383-388, 2008.
PubMed
6) Isobe K, Ejima Y, Tokumaru S, et al:Treatment of primary intraocular lymphoma with radiation therapy:a multi-institutional survey in Japan. Leuk Lymphoma 47:1800-1805, 2006.
PubMed
7) Cheah CY, Milgrom S, Chihara D, et al:Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol 18:575-581, 2016.
PubMed
8) Taoka K, Yamamoto G, Kaburaki T, et al:Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy. Br J Haematol 157:252-254, 2012.
PubMed
9) Kaburaki T, Taoka K, Matsuda J, et al:Combined intravitreal methotrexate and immunochemother-apy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Br J Haematol 179:246-255, 2017.
 
10) Fox CP, Phillips EH, Smith J, et al:Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 184:348-363, 2019.
PubMed
11) Malaise D, Houillier C, Touitou V, et al:Primary vitreoretinal lymphoma:short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. Curr Opin Oncol 33:420-431, 2021.
 
12) Karakawa A, Taoka K, Kaburaki T, et al:Clinical features and outcomes of secondary intraocular lymphoma. Br J Haematol 183:668-671, 2018.
PubMed
13) Baron M, Belin L, Cassoux N, et al:Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood 135:1811-1815, 2020.
PubMed
14) Ghesquieres H, Chevrier M, Laadhari M, et al:Lenalidomide in combination with intravenous rituximab(REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma:a multicenter prospective "proof of concept" phase II study of the French Oculo-Cerebral lymphoma(LOC) Network and the Lymphoma Study Association(LYSA). Ann Oncol 30:621-628, 2019.
PubMed
15) Soussain C, Choquet S, Blonski M, et al:Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma:final analysis of the phase II "proof-of-concept" iLOC study by the Lymphoma study association(LYSA) and the French oculo-cerebral lymphoma(LOC) network. Eur J Cancer 117:121-130, 2019.
PubMed
P.421 掲載の参考文献
1) Ferry JA:Lymphoma of the breast. In:Extranodal Lymphomas(ed by Schmitt WR), p116-132, Elsevier, Philadelphia, 2011.
 
2) Wiseman C, Liao KT:Primary lymphoma of the breast. Cancer 29:1705-1712, 1972.
PubMed
3) James ER, Miranda RN, Turner SD:Primary Lymphomas of the Breast:A Review. JPRAS Open 32:127-143, 2022.
PubMed
4) Aviv A, Tadmor T, Polliack A:Primary diffuse large B-cell lymphoma of the breast:looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol 24:2236-2244, 2013.
PubMed
5) Bobillo S, Joffe E, Lavery JA, et al:Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood 137:39-48, 2021.
 
6) Niitsu N, Okamoto M, Nakamine H, et al:Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma. Leuk Res 32:1837-1841, 2008.
PubMed
7) Fukuhara S, Watanabe T, Munakata W, et al:Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast:a retrospective analysis at a single institution. Eur J Haematol 87:434-440, 2011.
 
8) Miyazaki K, Asano N, Yamada T, et al:DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma:a single-arm, open-label, phase II study. Haematologica 105:2308-2315, 2020.
PubMed
9) Tilly H, Morschhauser F, Sehn LH, et al:Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386:351-363, 2022.
PubMed
10) Tomita N, Yokoyama M, Yamamoto W, et al:Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103:245-251, 2012.
PubMed
11) Ryan G, Martinelli G, Kuper-Hommel M, et al:Primary diffuse large B-cell lymphoma of the breast:prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19:233-241, 2008.
 
12) Lin YC, Tsai CH, Wu JS, et al:Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast-a review of 42 primary and secondary cases in Taiwanese patients. Leuk Lymphoma 50:918-924, 2009.
PubMed
13) Takahashi H, Sakai R, Sakuma T, et al:Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma:A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study. Indian J Hematol Blood Transfus 37:60-66, 2021.
 
14) Mehta-Shah N, Ghione P:An Updated Approach and Understanding of Breast Implant-Associated Anaplastic Large Cell Lymphoma. J Natl Compr Canc Netw 20:309-315, 2022.
PubMed
15) Ohishi Y, Mitsuda A, Ejima K, et al:Breast implant-associated anaplastic large-cell lymphoma:first case detected in a Japanese breast cancer patient. Breast Cancer 27:499-504, 2020.
 
P.426 掲載の参考文献
1) Kojo K, Kawai K, Kawahara T, et al:Recent malignant testicular tumor trend in Japan, a country with an aging population:a large-scale study of 2012-2015 hospital-based cancer registry data. Jpn J Clin Oncol 50:1201-1208, 2020.
 
2) Alaggio R, Amador C, Anagnostopoulos I, et al:The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022.
PubMed
3) Campo E, Jaffe ES, Cook JR, et al:The International Consensus Classification of Mature Lymphoid Neoplasms:a report from the Clinical Advisory Committee. Blood 140:1229-1253, 2022.
PubMed
4) Zucca E, Conconi A, Mughal TI, et al:Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20-27, 2003.
 
5) Booman M, Douwes J, Glas AM, et al:Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol 210:163-171, 2006.
 
6) Deng L, Xu-Monette ZY, Loghavi S, et al:Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era:a report from the International PTL Consortium. Leukemia 30:361-372, 2016.
 
7) Chapuy B, Roemer MG, Stewart C, et al:Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869-881, 2016.
PubMed
8) Chapuy B, Stewart C, Dunford AJ, et al:Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679-690, 2018.
PubMed
9) Schmitz R, Wright GW, Huang DW, et al:Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378:1396-1407, 2018.
PubMed
10) Minderman M, Amir A, Kraan W, et al:Immune evasion in primary testicular and central nervous system lymphomas:HLA loss rather than 9p24. 1/PD-L1/PD-L2 alterations. Blood 138:1194-1197, 2021.
PubMed
11) Kridel R, Telio D, Villa D, et al:Diffuse large B-cell lymphoma with testicular involvement:outcome and risk of CNS relapse in the rituximab era. Br J Haematol 176:210-221, 2017.
PubMed
12) Vitolo U, Chiappella A, Ferreri AJ, et al:First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation:final results of an international phase II trial. J Clin Oncol 29:2766-2772, 2011.
PubMed
13) Conconi A, Chiappella A, Orsucci L, et al:Intensified(intravenous and intrathecal) CNS prophylaxis in primary testicular diffuse large B-cell lymphoma:5-year results of the IELSG30 trial. Hematol Oncol 39:S2, 2021.
 
14) Cheah CY, Wirth A, Seymour JF:Primary testicular lymphoma. Blood 123:486-493, 2014.
PubMed
15) Wilson WH, Wright GW, Huang DW, et al:Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39:1643-1653. e3, 2021.
 
P.433 掲載の参考文献
1) William J, Variakojis D, Yeldandi A, et al:Lymphoproliferative neoplasms of the lung:a review. Arch Pathol Lab Med 137:382-391, 2013.
 
2) Sanguedolce F, Zanelli M, Zizzo M, et al:Primary Pulmonary B-Cell Lymphoma:A Review and Update. Cancers(Basel) 13:415, 2021.
PubMed
3) Swerdlow S, Campo E, Harris NL, et al(ed):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues(revised 4th edition), IARC, Lyon, 2017.
 
4) Travis WD, Brambilla E, Burke AP, et al(ed):WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart(4th edition). IARC, Lyon, 2015.
 
5) Borie R, Cadranel J, Guihot A, et al:Pulmonary manifestations of human herpesvirus-8 during HIV infection. Eur Respir J 42:1105-1118, 2013.
PubMed
6) Zucca E, Bertoni F:The spectrum of MALT lymphoma at different sites:biological and therapeutic relevance. Blood 127:2082-2092, 2016.
PubMed
7) Streubel B, Huber D, Wohrer S, et al:Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjogren's syndrome. Clin Cancer Res10:476-480, 2004.
 
8) Cascione L, Rinaldi A, Bruscaggin A, et al:Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica 104:e558-e561, 2019.
PubMed
9) Noy A, de Vos S, Coleman M, et al:Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma:long-term follow-up and biomarker analysis. Blood Adv 4:5773-5784, 2020.
PubMed
10) Song JY, Pittaluga S, Dunleavy K, et al:Lymphomatoid granulomatosis-a single institute experience:pathologic findings and clinical correlations. Am J Surg Pathol 39:141-156, 2015.
PubMed
11) Oiwa H, Mihara K, Kan T, et al:Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis. Intern Med 53:1873-1875, 2014.
 
12) Iuchi K, Ichimiya A, Akashi A, et al:Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Caner 60:1771-1775, 1987.
 
13) Chen GJ, Xia ZG, Jin J, et al:Characterization of artificial pneumothorax-unrelated pyothorax-associated lymphoma. J Oncol 2021:3869438, 2021.
 
14) Nakatsuka S, Yao M, Hoshida Y, et al:Pyothorax-associated lymphoma:a review of 106 cases. J Clin Oncol 20:4255-4260, 2002.
 
15) Narimatsu H, Ota Y, Kami M, et al:Clinicopathological features of pyothorax-associated lymphoma;a retrospective survey involving 98 patients. Ann Oncol 18:122-128, 2007.
PubMed
P.437 掲載の参考文献
1) Alvarez-Lesmes J, Chapman JR, Cassidy D, et al:Gastrointestinal Tract Lymphomas. Arch Pathol Lab Med 145:1585-1596, 2021.
PubMed
2) Delabie J, Holte H, Vose JM, et al:Enteropathy-associated T-cell lymphoma:clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 118:148-155, 2011.
PubMed
3) Nakamura S, Akazawa K, Yao T, et al:A clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Cancer 76:1313-1324, 1995.
 
4) Nakamura S, Matsumoto T, Takeshita M, et al:A clinicopathologic study of primary small intestine lymphoma:prognostic significance of mucosa-associated lymphoid tissue-derived lymphoma. Cancer 88:286-294, 2000.
PubMed
5) Rohatiner A, d'Amore F, Coiffier B, et al:Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5:397-400, 1994.
PubMed
6) Schizas D, Ntanasis-Stathopoulos I, Tsilimigras DI, et al:The Role of Endoscopic Ultrasound in the Diagnosis and Management of Primary Gastric Lymphoma. Gastroenterol Res Pract 2017:2397430, 2017.
 
7) Sugizaki K, Tari A, Kitadai Y, et al:Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma:A prospective, nationwide, multicenter study in Japan. Helicobacter 23:e12474, 2018.
PubMed
8) Fang P, Gunther JR, Pinnix CC, et al:A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue(MALT) Lymphoma. Int J Radiat Oncol Biol Phys 109:1414-1420, 2021.
PubMed
9) Zucca E, Conconi A, Martinelli G, et al:Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma:Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol 35:1905-1912, 2017.
PubMed
10) Aviles A, Nambo MJ, Neri N, et al:The role of surgery in primary gastric lymphoma:results of a controlled clinical trial. Ann Surg 240:44-50, 2004.
PubMed
11) Tanaka T, Shimada K, Yamamoto K, et al:Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era:a multicenter study of 95 patients in Japan. Ann Hematol 91:383-390, 2012.
 
12) Schmatz AI, Streubel B, Kretschmer-Chott E, et al:Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma:a retrospective study of 63 cases. J Clin Oncol 29:1445-1451, 2011.
 
13) Chuang SS, Ye H, Yang SF, et al:Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma. Histopathology 53:432-440, 2008.
PubMed
14) Kim SJ, Kang HJ, Kim JS, et al:Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma:surgical resection followed by chemotherapy versus chemotherapy alone. Blood 117:1958-1965, 2011.
PubMed
15) Sieniawski M, Angamuthu N, Boyd K, et al:Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 115:3664-3670, 2010.
PubMed
P.442 掲載の参考文献
1) WHO Classification of Tumours Online, Female Genital Tumours(5th ed. ). [https://tumourclassification.iarc.who.int/]
 
2) Nasioudis D, Kampaktsis PN, Frey M, et al:Primary lymphoma of the female genital tract:An analysis of 697 cases. Gynecol Oncol 145:305-309, 2017.
PubMed
3) Ensor AM, Sanchez CG, Ensor JE, et al:Primary diffuse large B-cell lymphoma of the uterus:A SEER database analysis. Medicine(Baltimore) 100:e27359, 2021.
 
4) Ishii Y, Fujisawa S, Ando T, et al:Primary uterine lymphoma:The Yokohama Cooperative Study Group for Hematology(YACHT) study. Asia Pac J Clin Oncol 14:e455-e459, 2018.
 
5) Dimopoulos MA, Daliani D, Pugh W, et al:Primary ovarian non-Hodgkin's lymphoma:outcome after treatment with combination chemotherapy. Gynecol Oncol 64:446-450, 1997.
PubMed
6) Stepniak A, Czuczwar P, Szkodziak P, et al:Primary ovarian Burkitt's lymphoma:a rare oncological problem in gynaecology:a review of literature. Arch Gynecol Obstet 296:653-660, 2017.
PubMed
7) Yun J, Kim SJ, Won JH, et al:Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma:A Consortium for Improving Survival of Lymphoma(CISL) report. Leuk Res 34:1175-1179, 2010.
 
8) Lagoo AS, Robboy SJ:Lymphoma of the female genital tract:current status. Int J Gynecol Pathol 25:1-21, 2006.
PubMed
9) Ollila TA, Olszewski AJ:Extranodal Diffuse Large B Cell Lymphoma:Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. Curr Treat Options Oncol 19:38, 2018.
 

[VII] 悪性リンパ腫に対する新規治療戦略の現状と展望

P.447 掲載の参考文献
1) Teeling JL, Mackus WJ, Wiegman LJ, et al:The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362-371, 2006.
PubMed
2) Wierda WG, Kipps TJ, Mayer J, et al:Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749-1755, 2010.
PubMed
3) Maloney DG, Ogura M, Fukuhara N, et al:A phase 3 randomized study(HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv 4:3886-3893, 2020.
PubMed
4) Marcus R, Davies A, Ando K, et al:Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 377:1331-1344, 2017.
PubMed
5) Hiddemann W, Barbui AM, Canales MA, et al:Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study:Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 36:2395-2404, 2018.
PubMed
6) Sehn LH, Chua N, Mayer J, et al:Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma(GADOLIN):a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081-1093, 2016.
PubMed
7) Cheson BD, Chua N, Mayer J, et al:Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol 36:2259-2266, 2018.
PubMed
8) Vitolo U, Trneny M, Belada D, et al:Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol 35:3529-3537, 2017.
 
9) Sehn LH, Martelli M, Trneny M, et al:A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma:final analysis of GOYA. J Hematol Oncol 13:71, 2020.
PubMed
10) Awan FT, Lapalombella R, Trotta R, et al:CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115:1204-1213, 2010.
PubMed
11) Salles G, Duell J, Gonzalez Barca E, et al:Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma(L-MIND):a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21:978-988, 2020.
 
12) Zhang L, French RR, Chan HT, et al:The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease. Ther Immunol 2:191-202, 1995.
PubMed
13) Polson AG, Yu SF, Elkins K, et al:Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 110:616-623, 2007.
PubMed
14) Dornan D, Bennett F, Chen Y, et al:Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114:2721-2729, 2009.
PubMed
15) Palanca-Wessels MC, Czuczman M, Salles G, et al:Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia:a phase 1 study. Lancet Oncol 16:704-715, 2015.
PubMed
16) Sehn LH, Herrera AF, Flowers CR, et al:Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 38:155-165, 2020.
 
17) Sehn LH, Hertzberg M, Opat S, et al:Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL:survival update and new extension cohort data. Blood Adv 6:533-543, 2022.
PubMed
18) Tilly H, Morschhauser F, Bartlett NL, et al:Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma:an open-label, non-randomised, phase 1b-2 study. Lancet Oncol 20:998-1010, 2019.
PubMed
19) Tilly H, Morschhauser F, Sehn LH, et al:Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386:351-363, 2022.
PubMed
20) Zammarchi F, Corbett S, Adams L, et al:ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131:1094-1105, 2018.
PubMed
21) Caimi PF, Ai W, Alderuccio JP, et al:Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma(LOTIS-2):a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22:790-800, 2021.
 
P.453 掲載の参考文献
1) Ishii T, Ishida T, Utsunomiya A, et al:Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 16:1520-1531, 2010.
PubMed
2) Ishida T, Utsunomiya A, Iida S, et al:Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma:its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9:3625-3634, 2003.
PubMed
3) Yamamoto K, Utsunomiya A, Tobinai K, et al:Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591-1598, 2010.
PubMed
4) Ishida T, Joh T, Uike N, et al:Defucosylated anti-CCR4 monoclonal antibody(KW-0761) for relapsed adult T-cell leukemia-lymphoma:a multicenter phase II study. J Clin Oncol 30:837-842, 2012.
PubMed
5) Ishida T, Jo T, Takemoto S, et al:Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma:a randomized phase II study. Br J Haematol 169:672-682, 2015.
PubMed
6) Shichijo T, Nosaka K, Tatetsu H, et al:Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma. Br J Haematol 198:983-987. 2022.
PubMed
7) Tanaka N, Mori S, Kiyotani K, et al:Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. Haematologica 107:2418-2431. 2022.
PubMed
8) Fuji S, Inoue Y, Utsunomiya A, et al:Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol 34:3426-3433, 2016.
PubMed
9) Ogura M, Ishida T, Hatake K, et al:Multicenter phase II study of mogamulizumab(KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 32:1157-1163, 2014.
PubMed
10) Duvic M, Pinter-Brown LC, Foss FM, et al:Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125:1883-1889, 2015.
PubMed
11) Katz J, Janik JE, Younes A:Brentuximab Vedotin(SGN-35). Clin Cancer Res 17:6428-6436, 2011.
PubMed
12) Pro B, Advani R, Brice P, et al:Brentuximab vedotin(SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma:results of a phase II study. J Clin Oncol 30:2190-2196, 2012.
 
13) Karube K, Aoki R, Nomura Y, et al:Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas:analysis of 490 cases. Pathol Int 58:89-97, 2008.
PubMed
14) Horwitz SM, Advani RH, Bartlett NL, et al:Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095-3100, 2014.
PubMed
15) Horwitz S, O'Connor OA, Pro B, et al:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma(ECHELON-2):a global, double-blind, randomised, phase 3 trial. Lancet 393:229-240, 2019.
PubMed
P.461 掲載の参考文献
1) Tawbi HA, Schadendorf D, Lipson EJ, et al:Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 386:24-34, 2022.
PubMed
2) Ansell SM:Checkpoint Blockade in Lymphoma. J Clin Oncol 39:525-533, 2021.
PubMed
3) Steidl C, Shah SP, Woolcock BW, et al:MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471:377-381, 2011.
PubMed
4) Kataoka K, Shiraishi Y, Takeda Y, et al:Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534:402-406, 2016.
PubMed
5) Ansell SM, Lesokhin AM, Borrello I, et al:PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015.
 
6) Armand P, Shipp MA, Ribrag V, et al:Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 34:3733-3739, 2016.
PubMed
7) Carey CD, Gusenleitner D, Lipschitz M, et al:Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420-2430, 2017.
PubMed
8) Zinzani PL, Ribrag V, Moskowitz CH, et al:Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130:267-270, 2017.
 
9) Armand P, Rodig S, Melnichenko V, et al:Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 37:3291-3299, 2019.
PubMed
10) Chapuy B, Roemer MG, Stewart C, et al:Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869-881, 2016.
PubMed
11) Ansell SM, Minnema MC, Johnson P, et al:Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation:A Single-Arm, Phase II Study. J Clin Oncol 37:481-489, 2019.
PubMed
12) Armand P, Engert A, Younes A, et al:Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation:Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 36:1428-1439, 2018.
 
13) Chen R, Zinzani PL, Fanale MA, et al:Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol 35:2125-2132, 2017.
PubMed
14) Kuruvilla J, Ramchandren R, Santoro A, et al:Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma(KEYNOTE-204):an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 22:512-524, 2021.
PubMed
15) Allen PB, Savas H, Evens AM, et al:Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 137:1318-1326, 2021.
PubMed
16) Brockelmann PJ, Buhnen I, Meissner J, et al:Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma:Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. J Clin Oncol, 2022.(DOI:10.1200/JCO. 22.02355)
 
17) Ramchandren R, Domingo-Domenech E, Rueda A, et al:Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma:Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol 37:1997-2007, 2019.
PubMed
18) Herrera AF, Burton C, Radford J, et al:Avelumab in relapsed/refractory classical Hodgkin lymphoma:phase 1b results from the JAVELIN Hodgkins trial. Blood Adv 5:3387-3396, 2021.
PubMed
19) Cubas RA, Mudd JC, Savoye AL, et al:Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 19:494-499, 2013.
 
20) Uldrick TS, Goncalves PH, Abdul-Hay M, et al:Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. JAMA Oncol 5:1332-1339, 2019.
 
21) Kiyasu J, Miyoshi H, Hirata A, et al:Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193-2201, 2015.
PubMed
22) Armand P, Janssens A, Gritti G, et al:Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood 137:637-645, 2021.
PubMed
23) Lesokhin AM, Ansell SM, Armand P, et al:Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy:Preliminary Results of a Phase Ib Study. J Clin Oncol 34:2698-2704, 2016.
 
24) Ding W, LaPlant BR, Call TG, et al:Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129:3419-3427, 2017.
PubMed
25) Ding W, LaPlant BR, Call TG, et al:Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129:3419-3427, 2017.
PubMed
26) He R, Ding W, Viswanatha DS, et al:PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL) and Large B-cell Richter Transformation(DLBCL-RT):A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. Am J Surg Pathol 42:843-854, 2018.
 
27) Heavican TB, Bouska A, Yu J, et al:Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 133:1664-1676, 2019.
PubMed
28) Watatani Y, Sato Y, Miyoshi H, et al:Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia 33:2867-2883, 2019.
 
29) Sugio T, Miyawaki K, Kato K, et al:Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv 2:2242-2252, 2018.
PubMed
30) Kataoka K, Miyoshi H, Sakata S, et al:Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 33:1687-1699, 2019.
PubMed
31) Kwong YL, Chan TSY, Tan D, et al:PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood 129:2437-2442, 2017.
PubMed
32) Chan TSY, Li J, Loong F, et al:PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase:efficacy and safety. Ann Hematol 97:193-196, 2018.
 
33) Wada DA, Wilcox RA, Harrington SM, et al:Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sezary syndrome. Am J Hematol 86:325-327, 2011.
PubMed
34) Khodadoust MS, Rook AH, Porcu P, et al:Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome:A Multicenter Phase II Study. J Clin Oncol 38:20-28, 2020.
PubMed
35) Barta SK, Zain J, MacFarlane AW 4th, et al:Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk19:356-364. e3, 2019.
PubMed
36) Bennani NN, Kim HJ, Pederson LD, et al:Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma:modest activity and cases of hyperprogression. J Immunother Cancer 10:e004984, 2022.
PubMed
37) Ratner L, Waldmann TA, Janakiram M, et al:Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. N Engl J Med 378:1947-1948, 2018.
PubMed
38) Wartewig T, Kurgyis Z, Keppler S, et al:PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552:121-125, 2017.
PubMed
39) Rauch DA, Conlon KC, Janakiram M, et al:Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood 134:1406-1414, 2019.
PubMed
40) Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al:Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J Immunol 171:1272-1277, 2003.
 
41) Soiffer RJ:Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 54(Suppl 2):798-802, 2019.
PubMed
42) Merryman RW, Kim HT, Zinzani PL, et al:Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 129:1380-1388, 2017.
PubMed
43) Haverkos BM, Abbott D, Hamadani M, et al:PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant:high response rate but frequent GVHD. Blood 130:221-228, 2017.
PubMed
44) Herbaux C, Gauthier J, Brice P, et al:Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129:2471-2478, 2017.
PubMed
45) Minson A, Douglas G, Bilmon I, et al:Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD. Br J Haematol 184:840-844, 2019.
PubMed
46) Ijaz A, Khan AY, Malik SU, et al:Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Biol Blood Marrow Transplant 25:94-99, 2019.
 
47) Ito A, Kim SW, Matsuoka KI, et al:Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma:a multicenter retrospective study. Int J Hematol 112:674-689, 2020.
PubMed
48) Merryman RW, Castagna L, Giordano L, et al:Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 35:2672-2683, 2021.
PubMed
49) Schoch LK, Cooke KR, Wagner-Johnston ND, et al:Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229, 2018.
PubMed
50) Paul S, Zahurak M, Luznik L, et al:Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma:A Retrospective Cohort Study. Biol Blood Marrow Transplant 26:1679-1688, 2020.
PubMed
51) Ikegawa S, Meguri Y, Kondo T, et al:PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade. Blood Adv 3:4081-4094, 2019.
PubMed
52) Davids MS, Kim HT, Costello C, et al:A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood 135:2182-2191, 2020.
 
53) Herbaux C, Merryman R, Devine S, et al:Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma:taming a necessary evil. Blood 132:9-16, 2018.
PubMed
54) Merryman RW, Redd RA, Nishihori T, et al:Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv 5:1648-1659, 2021.
PubMed
55) Roemer MG, Advani RH, Ligon AH, et al:PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol 34:2690-2697, 2016.
PubMed
56) Zhou H, Du X, Zhao T, et al:Distribution and influencing factors of tumor mutational burden in different lymphoma subtypes. J Clin Oncol 37(15 Suppl):e19053, 2019.
 
57) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
58) Wright GW, Huang DW, Phelan JD, et al:A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37:551-568. e14, 2020.
 
59) Kotlov N, Bagaev A, Revuelta MV, et al:Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov 11:1468-1489, 2021.
PubMed
60) Miyawaki K, Kato K, Sugio T, et al:A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. Blood Adv 6:2388-2402, 2022.
PubMed
61) Song W, Zhang M:Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol 214:108382, 2020.
 
62) Advani R, Flinn I, Popplewell L, et al:CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med 379:1711-1721, 2018.
PubMed
63) Ennishi D, Healy S, Bashashati A, et al:TMEM30A loss-of-function mutations drive lymphomagene-sis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med 26:577-588, 2020.
 
P.471 掲載の参考文献
1) Burger JA, Wiestner A:Targeting B cell receptor signalling in cancer:preclinical and clinical advances. Nat Rev Cancer 18:148-167, 2018.
PubMed
2) Coutre SE, Furman RR, Flinn IW, et al:Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Cancer Res 23:1149-1155, 2017.
PubMed
3) Wang ML, Rule S, Martin P, et al:Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507-516, 2013.
PubMed
4) Burger JA, Barr PM, Robak T, et al:Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL:5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34:787-798, 2020.
PubMed
5) Visco C, Di Rocco A, Evangelista A, et al:Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma:results from the MANTLE-FIRST study. Leukemia 35:787-795, 2021.
PubMed
6) Wang ML, Jurczak W, Jerkeman M, et al:Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med 386:2482-2494, 2022.
PubMed
7) Younes A, Sehn LH, Johnson P, et al:Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol 37:1285-1295, 2019.
PubMed
8) Ghia P, Pluta A, Wach M, et al:ASCEND:Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 38:2849-2861, 2020.
 
9) Byrd JC, Hillmen P, Ghia P, et al:Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia:Results of the First Randomized Phase III Trial. J Clin Oncol 39:3441-3452, 2021.
PubMed
10) Sekiguchi N, Rai S, Munakata W, et al:Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia. Cancer Sci 113:2085-2096, 2022.
PubMed
11) Brown JR, Eichhorst B, Hillmen P, et al:Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 388:319-332, 20232.
 
12) Mato AR, Shah NN, Jurczak W, et al:Pirtobrutinib in relapsed or refractory B-cell malignancies(BRUIN):a phase 1/2 study. Lancet 397:892-901, 2021.
 
13) Jones JA, Robak T, Brown JR, et al:Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia:an open-label, randomised phase 3 trial. Lancet Haematol 4:e114-e126, 2017.
PubMed
14) Sedlarikova L, Petrackova A, Papajik T, et al:Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents. Front Oncol 10:894, 2020.
PubMed
15) Wang E, Mi X, Thompson MC, et al:Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med 386:735-743, 2022.
PubMed
P.476 掲載の参考文献
1) Rai S:Development of mechanism-based targeted therapies for malignant lymphoma. Rinsho Ketsueki 61:1266-1274, 2020.
PubMed
2) Beguelin W, Popovic R, Teater M, et al:EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677-692, 2013.
PubMed
3) Souroullas GP, Jeck WR, Parker JS, et al:An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med 22:632-640, 2016.
PubMed
4) Ennishi D, Takata K, Beguelin W, et al:Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 9:546-563, 2019.
PubMed
5) Morin RD, Johnson NA, Severson TM, et al:Somatic mutations altering EZH2(Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181-185, 2010.
 
6) DuPage M, Chopra G, Quiros J, et al:The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42:227-238, 2015.
PubMed
7) Fujikawa D, Nakagawa S, Hori M, et al:Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood 127:1790-1802, 2016.
PubMed
8) Kataoka K, Nagata Y, Kitanaka A, et al:Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47:1304-1315, 2015.
PubMed
9) Kogure Y, Kameda T, Koya J, et al:Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood 139:967-982, 2022.
PubMed
10) Italiano A, Soria JC, Toulmonde M, et al:Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours:a first-in-human, open-label, phase 1 study. Lancet Oncol 19:649-659, 2018.
PubMed
11) Hoy SM:Tazemetostat:First Approval. Drugs 80:513-521, 2020.
PubMed
12) Rothbart SB, Baylin SB:Epigenetic Therapy for Epithelioid Sarcoma. Cell 181:211, 2020.
PubMed
13) Izutsu K, Ando K, Nishikori M, et al:Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci 112:3627-3635, 2021.
PubMed
14) Margueron R, Li G, Sarma K, et al:Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 32:503-518, 2008.
PubMed
15) Shen X, Liu Y, Hsu YJ, et al:EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 32:491-502, 2008.
PubMed
16) Yamagishi M, Hori M, Fujikawa D, et al:Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. Cell Rep 29:2321-2337. e7, 2019.
 
17) Izutsu K, Makita S, Nosaka K, et al:An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood, 2022.(DOI:10.1182/blood. 2022016862)
PubMed
18) Zhang Q, Wang S, Chen J, et al:Histone Deacetylases(HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci 16:424-442, 2019.
 
19) Zhang H, Lv H, Jia X, et al:Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma. Oncol Lett 18:1415-1423, 2019.
PubMed
20) Dupuis J, Morschhauser F, Ghesquieres H, et al:Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma:a non-randomised, phase 1b/2 study. Lancet Haematol 2:e160-165, 2015.
PubMed
21) Bachy E, Camus V, Thieblemont C, et al:Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma:Results of the Ro-CHOP Phase III Study(Conducted by LYSA). J Clin Oncol 40:242-251, 2022.
PubMed
22) Falchi L, Ma H, Klein S, et al:Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL:a multicenter phase 2 study. Blood 137:2161-2170, 2021.
PubMed
23) Dong M, Ning ZQ, Xing PY, et al:Phase I study of chidamide(CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol 69:1413-1422, 2012.
PubMed
24) Shi Y, Dong M, Hong X, et al:Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26:1766-1771, 2015.
PubMed
25) Yoshimitsu M, Ando K, Ishida T, et al:Oral histone deacetylase inhibitor HBI-8000(tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma:phase I safety and efficacy. Jpn J Clin Oncol 52:1014-1020, 2022.(DOI:10.3324/haematol. 2022.280996)
PubMed
26) Rai S, Kim WS, Ando K, et al:Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma:phase IIb results. Haematologica, 2022.(DOI:10. 3324/haema tol. 2022.280996)
PubMed
27) Utsunomiya A, Izutsu K, Jo T, et al:Oral histone deacetylase inhibitor tucidinostat(HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma:Phase IIb results. Cancer Sci 113:2778-2787, 2022.
PubMed
P.482 掲載の参考文献
1) Kitada S, Andersen J, Akar S, et al:Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia:correlations with In vitro and In vivo chemoresponses. Blood 91:3379-3389, 1998.
PubMed
2) Souers AJ, Leverson JD, Boghaert ER, et al:ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208, 2013.
 
3) Blombery P, Anderson MA, Gong JN, et al:Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov 9:342-353, 2019.
PubMed
4) Fischer K, Al-Sawaf O, Bahlo J, et al:Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 380:2225-2236, 2019.
PubMed
5) Al-Sawaf O, Zhang C, Tandon M, et al:Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia(CLL14):follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 21:1188-1200, 2020.
PubMed
6) Haselager MV, Kielbassa K, Ter Burg J, et al:Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood 136:2918-2926, 2020.
PubMed
7) Lu P, Wang S, Franzen CA, et al:Ibrutinib and venetoclax target distinct subpopulations of CLL cells:implication for residual disease eradication. Blood Cancer J 11:39, 2021.
PubMed
8) Cervantes-Gomez F, Lamothe B, Woyach JA, et al:Pharmacological and Protein Profiling Suggests Venetoclax(ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res 21:3705-3715, 2015.
PubMed
9) Deng J, Isik E, Fernandes SM, et al:Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31:2075-2084, 2017.
PubMed
10) Wierda WG, Allan JN, Siddiqi T, et al:Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia:Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 39:3853-3865, 2021.
PubMed
11) Kater A, Owen C, Moreno C, et al:Fixed-duration ibrutinib and venetoclax(I+V) versus chlorambucil plus Obinutuzumab(CLB+O) for first-line(1L) chronic lymphocytic leukemia(CLL):primary analysis of the phase 3 GLOW study. EHA 2021, LB1902, 2021.
 
12) Rogers KA, Huang Y, Ruppert AS, et al:Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 38:3626-3637, 2020.
PubMed
13) Eichhorst B, Niemann C, Kater AP, et al:A randomized Phase III study of Venetoclax-Based Time-Limited Combination Treatments(RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy(CIT:FCR/BR) in Frontline Chronic Lymphocytic Leukemia(CLL) of Fit Patients:First Co-Primary Endpoint Analysis of the International Intergroup GAIA(CLL13) Trial. Blood 138(Suppl 1):71, 2021.
 
14) Davids MS, Roberts AW, Seymour JF, et al:Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 35:826-833, 2017.
 
15) Dreyling M, Jurczak W, Jerkeman M, et al:Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma:an international, randomised, open-label, phase 3 study. Lancet 387:770-778, 2016.
 
16) Wang M, Ramchandren R, Chen R, et al:Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma:the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol 14:179, 2021.
PubMed
17) Morschhauser F, Feugier P, Flinn IW, et al:A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood 137:600-609, 2021.
 
P.489 掲載の参考文献
1) Topp MS, Gokbuget N, Zugmaier G, et al:Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134-4140, 2014.
PubMed
2) Kantarjian H, Stein A, Gokbuget N, et al:Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:837-847, 2017.
 
3) Liu L, Lam CK, Long V, et al:MGD011, A CD19×CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies. Clin Cancer Res 23:1506-1518, 2017.
 
4) Robinson HR, Qi J, Cook EM, et al:A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood 132:521-532, 2018.
PubMed
5) Braig F, Brandt A, Goebeler M, et al:Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129:100-104, 2017.
PubMed
6) Reusch U, Duell J, Ellwanger K, et al:A tetravalent bispecific TandAb(CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs 7:584-604, 2015.
PubMed
7) Betts A, van der Graaf PH:Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology. Clin Pharmacol Ther 108:528-541, 2020.
PubMed
8) Wu X, Sereno AJ, Huang F, et al:Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 7:470-482, 2015.
PubMed
9) Bacac M, Colombetti S, Herter S, et al:CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res 24:4785-4797, 2018.
PubMed
10) Hosseini I, Gadkar K, Stefanich E, et al:Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL:impact of translational system modeling. NPJ Syst Biol Appl 6:28, 2020.
 
11) Chen X, Kamperschroer C, Wong G, et al:A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment:Methodology and Opportunities. Clin Transl Sci 12:600-608, 2019.
 
12) Hutchings M, Mous R, Clausen MR, et al:Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma:an open-label, phase 1/2 study. Lancet 398:1157-1169, 2021.
PubMed
13) Hutchings M, Morschhauser F, Iacoboni G, et al:Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma:A Phase I Trial. J Clin Oncol 39:1959-1970, 2021.
PubMed
14) Smith EJ, Olson K, Haber LJ, et al:A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 5:17943, 2015.
PubMed
15) Bannerji R, Arnason JE, Advani RH, et al:Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies(ELM-1):results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 9:e327-e339, 2022.
 
16) Budde LE, Assouline S, Sehn LH, et al:Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas:Phase I Dose-Escalation Study. J Clin Oncol 40:481-491, 2022.
PubMed
17) Braig F, Brandt A, Goebeler M, et al:Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129:100-104, 2017.
PubMed
18) Matasar MJ, Cheah CY, Yoon DH, et al:Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma:Promising safety and encouraging efficacy in dose escalation cohorts. Blood 136(Suppl 1):45-46, 2020.
 
19) Csizmar CM, Ansell SM:Engaging the innate and adaptive antitumor immune response in lymphoma. Int J Mol Sci 22:3302, 2021.
PubMed
P.496 掲載の参考文献
1) Locke FL, Ghobadi A, Jacobson CA, et al:Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1):a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20:31-42, 2019.
 
2) Abramson JS, Palomba ML, Gordon LI, et al:Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001):a multicentre seamless design study. Lancet 396:839-852, 2020.
PubMed
3) Schuster SJ, Tam CS, Borchmann P, et al:Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas(JULIET):a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22:1403-1415, 2021.
 
4) Bishop MR, Dickinson M, Purtill D, et al:Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 386:629-639, 2022.
PubMed
5) Kamdar M, Solomon SR, Arnason J, et al:Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma(TRANSFORM):results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:2294-2308, 2022.
PubMed
6) Locke FL, Miklos DB, Jacobson CA, et al:Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386:640-654, 2022.
 
7) Sehgal A, Hoda D, Riedell PA, et al:Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation(PILOT):an open-label, phase 2 study. Lancet Oncol 23:1066-1077, 2022.
 
8) Fowler NH, Dickinson M, Dreyling M, et al:Tisagenlecleucel in adult relapsed or refractory follicular lymphoma:the phase 2 ELARA trial. Nat Med 28:325-332, 2022.
 
9) Jacobson CA, Chavez JC, Sehgal AR, et al:Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma(ZUMA-5):a single-arm, multicentre, phase 2 trial. Lancet Oncol 23:91-103, 2022.
PubMed
10) Wang M, Munoz J, Goy A, et al:Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol 41:555-567, 2023.
PubMed
11) Kawalekar OU, O'Connor RS, Fraietta JA, et al:Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 44:380-390, 2016.
 
12) Bachy E, Le Gouill S, Di Blasi R, et al:A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28:2145-2154, 2022.
PubMed
13) Schuster SJ, Bishop MR, Tam CS, et al:Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380:45-56, 2019.
 
14) Neelapu SS, Locke FL, Bartlett NL, et al:Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377:2531-2544, 2017.
 
15) Bethge WA, Martus P, Schmitt M, et al:GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140:349-358, 2022.
 
16) Hirayama AV, Gauthier J, Hay KA, et al:The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133:1876-1887, 2019.
 
17) Vercellino L, Di Blasi R, Kanoun S, et al:Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 4:5607-5615, 2020.
PubMed
18) Dreger P, Dietrich S, Schubert ML, et al:CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma:an intent-to-treat comparison. Blood Adv 4:6157-6168, 2020.
 
19) Abramson JS, Solomon SR, Arnason JE, et al:Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma:primary analysis of phase 3 TRANSFORM study. Blood. 2022. [https://doi.org/10.1182/blood.2022018730 ]
 
20) Jo T, Arai Y, Yoshihara S, et al:Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure. Blood 140(Suppl 1):1608-1609, 2022.
 
21) Neelapu SS, Dickinson M, Munoz J, et al:Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma:the phase 2 ZUMA-12 trial. Nat Med 28:735-742, 2022.
 
22) Feucht J, Sadelain M:Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors. Immunooncol Technol 8:2-11, 2020.
 
23) Buechner J, Caruana I, Kunkele A, et al:Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia:Curative Treatment Option or Bridge to Transplant? Front Pediatr 9:784024, 2021.
PubMed
24) 藤原 弘:CAR-T 療法開発;その最新の世界情勢. 日本造血・免疫細胞療法学会雑誌 11:1-9, 2022.
Medical*Online
P.503 掲載の参考文献
1) Bacher U, Klyuchnikov E, Le-Rademacher J, et al:Conditioning regimens for allotransplants for diffuse large B-cell lymphoma:myeloablative or reduced intensity? Blood 120:4256-4262, 2012.
PubMed
2) Hamadani M, Ngoya M, Sureda A, et al:Outcome of allogeneic transplantation for mature T-cell lymphomas:impact of donor source and disease characteristics. Blood Adv 6:920-930, 2022.
PubMed
3) Dreger P, Sureda A, Ahn KW, et al:PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv 3:360-369, 2019.
PubMed
4) Sakatoku K, Kim SW, Okamura H, et al:Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malig-nant lymphoma:impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil. Ann Hematol 101:2743-2757, 2022.
 
5) Fenske TS, Ahn KW, Graff TM, et al:Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol 174:235-248, 2016.
 
6) Hamadani M, Saber W, Ahn KW, et al:Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 19:746-753, 2013.
 
7) Dreger P, Dietrich S, Schubert ML, et al:CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma:an intent-to-treat comparison. Blood Adv 4:6157-6168, 2020.
 
8) Zurko J, Ramdial J, Shadman M, et al:Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica 108:98-109, 2023.
 
9) Klyuchnikov E, Bacher U, Kroger NM, et al:Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant 21:2091-2099, 2015.
PubMed
10) Tessoulin B, Ceballos P, Chevallier P, et al:Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation:a national survey of the SFGM-TC. Bone Marrow Transplant 51:1184-1190, 2016.
PubMed
11) Schmitz N, Truemper L, Bouabdallah K, et al:A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 137:2646-2656, 2021.
PubMed
12) Kameda K, Kako S, Kim SW, et al:Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia 36:1361-1370, 2022.
 
13) Smith SM, Burns LJ, van Besien K, et al:Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31:3100-3109, 2013.
PubMed
14) Fuji S, Inoue Y, Utsunomiya A, et al:Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol 34:3426-3433, 2016.
PubMed
15) Yamaguchi M, Kwong YL, Kim WS, et al:Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer(NK)/T-cell lymphoma, nasal type:the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410-4416, 2011.
PubMed
16) Kako S, Izutsu K, Kato K, et al:The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Am J Hematol 90:132-138, 2015.
PubMed
17) Ito A, Kim SW, Matsuoka KI, et al:Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma:a multicenter retrospective study. Int J Hematol 112:674-689, 2020.
PubMed

[VIII] 悪性リンパ腫治療における支持療法・患者管理のチップス

P.510 掲載の参考文献
1) 発熱性好中球減少症(FN)診療ガイドライン(改訂第2版)(日本臨床腫瘍学会 編), 南江堂, 2017.
 
2) Cullen M, Steven N, Billingham L, et al:Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988-998, 2005.
PubMed
3) 3.2022 NGV. Prevention and Treatment of Cancer-Related Infections. 2022.
 
4) Taplitz RA, Kennedy EB, Flowers CR:Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression:ASCO and IDSA Clinical Practice Guideline Update Summary. J Oncol Pract 14:692-695, 2018.
 
5) G-CSF 適正使用ガイドライン 2013年版 ver. 5(日本癌治療学会 編), 2018.
 
6) Tilly H, Morschhauser F, Sehn LH, et al:Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386:351-363, 2022.
PubMed
7) Negishi S, Miyao K, Ohara F, et al:Feasibility of trimethoprim/sulfamethoxazole desensitization therapy in hematological diseases. Clin Exp Med, 2022.(DOI:10.1007/s10238-022-00868-3)
 
8) Fung M, Jacobsen E, Freedman A, et al:Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clin Infect Dis 68:247-255, 2019.
PubMed
9) 三原圭一朗, 石井智徳, 花本 仁, ほか:二次性低ガンマグロブリン血症におけるグロブリン補充療法. 日本輸血細胞治療学会誌 67:549-558, 2021.
Medical*Online
10) Okamoto A, Fujigaki H, Iriyama C, et al:CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv 6:3230-3233, 2022.
 
11) Levin MJ, Ustianowski A, De Wit S, et al:Intramuscular AZD7442(Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med 386:2188-2200, 2022.
PubMed
12) Yri OE, Torfoss D, Hungnes O, et al:Rituximab blocks protective serologic response to influenza A(H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118:6769-6771, 2011.
PubMed
13) Re D, Seitz-Polski B, Brglez V, et al:Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nat Commun 13:864, 2022.
PubMed
14) Riise J, Meyer S, Blaas I, et al:Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol 197:697-708, 2022.
PubMed
P.512 掲載の参考文献
1) Fuji S, Einsele H, Savani BN, et al:Systematic Nutritional Support in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant 21:1707-1713, 2015.
PubMed
2) Arends J, Baracos V, Bertz H, et al:ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr 36:1187-1196, 2017.
 
3) Miller J, Wells L, Nwulu U, et al:Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition:a systematic review. Am J Clin Nutr 108:1196-1208, 2018.
PubMed
4) Kiss N, Loeliger J, Findlay M, et al:Clinical Oncology Society of Australia:Position statement on cancer-related malnutrition and sarcopenia. Nutr Diet 77:416-425, 2020.
PubMed
5) Landi F, Camprubi-Robles M, Bear DE, et al:Muscle loss:The new malnutrition challenge in clinical practice. Clin Nutr 38:2113-2120, 2019.
PubMed
6) Cederholm T, Barazzoni R, Austin P, et al:ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 36:49-64, 2017.
PubMed
7) Schuetz P, Fehr R, Baechli V, et al:Individualised nutritional support in medical inpatients at nutritional risk:a randomised clinical trial. Lancet 393:2312-2321, 2019.
 
P.518 掲載の参考文献
1) Frei E 3rd, Bentzel CJ, Rieselbach R, et al:Renal complications of neoplastic disease. J Chronic Dis 16:757-776, 1963.
PubMed
2) Hande KR, Garrow GC:Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 94:133-139, 1993.
PubMed
3) Cairo MS, Bishop M:Tumor lysis syndrome:new therapeutic strategies and classification. Br J Heamatol 127:3-11, 2004.
 
4) Coiffier B, Altman A, Pui CH, et al:Guidelines for the management of pediatric and adult tumor lysis syndrome:an evidence-based review. J Clin Oncol 26:2767-2778, 2008.
PubMed
5) Cairo MS, Coiffier B, Reiter A, et al:Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome(TLS) in adults and children with malignant disease:an expert TLS panel consensus. Br J Heamatol 149:578-586, 2010.
 
6) 腫瘍崩壊症候群(TLS)診療ガイダンス(第1版)(日本臨床腫瘍学会 編), 金原出版, 2013.
 
7) 腫瘍崩壊症候群(TLS)診療ガイダンス(第2版)(日本臨床腫瘍学会 編), 金原出版, 2021.
 
8) Howard SC, Jones DP, Pui CH:The tumor lysis syndrome. N Engl J Med 364:1844-1854, 2011.
PubMed
9) Jeha S, Kantarjian H, Irwin D, et al:Efficacy and safety of rasburicase, a recombinant urate oxidase(Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients:final results of a multicenter compassionate use trial. Leukemia 19:34-38, 2005.
 
10) Goldman SC, Holcenberg JS, Finklestein JZ, et al:A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998-3003, 2001.
PubMed
11) Pei Y, Li Y, Liang Y, et al:Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies. Int J Clin Pharm 42:1440-1446, 2020.
 
12) Vachhani P, Baron J, Freyer CW, et al:A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia. Leuk Res 107:106588, 2021.
PubMed
13) Seymour JF, Kipps TJ, Eichhorst B, et al:Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 378:1107-1120, 2018.
 
14) Schuster SJ, Bishop MR, Tam CS, et al:Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380:45-56, 2019.
 
P.525 掲載の参考文献
1) Hausheer FH, Schilsky RL, Bain S, et al:Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15-49, 2006.
PubMed
2) Argyriou AA, Bruna J, Marmiroli P, et al:Chemotherapy-induced peripheral neurotoxicity(CIPN):an update. Crit Rev Oncol Hematol 82:51-77, 2012.
PubMed
3) Hershman DL, Till C, Wright JD, et al:Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 34:3014-3022, 2016.
PubMed
4) Gu J, Lu H, Chen C, et al:Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy:a meta-analysis. Support Care Cancer 29:7461-7469, 2021.
 
5) Saito T, Okamura A, Inoue J, et al:Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy. Oncol Res 27:469-474, 2019.
PubMed
6) van Schie RM, Bruggemann RJ, Hoogerbrugge PM, et al:Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother 66:1853-1856, 2011.
 
7) DeVries AH, Howe BM, Spinner RJ, et al:B-cell peripheral neurolymphomatosis:MRI and 18F-FDG PET/CT imaging characteristics. Skeletal Radiol 48:1043-1050, 2019.
PubMed
8) Graus F, Arino H, Dalmau J:Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 123:3230-3238, 2014.
PubMed
9) Fonkem E, Dayawansa S, Stroberg E, et al:Neurological presentations of intravascular lymphoma(IVL):meta-analysis of 654 patients. BMC Neurol 16:9, 2016.
PubMed
10) Tay CG, Lee VWM, Ong LC, et al:Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 64:e26471, 2017.
 
11) 荒川和彦, 鳥越一宏, 葛巻直子, ほか:抗がん剤による末梢神経障害の特徴とその作用機序. 日本緩和医療薬学雑誌 4:1-13, 2011.
 
12) Corbin ZA, Nguyen-Lin A, Li S, et al:Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sezary Syndrome. J Neurooncol 132:439-446, 2017.
PubMed
13) Lu D, Gillespie WR, Girish S, et al:Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens. CPT Pharmacometrics Syst Pharmacol 6:401-408, 2017.
PubMed
14) Li T, Mizrahi D, Goldstein D, et al:Chemotherapy and peripheral neuropathy. Neurol Sci 42:4109-4121, 2021.
PubMed
15) Dalla Torre C, Zambello R, Cacciavillani M, et al:Lenalidomide long-term neurotoxicity:Clinical and neurophysiologic prospective study. Neurology 87:1161-1166, 2016.
PubMed
16) Mohn N, Beutel G, Gutzmer R, et al:Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. J Clin Med 8:2019.
PubMed
17) Loprinzi CL, Lacchetti C, Bleeker J, et al:Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers:ASCO Guideline Update. J Clin Oncol 38:3325-3348, 2020.
PubMed
18) 神経障害性疼痛薬物療法ガイドライン[改訂第2版](日本ペインクリニック学会 神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ 編), 真興交易医書出版部, 2016.
 
19) がん薬物療法に伴う末梢神経障害マネジメントの手引き[2017年版](日本がんサポーティブケア学会 編著), 金原出版, 2017.
 
P.531 掲載の参考文献
1) Warren S, Gates O:Multiple primary malignant tumors. A survey of the literature and a statistical study. Am J Cancer 16:1358-1414, 1932.
 
2) Travis LB, Hill DA, Dores GM, et al:Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003.
PubMed
3) Rock CB, Chipman JJ, Parsons MW, et al:Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up:Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol 7:101035, 2022.
 
4) Myers RM, Hill BT, Shaw BE, et al:Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825, 2018.
PubMed
5) Inano S, Iwasaki M, Iwamoto Y, et al:Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients:a single-center study in Japan. Int J Hematol 99:162-168, 2014.
 
6) Tao L, Clarke CA, Rosenberg AS, et al:Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol 178:72-80, 2017.
PubMed
7) Cho SF, Wu WH, Yang YH, et al:Risk of second primary cancer in patients with B-cell non-Hodgkin lymphoma receiving rituximab-containing chemotherapy:a nationwide population-based study. Anticancer Res 35:1809-1814, 2015.
PubMed
8) Coiffier B, Thieblemont C, Van Den Neste E, et al:Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045, 2010.
 
9) Tanba K, Chinen Y, Uchiyama H, et al:Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma. Blood Cancer J 8:1, 2018.
PubMed
10) Chinen Y, Tanba K, Takagi R, et al:Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. Leuk Lymphoma 61:3378-3386, 2020.
PubMed
11) Huang Y, Hu S, Larson DP, et al:Composite Classic Hodgkin Lymphoma and Follicular Lymphoma:A Clinicopathologic Study of 22 Cases With Review of 27 Additional Cases in the Literature. Am J Surg Pathol 46:793-800, 2022.
 
P.535 掲載の参考文献
1) Loren AW, Mangu PB, Beck LN, et al:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500-2510, 2013.
 
2) Behringer K, Thielen I, Mueller H, et al:Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma(HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 23:1818-1825, 2012.
 
3) Amzai G, Karanfilski O, Stavrikj SG, et al:Reproductive Issues in Long-Term Surviving Patients following Therapy for Hodgkin's Disease in the Republic of North Macedonia:Risks of Infertility According to First-Line Treatment Regimens. Hematol Rep 14:85-94, 2022.
PubMed
4) Hodgson DC, Pintilie M, Gitterman L, et al:Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 25:11-15, 2007.
PubMed
5) Paoli D, Rizzo F, Fiore G, et al:Spermatogenesis in Hodgkin's lymphoma patients:a retrospective study of semen quality before and after different chemotherapy regimens. Hum Reprod 31:263-272, 2016.
PubMed
6) Ansell SM, Radford J, Connors JM, et al:Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med 387:310-320, 2022.
 
7) Behringer K, Mueller H, Goergen H, et al:Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31:231-239, 2013.
 
8) Meissner J, Tichy D, Katzke V, et al:Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Ann Oncol 26:1771-1776, 2015.
PubMed
9) Gharwan H, Lai C, Grant C, et al:Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. Leuk Lymphoma 57:1616-1624, 2016.
PubMed
10) Pallotti F, Pelloni M, Faja F, et al:Semen quality in non-Hodgkin lymphoma survivors:a monocentric retrospective study. Hum Reprod 36:16-25, 2021.
PubMed
11) Salooja N, Szydlo RM, Socie G, et al:Pregnancy outcomes after peripheral blood or bone marrow transplantation:a retrospective survey. Lancet 358:271-276, 2001.
PubMed
12) Donnez J, Dolmans MM:Fertility Preservation in Women. N Engl J Med 377:1657-1665, 2017.
PubMed
13) Kobayashi H, Tamura K, Tai T, et al:Semen cryopreservation as an oncofertility treatment in 122 Japanese men with cancer:A decade-long study. Reprod Med Biol 16:320-324, 2017.
 
14) Ferrari S, Paffoni A, Filippi F, et al:Sperm cryopreservation and reproductive outcome in male cancer patients:a systematic review. Reprod Biomed Online 33:29-38, 2016.
PubMed
15) Shin T, Kobayashi T, Shimomura Y, et al:Microdissection testicular sperm extraction in Japanese patients with persistent azoospermia after chemotherapy. Int J Clin Oncol 21:1167-1171, 2016.
PubMed
P.541 掲載の参考文献
1) Vogel WH:Infusion reactions:diagnosis, assessment, and management. Clin J Oncol Nurs 14:E10-E21, 2010.
PubMed
2) Rombouts MD, Swart EL, van den Eertwegh AJM, et al:Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. Anticancer Res 40:1201-1218, 2020.
PubMed
3) Plosker GL, Figgitt DP:Rituximab:a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803-843, 2003.
PubMed
4) A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc 32:79, 2011.
 
5) Picard M, Galvao VR:Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. J Allergy Clin Immunol Pract 5:600-609, 2017.
PubMed
6) Umemura T, Tanaka E, Kiyosawa K, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-56, 2008.
PubMed
7) Kusumoto S, Tanaka Y, Mizokami M, et al:Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13-23, 2009.
PubMed
8) B型肝炎治療ガイドライン第4版(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2022.
 
9) Yeo W, Chan PK, Zhong S, et al:Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000.
PubMed
10) 日本心エコー図学会:抗がん剤治療関連心筋障害の診療における心エコー図検査の手引, 2020.
 
11) Zhang S, Liu X, Bawa-Khalfe T, et al:Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639-1642, 2012.
PubMed
12) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al:2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC). Eur Heart J 37:2768-2801, 2016.
 
13) McGowan JV, Chung R, Maulik A, et al:Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther 31:63-75, 2017.
PubMed
14) Lyon AR, Lopez-Fernandez T, Couch LS, et al:2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association(EHA), the European Society for Therapeutic Radiology and Oncology(ESTRO) and the International Cardio-Oncology Society(IC-OS). Eur Heart J 43:4229-4361, 2022.
 
15) Cardinale D, Colombo A, Bacchiani G, et al:Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981-1988, 2015.
PubMed

書評

最近チェックした商品履歴

Loading...